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ABSTRACT

Compositions and methods for reducing the level of nomicotine and N'-nitrosonornicotine (NNN) inNicotiana plants and
plant parts thereof are provided. The compositions comprise
isolated polynucleotides and polypeptides for cytochrome
P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression cassettes, vectors, plants, and plant parts thereof comprising inhibitory
sequences that target expression or function of the disclosed
cytochrome P450 polypeptides are also provided. Methods
for the use of these novel sequences to inhibit expression or
function of cytochrome P450 polypeptides involved in this
metabolic conversion are also provided. The methods find use
in the production of tobacco products that have reduced levels
of nornicotine and its carcinogenic metabolite, NNN, and
thus reduced carcinogenic potential for individuals consuming these tobacco products or exposed to secondary smoke
derived from these products.
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TTCCTATGGACAAAAAAATCTCAAAAAC~TGCAAAACCCTTACCACCGAAAATCCCCGGA

TTCCTATGiflACAAAAAAATCTCAAAAACii.TT'cAAAGCCCTTACC~CGAAAATCCCCGGA
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ftd ····!
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~iii-1
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TTCCTATGGACAAAAAAATCTCAAAAAC~T~CAAAACCCTTACCACCGAAAATCCCCGGA

TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGA
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGA
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCC~GGA
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3D C12-15
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7D A06

GGATGGCCGGTAATCGGCCATCTTTT~CACTTCAATAACGACGGCGACGACCGTCCATT~
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAATAACGACGGCGACGACCGTCCATT~

GGATGGCCGGTAATCGGCCATCTTTTT:CACTTCAATAACGACGGCGACGACCGTCCATTA

GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAAT~CGACGGCGACGACCGTCCATTA
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAAT~ACGACGGCGACGACCGTCCATTA
GGATGGCCGGTAATCGGCCATCTTTTC~~CTTC~AT~ACGACGGCGACGACCGTCCATTA
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GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT
GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT
GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT
GCTCGAAAACTCGGAGACTTAGCTGA~TACGGCCCCGTTTTCACTTTTCGGCTAG~
GCTCGAAAACTCGGAGACTTAGCTGA,~TACGGCCCCGTTTTCACTTTTCGGCTAGG~

GCTCGAAAACTCGGAGACTTAGCTGA~AAATACGG~CCCGTTTTCACTTTTCGGCTAGG~
**************************-********-***********************-
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Figure 3B
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3D 12
131A A02
3D C12-15
3D 12-10
3D 12-7
7D A06

CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT
CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT
CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT

3D C12
131A A02
3D C12-15
3D C12-10
3D 12-7
7D A06

GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTACAATAAT
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTACAATAAT
GAi!!GCCATTTTCTCCAATCGTCCAGCTTTTCTTTAii'!GGCGAATACCTTGGCTACAGTAAT
GACGCCATTTTWTCCAATCGTCCAGCTTTTCTTTACGGCGA\VTACCTTGGCTACAATAAT
~
GACGCCATTTTITCCAATCGTCCAGCTTTTCTTTACGGCGAWTACCTTGGCTACAATAAT

CTTCCCCTTGT~~TAGTTGTAAGCAGTTACGAAGCT~TAAAAGA~TG~TTCTCTACAAAT

CTTCCCCTTGTdWTAGTTGTAAGCAGTTACGAAGCT~TAAAAGA~TG~TTCTCTACAAAT
CTTCCCCTTGTGfTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGITTCTCTACAAAT
***********--***********************-*******-**-************
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GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTAC~T
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3D C12-15
3D 12-10
3D 12-7
7D A06

~c®ATGCT~TT~TJGCAAATTACGGACCTTACTGGCGAAAAAATCGTAAATTAGTCATT

~C~TGCT~TT~T~GCAAATTACGGACCTTACTGGCGAAAAAATCGTAAATTAGTCATT

GCCATGCTATTT-TGicAAAiTACGGACCTTACTGGCGAAAAAAT~G~TTAGTCATT

GCCATGCTATTTTTGGC~AATTACGGACCTTACTGGCGAAAAAATCG~TTAGT~ATT
GCCATGCTATTTTTGGC~AATTACGGA~CTTACTGGCGAAAAAATCGAAAATTA~T~ATT
GCCATGCTATTTTTGGCAAATTACGGAlCTTACTGGCGAAAAAATCGTAAATT~T~ATT
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3D 12
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3D Cl2-15
3D 12-10
3D 12-7
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CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACAAGTGAGATTC~CCAGAATT

CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACAAGTGAGATTC~CCAGAATT
CAGGAAGTTCTCT~TGCTAGTCGTCTCGAAAAATT~AA~CACGTGAGATT~GGT:G;2\:AATT
CAGGAAGTTCTCTC~GCTAGTCGTCTCGAAAAATTCAAACACGTGAGATT~G<::j.AGAATT
CAGGAAGTTCTCTC~GCTAGTCGTCTCGAAAAATTCAAACACGTGAGATT~GC~GAATT

CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACACGTGAGATTCGCCAGAATT
*************--********************-**-**-********------****
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Figure 3C
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3D 12
131A A02
3D C12-15
3D 12-10
3D 12-7
7D A06

3D 12
131A A02
3D C12-15
3D 12-10
3D 12-7
7D A06

CAAACGAGCATTAAGAATTTATACACTCGAATT~TGGAAATTCGAGTACGATAAATCTA

CAAACGAGCATTAAGAATTTATACACTCGAATTAATGGAAATTCGAGTACGATAAATCTA

CA~ACGAGCATTAAGAATTTATACACTCGAATTGATGGAAATTCGAGTACGATAAATCTA
CAA~CGAGCATTAAGAATTTAT~~ACTCGAATTGATGGAAATTCGAGTACGATAAAT~TA
CAA§CGAGCATTAAGAATTTAT~~ACTCGAATTGATGGAAATTCGAGTACGATAAAT~TA

CAAACGAGCATTAAGAATTTATACACTCGAATTGATGGAAATTCGAGTACGATAAAT~TA
**--*******************-*********-***********************-**

ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAAATGATCGCTGGGAAAAAT
~~TGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAAATGATCGCTGGGAAAAAT
AC~

ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGG~T
~

ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGG~T

ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAiATGATCGCTGGGAAAAAT
*--**************************************-***********-******
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3D 12
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3D 12-10
3D 12-7
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TATGAATCCGGTAAAGGAGATGAACAAGTGGAiAGATTTAAGAAWGCGTTTAAGGATTTT

3D 12
131A A02
3D 12-10
3D 12-7
7D A06

ATGGTTTTATCAATGGAATTTGTATTATGGGATGCATTTCCAATTCCATTATTTAAATGG

-

-

TATGAATCCGGTAAAGGAGATGAACAAGTGG~GATTTAAGAA~GCGTTTAAGGATTTT

TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT
********************************-***********-***************
~~IT

~

ATGATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGG
ATGATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGG
ATGATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGG
***-*************-*****-************************************
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Figure 3D
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3D
3D
3D
7D

3D
3D
3D
7D

12
12-10
12-7
A06

12
12-10
12-7
A06

~

GTGGATTTTCAAGG~CATiTTAAGGCIATGAAAAGGAC~TTTAA~GATATAGATTCTGTT
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT
**************-***-*******-***********-*****-***************

777
777
777
777

TTTCAGAA~TGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT- - - GGAGGTT~,~TGCA

834
834
834
837

TTTCAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT---GGAGGTT~TGCA
>:;T~!i

TTTCAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT---GGAGGTT~TGCA

TTTCAGAATTGGTTAGAGGAACATATTAA~~GAGAAAAAAT~~GGAGGTTGGT~CA
********-********************-**************---*******--*-**

3D
3D
3D
7D

3D
3D
3D
7D

12
12-10
12-7
A06

12
12-10
12-7
A06

GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAITGAGTAAlGAATATCTT
GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT
GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT
GAAGGGAATGAACAAGATTTIDATAGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT
~
********************-**-******************-*******-*********
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894
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GiTGAAGGTTACTCTCGTGATACTGTCATTAAAGCAACAGT~TTTAGTTTGGTCTTGGAT

954
954

-

GGTGAAGGTTACTCTCGTGATACTGTCATTAAAGCAACSGTGTTTAGTTTGGTCTTGGAT

GGTGAAGGTTACTCTCGTGATACTGTCATT~GCAAC~GTGTTTAGTTTGGTCTTGGAT
GGOOAAGGTTACTCTC~GATACTGTCATMA.iGCAACAGTIJTTTAGTTTGGTCTTGGAT
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*--**************-***********-**-*****-**-******************
3D
3D
3D
7D

12
12-10
12-7
A06

GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATG~CATTATTGATAAACAATCAA

GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATTGATAAACAATCAA
GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATTGATAAACAATCAA
GCAGCAGACACAGTTGCTCTTCACATAAATTG~GGAATGGCATTATTGATAAACAATCAA
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Figure 3E
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AATGCCTTGAmGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGATAGATGGGTA
~~··

'

'<" :

"

"

~GCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGACAGATGGGTA

AA~GCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGA~AGATGGGTA
AATGCCTTG~GAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGATAGATGGGTA
~
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1074
1077

**-*******-***************************************-*********
3D
3D
3D
7D

3D
3D
3D
7D

12
12-10
12-7
A06

12
12-10
12-7
A06

GAAGAGAGTGATATTAAGGATTT~GTATACCTCCAAGCTATTGTTAAAfiA~GTGTTACGA

GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGA
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGA
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGA
***********************-************************-*-*********
TTATATCCACCAGGACCTTTGTTAGTACCACAWGAAAATGT~~GATTGTGTTGTTAGT

TTATATCCACCAGGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGT
TTATATCCACCAGGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGT
TTATATCCACC~GGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGT
~
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GGATATCACATTCCTAAAGAGACTAGATTATTCGCAAACGTCATGAAACTGCAijC~GAT

GGATATCACATTCCTAAAGGGAC~GATTATTCGCAAACGTCATGAAACTGCAACGTGAT
GGATATCACATTCCTAAAGGGAC~GATTATTCGCAAACGTCATGAAACTGCAACGTGAT

GGATATCACATTCCTAAAGGAACTAGA~TATTCGCAAAIDGTiA.TGAAACTiCAACGTGAT
n-'~

•; ''

·~\i~

mi1

;i'~;

=
~

z0
~
....

~-....l
N

....

0

Ul

1194
1194
1194
1197

***********-********************-*********-*-***************
3D
3D
3D
7D

~

1254
1254
1254
1257

rFJ

=-

('D
('D

.....

-....l
0

.........
.j;o.

*******************--**-***-**********-**-********-**-**-***
3D
3D
3D
7D

12
12-10
12-7
A06

CCTAAACTCTreGTCAAATCCTGATAAGTTCGATCCAGAGAGATTCATCGCT~GTGATATT

ccTAAACTCTGGTc~;~ATCCTGAT~~~TTCGATCCAGAGAGATTCAT~GCT~TGATATT
CCTAAACTCTGGTCm~ATCCTGATA~~TTC~ATCCAGAGAGATTCATW:GCTA~TGATATT
CCTAAACTCTGGTCAAATCCTGATAAGTTC~TCCAGAGAGATTCATCGCT~GTGATATT
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Figure 3F
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GACTT~CGTGGTCA~~CTAT~AGTmTATCCC~TTTGGTTCTGGAAGACGATCTTGTCC~
GACTTTCGTGGTCAGTACTAT~GTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCC~

GACTTTCGTGGTCAGTACTAT~GTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCC~
GACTTTCiTGGTCAGqACTATGAGTATATCCCGTTTGGTTCTGGAAGACG~TCTTGTCCG

~
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12
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12
12-10
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A06

GGGATGACTTATGCATTGCAAGTGGAACACCTAACAATGGCACATTT~TCCAGGGTTTC
~

GGGATGACTTATGCATTGCAAGTGGAACAC~TAACAATGGCACATTTGATCCA!GGTTTC
GGGATGACTTATGCATTGCAAGTGGAACAC~TAACAATGGCACATTTGATCCAAGGTTTC
a
~

GGGATGACTTATGCATTGCAAGTGGAACACCTAACAATGGCACATTTGATCCAGGGTTTC
******************************-****************-*****-******
AATTACAiAACTCCAAATGACGAG~CCTTGGATATGAAGGAAGGTGCAGGCATAAC~TA

AATTACAGAACTCCAAATGACGAGCCCTTGGATATGAAGGAAGGTGCAGGCATAACTATA
AATTACAGAACTCCAAATGACGAGCCCTTGGAEATGAAGGAAGGTGCAGGCATAACTATA

AATTACAGAACTCCAAgTG~~GAGCCCTTGGATATG~GAAGGTGCAGGCATAACTATA

1434
1434
1434
1437

12
12-10
12-7
A06

CGTAAGGTAAATCC~GTGGAA~TGATAATAACGCCTCGCTTGGCACCTGAGCTTTAjTAA
CGTAAGGTAAATCCTGTGGAACTGATAATA~CGCCTCGC~TGGCACCTGAGCTTTATTAA

CGTAAGGTAAATCCTGTGGAACTGATAATAGCGCCTCGCGTGGCACCTGAGCTTTATTAA

CGTAAGGTAAATCCTGTG~GTGATAATroACGCCTCGCTTGGCACCTGAGCTTTATTAA
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AACCTAAGATCTTTCATCTTGGTTGATCATTGTTTAATACTCCTAGATGGGTATTCATTT
AACCTAAGATCTTTCATCTTGGTTGATCATTGT~TAATACTCCTA!ATGGATATTCATTT

AACCTAAGATCTTTCATCTTGGTTGATCATTGT~TAATACTCCTAiATGJ~TATTCATTT
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AA~CTAAGAT~TTTCATCTTGGTTGATCATTGTTTAATACTCCTAGATGGGTATTCAT~T
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Figure 3G
3D
3D
3D
7D

12
12-10
12-7
A06

ACCTTTTTTCAATTAATT~~~GTACGAG~TTTTTTAATTTGGTA~ATTTGTAA~AATAA

ACCTTTTiTCAATTAATTGTCAGTACGAGTTTTT~TAATTTGGTACATTTGTAATAATAA
=
~

ACCTTTTITCAATTAATTGTCAGTACGAGTTTTT€TAATTTGGTACATTTGTAATAATAA

ACCTTTTTTCAATTA~TTGTC~GTACGI~TTTTTTTAATTTGGTAI~TTTGTAATAATAA
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GTAAAGAATGATTGTGCTAATATATAAAG~TTTGCAGAAGATAATTGACTGATTGTCCC
GTAAAGAAT~TTGTGCTAATATATAAAGGTTTG~AGAAGATAATTGACTGATTGTCCC

GTAAAGAATiATTGTGCTAATATATAAAGGTTTGiAGAAGAT~ATTGACTGATTGTCCC
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Figure 4
3D
3D
3D
7D

C12
C12-7
C12-10
A06

MVFPIE~GLVTFTFL~-g:FLWTKKSQK~~;KPLPPKIPGGWPVIGHLFHF~GDDRPLA 60
MVFPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVIGHLFHFNDDGDDRPLA 60
MLSPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVIGHLFHFNDDGDDRPLA 60
MVFP!EAIVGLVTFTFLF~FLWTKKSQKPSKPLPPKIPGGWPVIGHLF~F~DDGDDRPLA 60

3D
3D
3D
7D

C12
C12-7
C12-10
A06

RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAlKDCFSTNDAIFSNRPAFLYG11;YLGYNNW 120
RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120
RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120
RKLGDLADKYGPVFTFRLGLPLVLVVSSYE~KDCFSTNDAIFSNRPAFLYG§YLGY~NA 120

3D
3D
3D
7D

C12
C12-7
C12-10
A06

MLFLANYGPYWRKNRKLVIQEVLSASRLEKFK~VRFWRIQ~SIKNLYTRI~GNSSTINLT 180

*: *:**!*********::*********

******************:*::********

*******************************~********************;****;*:

MLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQASIKNLYTRIDGNSSTINLT 180
MLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQASIKNLYTRIDGNSSTINLT 180
MLFLANYG?YWRKNRKL~IQEVLSASRLEKFKHVRFARIQmsrKNLYTRIDGNSSTINLT 180

********·********:**************;***:***:*********:*********
3D
3D
3D
7D

C12
C12-7
C12-10
A06

DWLEELNFGLIVKMIAGKNYESGKGDEQVERFK~AFKDFMYLSMEFVLWDAFPIPLFKWV 240
DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240
DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240
DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240
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3D
7D

C12
C12-7
C12-10
A06

DFQGH~KAMKRTFKDIDSVFQNWLEEHINKREK-MEV~AEGNEQDFIDVVLSK~S~EYLg 299
DFQGHVKAMKRTFKDIDSVFQNWLEEHINKREK-MEVNAEGNEQDFIDVVLSKMSNEYLG 299
DFQGHVKAMKRTFKDIDSVFQNWLEEHINKREK-MEVNAEGNEQDFIDVVLSKMSNEYLG 299
DFQGHVKAMKRTFKDIDSVFQNWLEEHI~REK:i;,MEV~-;eEGNEQDFIDVVLSKMSNEYLG 3 0 0
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EGYSRDTVIKATVFSLVLDAADTVALHINWGMWLLINNQ~A~KAQEEIDTKVGKDRWVE 359
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ESDIKDLVYLQAIVK~LRLYPPGPLLVPH~DCVVSGYHIPK!TRLFANVMKLQRDP 419
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KL~S~PD~FDPERFIA~DIDFRGn~y~~IPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN

*****;**********************:**** ***.:**************:*;***·
EGYSRDTVIKATVFSLVLDAADTVALHINWGMALLINNQKALTKAQEEIDTKVGKDRWVE 359
EGYSRDTVIKATVFSLVLDAADTVALHINWGMALLINNQKALTKAQEEIDTKVGKDRWVE 359
EGYSRDTVIKATVFSLVLDAADTVALHIN~GMALLINNQ~AL~KAQEEIDTKVGKDRWVE 360

***************************** **;******!********************
ESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDP 419
ESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDP 419
ESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDP 420

***************;*****************;*********** **************
479
KLWSDPDTFDPERFIATDIDFRGQYYKYIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 479
KLWSDPDTFDPERFIATDIDFRGQYYKYIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 479
KLWS~PD~F~PERFIA~IDF~GQijY1YIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 480

** *:**.*:****** ****:*::*::********************************
3D
3D
3D
7D

C12
C12-7
C12-10
A06

Y~TPNDE~LDMKEGAGITIRKVNPVELII~PRLAPELY 517
YRTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517
YRTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517
YRTP~DEPLDMKEGAGITIRKVNPV~II~PRLAPELY 518

*:**·**·*****************: :**:********
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Figure 5
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Figure 7

CTGTCATTAAAGCAACGGTGTTTGTAAGTTCATCTGTCATTTTTCATTTATTCACTTTT
ATTTTGAGGAGCAGACATGTTAATAATAATTTGGAGCAACTGTAAAGTTATCTATGTGT
AC1 GGTTCGAGCCTCAGGTGCAACCACTMTGCTTGTATTA GATTATGTTGTCTGCAT
CATACCCCTAA TTGGA GTGTGGCTCTTCCCGAACCCTGCAA TGCTGGATGCTGGATGC
TTTATGTATCAGACTGACCTTTTTGTTAAACTATCTAAATACTAAGGATGATTTAATAA
AAA TATA GAATGGTAAACAGAAAAAGATGA GATTATTTTTGGGGCTATATGGATTCGC
CCGGGCTTTGGGAGGTAAAACGGTATCTACCAGTTGAGACTTTACTCCAGMCTTTAT
CTCGAGAGCTCTGAATAAAAATGAAATAGTATTTACCACTCCAAAATCTTTGATGGTAA
AAAGATGAGATATAACCTCTTATAATTGATTGAACCACGTTGATAGAATAAAACTTCTT
TACTCCCATTCAGC1TAAGAAAAATGAAACCAAACGGAATTCTTCTCTTTTTTAGGGGG
AAATTCCTTAATTGCTTGTTGAATATAGATTCATGTCGTTATTCTATTTTTAATAATGAT
GAAAATCAATATAGTCAAAGTTAATACTTATGTCATTTGGTTTGCGGACAAGTTATATT
GGAA C1:A1:41:4ATACGTC1:4 T1:41:4 GAA1:4 GTGATTATTTA GA GGATATA CA TTTTTTT
TGGATAAATATTTGATTTATTGGATTAAAAATAGAATATACAGGTAAGGTCTAAAACGT
GTGTTTGCTTTTACACTAAATAAACTTGACCTCGTACAATTCTAAGAAAATATTTGAAA
TAAA TGAA TTATTTTATTGTTAATCAA T1:4AAAAAA TCATA GTATAGATGAGATGTGTG
CATACTTGGCAATAACTATACTAACTAAAACAAGGTATGTGAATAATTGATATTCCTTT
TTTAA TTATTCTTTTTTCCA GAGTTTGGTCTTGGATGCAGCAGACACAG'lTGCTCTTCA

CATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCCTTGACGAAAGCAC
AAG
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ALTERATION OF TOBACCO ALKALOID
CONTENT THROUGH MODIFICATION OF
SPECIFIC CYTOCHROME P450 GENES

tion of curing conditions while maintammg acceptable
quality standards have not proven to be successful for the
air-cured tobaccos.
In Burley tobaccos, a positive correlation has been found
between the nornicotine content of the leaf and the amount of
NNN that accumulates in the cured product (Bush et a!.
(2001) Rec. Adv. Tab. Sci. 27:23-46; Shi eta!. (2000) Tab.
Chern. Res. Conf 54:Abstract 27). However, keeping nornicotine levels at a minimum has been difficult because of the
conversion phenomenon that results in a continual introduction of high nornicotine-producing plants within commercially grown Burley populations. Minimizing the number of
Burley plants that accumulate high levels of nornicotine has
traditionally been the responsibility of plant breeders and
seed producers. Though the percentage of converter plants
that are ultimately grown in farmers' fields can be reduced
through the roguing of converter plants during the propagation of seed stocks, this process is costly, time-consuming,
and imperfect.
Previous studies have shown that once a plant has converted, the high nornicotine trait is inherited as a single dominant gene (Griffith eta!. (1955) Science 121:343-344; Burk
and Jeffrey (1958) Tab. Sci. 2:139-141; Mann eta!. (1964)
Crop Sci. 4:349-353). The nature of this gene, however, is
currently unknown. In the most simple of scenarios, the conversion locus may represent a nonfunctional nicotine N -demethylase gene that regains its function in converter plants,
possibly through the mobilization of a mutation-inducing
transposable element. Alternatively, the converter locus may
encode a protein that initiates a cascade of events that ultimately enables the plant to metabolize nicotine to nornicotine, which would mean that multiple genes may be involved.
Regardless of whether there are one or many genes associated with the conversion process, it is clear that the gene(s)
encoding polypeptides having nicotine demethylase activity
play a pivotal role in this process. Although the inability to
purify active nicotine N-demethylase from crude extracts has
impeded the isolation and identification of this enzyme, there
is some evidence that a member of the cytochrome P450
superfamily of monooxygenases may be involved (Hao and
Yeoman (1996) Phytochern. 41:477-482; Hao and Yeoman
(1996) Phytochern. 42:325-329; Chelvarajan eta!. (1993) J.
Agric. Food Chern. 41:858-862; Hao and Yeoman (1998) J.
Plant Physiol. 152:420-426). However, these studies are not
conclusive, as the classic P450 inhibitors carbon monoxide
and tetcylasis have failed to lower enzyme activity at rates
comparable to other reported P450-mediated reactions (Chelvarajan eta!. (1993) J. Agric. Food Chern. 41:858-862).
Furthermore, the cytochrome P450s are ubiquitous, transmembrane proteins that participate in the metabolism of a
wide range of compounds (reviewed by Schuler (1996) Crit.
Rev. Plant Sci. 15:235-284; Schuler and Werck-Reichhart
(2003) Annu. Rev. Plant Biol. 54:629-667). Examples ofbiochemical reactions mediated by cytochrome P450s include
hydroxylations, demethylations, and epoxidations. In plants,
the cytochrome P450 gene families are very large. For
example, total genome sequence examination has revealed
272 predicted cytochrome P450 genes in Arabidopsis and at
least 455 unique cytochrome P450 genes in rice (see, for
example, Nelson et a!. (2004) Plant Physiol. 135(2):756772). Even though cytochrome P450 has been implicated as
having a role in the metabolic conversion of nicotine to nornicotine, identification of key participating members of this
protein family remains a challenge.
Aside from serving as a precursor for NNN, recent studies
suggest that the nornicotine found in tobacco products may
have additional undesirable health consequences. Dickerson

CROSS-REFERENCE TO RELATED
APPLICATION
This application is a continuation of U.S. application Ser.
No. 11/580,765, filed Oct. 13, 2006, which is a continuationin-part of International Application No. PCTIUS2005/
005665, filed Feb. 23, 2005, the contents of which are herein
incorporated by reference in their entirety.
FIELD OF THE INVENTION
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The invention relates to compositions and methods for
reducing the level of nornicotine and its metabolite, N'-nitrosonornicotine, in a plant that is a member of the genus
Nicotiana, particularly compositions and methods for inhibiting expression or function of a cytochrome P450 polypeptide involved in the metabolic conversion of nicotine to nornicotine.

20

BACKGROUND OF THE INVENTION
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The predominant alkaloid found in commercial tobacco
varieties is nicotine, typically accounting for 90-95% of the
total alkaloid pool. The remaining alkaloid fraction is comprised primarily of three additional pyridine alkaloids: nornicotine, anabasine, and anatabine. Nornicotine is generated
directly from nicotine through the activity of the enzyme
nicotine N-demethylase (FIG. 1). Nornicotine usually represents less than 5% of the total pyridine alkaloid pool, but
through a process termed "conversion," tobacco plants that
initially produce very low amounts of nornicotine give rise to
progeny that metabolically "convert" a large percentage of
leaf nicotine to nornicotine. In tobacco plants that have
genetically converted (termed "converters"), the great majority of nornicotine production occurs during the senescence
and curing of the mature leaf (Wernsman and Matzinger
(1968) Tab. Sci. 12:226-228). Burley tobaccos are particularly prone to genetic conversion, with rates as high as 20%
per generation observed in some cultivars.
During the curing and processing of the tobacco leaf, a
portion of the nornicotine is metabolized to the compound
N'-nitrosonornicotine (NNN; FIG. 1), a tobacco-specific nitrosamine (TSNA) that has been shown to be carcinogenic in
laboratory animals (Hecht and Hoffmann (1990) Cancer Surveys 8:273-294; Hoffmann eta!. (1994) J. Toxicol. Environ.
Health 41:1-52; Hecht (1998) Chern. Res. Toxicol. 11:559603). In flue-cured tobaccos, TSNAs were found to be predominantly formed through the reaction of alkaloids with the
minute amounts of nitrogen oxides present in combustion
gases formed by the direct-fired heating systems found in
traditional curing barns (Peele and Gentry (1999) "Formation
of Tobacco-specific Nitrosamines in Flue-cured Tobacco,"
CORESTA Meeting, Agro-Phyto Groups, Suzhou, China).
Retrofitting these curing barns with heat-exchangers virtually
eliminated the mixing of combustion gases with the curing air
and dramatically reduced the formation ofTSNAs in tobaccos cured in this marmer (Boyette and Hamm (2001) Rec. Adv.
To b. Sci. 27:17-22.). In contrast, in theair-curedBurleytobaccos, TSNA formation proceeds primarily through reaction of
tobacco alkaloids with nitrite, a process catalyzed by leafborne microbes (Bush eta!. (2001) Rec. Adv. To b. Sci. 27:2346). Thus far, attempts to reduce TNSAs through modifica-
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and Janda demonstrated that nornicotine causes aberrant protein glycation within the cell (Dickerson and Janda (2002)
Proc. Nat!. Acad. Sci. USA 99: 15084-15088). Concentrations
of nornicotine-modified proteins were found to be much
higher in the plasma of smokers compared to nonsmokers.
Furthermore, this same study showed that nornicotine can
covalently modify commonly prescribed steroid drugs such
as prednisone. Such modifications have the potential of altering both the efficacy and toxicity of these drugs.
In view of the difficulties associated with conversion and
the undesirable health effects of nornicotine accumulation,
improved methods for reducing the nornicotine content in
tobacco varieties, particularly Burley tobacco, are therefore
desirable. Such methods would not only help ameliorate the
potential negative health consequences of the nornicotine per
se as described above, but should also concomitantly reduce
NNNlevels.

The methods of the invention find use in the production of
Nicotiana plants that have decreased levels of nornicotine and
its metabolite, the nitrosamine N'-nitrosonornicotine, within
the leaf and stem tissues. When harvested, the leaf and stem
tissues of these plants can be utilized to produce tobacco
products having reduced levels of nornicotine and this
tobacco-specific nitrosamine, and thus reduced carcinogenic
potential for individuals consuming these products or
exposed to secondary smoke derived from these products.
Also provided are transgenic Nicotiana plants having a
nicotine to nornicotine conversion rate ofless than about 2%,
where the plants comprise a heterologous nucleic acid construct comprising a promoter capable of functioning in a plant
cell operably linked to a nucleic acid sequence having a first
nucleotide sequence comprising a fragment ofbetween about
100 nucleotides and about 400 nucleotides of a Nicotiana
nicotine demethylase polynucleotide and a second nucleotide
sequence capable of forming a double-stranded RNA with the
first nucleotide sequence, where the transgenic Nicotiana
plants are transgenic converter lines of Nicotiana. In some
embodiments, the Nicotiana nicotine demethylase polynucleotide is a tobacco nicotine demethylase polynucleotide.
The present invention also provides a recombinant nucleic
acid construct comprising a promoter capable of functioning
in a plant cell operably linked to a nucleic acid sequence
having a first nucleotide sequence comprising a fragment of
between about 100 nucleotides and about 400 nucleotides of
a tobacco nicotine demethylase polynucleotide and a second
nucleotide sequence capable of forming a double-stranded
RNA with the first nucleotide sequence.
Also provided are methods of reducing the conversion of
nicotine to nornicotine in a Nicotiana plant comprising transforming a Nicotiana plant with a recombinant nucleic acid
construct comprising a promoter capable of functioning in a
plant cell operably linked to a nucleic acid sequence having a
first nucleotide sequence comprising a fragment of between
about 100 nucleotides and about 400 nucleotides of a Nicotiana nicotine demethylase polynucleotide and a second nucleotide sequence capable of forming a double-stranded RNA
with the first nucleotide sequence; and regenerating a transgenic Nicotiana plant. In some embodiments, the Nicotiana
nicotine demethylase polynucleotide is a tobacco nicotine
demethylase polynucleotide.
The present invention also provides seed obtained from the
transgenic Nicotiana plant having a nicotine to nornicotine
conversion rate of less than about 2%, where the seed comprises a heterologous nucleic acid construct comprising a
promoter capable of functioning in a plant cell operably
linked to a nucleic acid sequence having a first nucleotide
sequence comprising a fragment ofbetween about 100 nucleotides and about 400 nucleotides of a Nicotiana nicotine
demethylase polynucleotide and a second nucleotide
sequence capable of forming a double-stranded RNA with the
first nucleotide sequence, where the transgenic Nicotiana
plants are transgenic converter lines of Nicotiana. In some
embodiments, the Nicotiana nicotine demethylase polynucleotide is a tobacco nicotine demethylase polynucleotide.
The present invention also provides transgenic plant cells
comprising a nucleic acid molecule having a promoter functional in a plant cell and a nucleic acid sequence encoding a
nicotine demethylase having an isoleucine residue at position
274 and a tryptophan residue at position 329.
The present invention also provides methods of screening
for a nicotine demethylase sequence comprising: obtaining a
nucleic acid sequence that has greater than about 90%

SUMMARY OF THE INVENTION
Compositions and methods for reducing the nornicotine
content in plants that are members of the genus Nicotiana are
provided. Compositions include isolated cytochrome P450
polynucleotides and polypeptides that are involved in the
metabolic conversion of nicotine to nornicotine in plants,
particularly Nicotiana species. The isolated polynucleotides
comprise the nucleotide sequence set forth in SEQ ID NO: 1,
3, 5, 7, 9, or 11, a nucleotide sequence encoding a polypeptide
as set forth in SEQ ID N0:2, 4, 6, 8, 10, or 12, and fragments
and variants thereof. Isolated polypeptides of the invention
comprise an amino acid sequence set forth in SEQ ID N0:2,
4, 6, 8, 10, or 12, an amino acid sequence encoded by the
nucleotide sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, or
11, and fragments and variants thereof.
The polynucleotides of the invention find use in suppressing expression of a cytochrome P450 that is involved in the
metabolic conversion of nicotine to nornicotine in a plant,
including the cytochrome P450s of the present invention. In
this manner, compositions further include expression cassettes comprising an inhibitory sequence that is capable of
inhibiting expression or function of a cytochrome P450
polypeptide of the invention, where the inhibitory sequence is
operably linked to a promoter that is functional in a plant cell.
In some embodiments, the inhibitory sequence comprises the
sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 14, 15,
or 16, or a complement or fragment thereof. Compositions
also include transformed plants and plant parts that comprise
an expression cassette of the present invention, optionally
stably incorporated into the genome of the plant. Further
provided are tobacco products, including chewing tobacco,
snuff, cigarettes, pipe tobacco, and cigars, having a reduced
level of nornicotine, and its related nitrosamine, N'-nitrosonornicotine.
The methods of the invention comprise inhibiting the
expression or function of a cytochrome P450 polypeptide of
the present invention. In some embodiments, an expression
cassette comprising an inhibitory sequence that targets
expression or function of a cytochrome P450 polypeptide of
the present invention is introduced into the plant or plant part
of interest, wherein expression of the inhibitory sequence
produces a polynucleotide or polypeptide that inhibits
expression or function of a cytochrome P450 polypeptide of
the invention. In one such embodiment, the inhibitory
sequence comprises a sequence set forth in SEQ ID NO: 1, 3,
5, 7, 9, 11, 13, 14, 15, or 16, or a complement or fragment
thereof.
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sequence identity with SEQ ID N0:5 and identifYing a codon
sequence encoding for a tryptophan residue at position 329 of
the encoded polypeptide.
Further provided are methods for screening for a nicotine
demethylase having an isoleucine at position 274 or a tryptophan at position 329 comprising obtaining a nucleic acid
sequence that has greater than about 90% sequence identity
with SEQ ID N0:5 and identifYing a first codon sequence
encoding for an isoleucine residue at position 27 4 or a second
codon sequence encoding a tryptophan residue at position
329 of the encoded polypeptide.

FIG. 7 shows a genomic sequence of a fragment of the
3D_C12-10 gene possessing an intron. Intron sequences are
indicated in bold, italicized type. Exon sequences are shown
in plain type. The sequences corresponding to the PCR primers used to amplifY the fragment from the tobacco genomic
DNA are underlined.
FIG. 8 shows a diagram of the RNAi constructs used to
silence expression of members of the 3D_CD12 gene family.

5

10

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the structures of nicotine, nornicotine, and
N'-nitrosonornicotine (NNN).
FIG. 2 shows Northern blot analysis of converter and nonconverter RNAs using 7D_A06 as a hybridization probe.
Lanes 1 and 2 show RNAs isolated from sodium bicarbonatetreated leaves of genotypes DH 98-325-5 (nonconverter) and
DH 98-325-6 (converter), respectively. Lanes 3 and 4 show
RNAs isolated from ethephon-treated leaves of genotypes
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter),
respectively. Estimated size of the hybridizing band is indicated in kilo bases (kb).
FIGS. 3A-3G shows a nucleotide sequence aligument of
members of the 3D_C12 gene family. Asterisks denote positions where sequence identity is conserved among all
sequences compared. Positions where differences are found
are indicated with dashes and the corresponding residues are
shaded grey. The nucleotide sequences present in the alignment include 3D_C12 (SEQ ID N0:1), 3D_C12-10 (SEQ ID
N0:3); 3D_C12-7 (SEQIDN0:5); 7D_A06 (SEQIDN0:7);
3D_C12-15 (SEQ ID N0:9); and 131A_A02 (SEQ ID
NO:ll). The 3D_C12-15 and 131A_A02 entries are partiallength eDNA sequences. The 99 bp region of 3D_C12 that
was used to make the RNAi-based construct is underlined.
FIG. 4 shows an alignment of predicted amino acid
sequences for full-length members of the 3D_C12 family of
P450 genes. The amino acid sequences present in the alignment include 3D_C12 (SEQ ID N0:2), 3D_C12-10 (SEQ ID
N0:4); 3D_C12-7 (SEQ ID N0:6); and 7D_A06 (SEQ ID
NO: 8). Asterisks denote positions conserved among all four
sequences. Residues that differ among the members are
shaded in grey.
FIG. 5 shows a Northern blot analysis of transgenic plants
possessing the 3D_C12/RNAi construct. (A) Hybridization
of the 3D_C12-7 probe to RNAs isolated from ethephontreated, cured leaves of transgenic plants displaying low nornicotine phenotypes (3D_C12/RNAi-1, 3, and 4) and high
nornicotine phenotypes (3D_C12/RNAi-6, 7, and vectoronly control plant 11). Estimated size of hybridizing band is
indicated in kilo bases (kb ). (B) Ethidium bromide staining of
the portion of the gel used in (A) that contains the 28S ribosomal RNA to show the relative equivalence of RNA loading
among the lanes.
FIG. 6 shows a Northern blot analysis of transgenic plants
possessing sense-orientation constructs of members of the
3D_C12 gene family. (A) Hybridization of the 3D_C12-7
probe to RNAs isolated from nontreated leaves of independent transgenic lines expressing 3D_C12-7, 3D_C12, and
7D_A06 constructs and a vector-only control (control 8).
Estimated size of hybridizing band is indicated in kilobases
(kb ). (B) Ethidium bromide staining of the portion of the gel
used in (A) that contains the 28S ribosomal RNA to show the
relative equivalence of RNA loading among the lanes.
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DETAILED DESCRIPTION OF THE INVENTION
Background and Definitions
Before describing the present invention in detail, it is to be
understood that many modifications and other embodiments
of the inventions set forth herein will come to mind to one
skilled in the art to which this invention pertains having the
benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the invention is not to be limited to the specific
embodiments disclosed and that modifications and other
embodiments are intended to be included within the scope of
the appended claims. Rather, these embodiments are provided so that this disclosure will satisfY applicable legal
requirements.
Although specific terms are employed herein, they are used
in a generic and descriptive sense only and not for purposes of
limitation. Like numbers refer to like elements throughout.
Further, the article "a" and "an" are used herein to refer to one
or more than one (i.e., to at least one) of the grammatical
object of the article. By way of example, "an element" means
one or more element. Throughout the specification the word
"comprising," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated
element, integer or step, or group of elements, integers or
steps, but not the exclusion of any other element, integer or
step, or group of elements, integers or steps.
The present invention is drawn to compositions and methods for inhibiting the expression or function of cytochrome
P450 polypeptides that are involved in the metabolic conversion of nicotine to nornicotine in a plant, particularly plants of
the Nicotiana genus, including tobacco plants of the various
commercial varieties. As used herein, the terms "inhibit,"
"inhibition," and "inhibiting" are defined as any method
known in the art or described herein that decreases the expression or function of a gene product of interest (i.e., the target
gene product). "Inhibition" can be in the context of a comparison between two plants, for example, a genetically altered
plant versus a wild-type plant. Alternatively, inhibition of
expression or function of a target gene product can be in the
context of a comparison between plant cells, organelles,
organs, tissues, or plant parts within the same plant or
between different plants, and includes comparisons between
developmental or temporal stages within the same plant or
plant part or between plants or plant parts. "Inhibition"
includes any relative decrement of function or production of
a gene product of interest, up to and including complete
elimination of function or production of that gene product.
The term "inhibition" encompasses any method or composition that down-regulates translation and/or transcription of
the target gene product or functional activity of the target gene
product.
The term "inhibitory sequence" encompasses any polynucleotide or polypeptide sequence capable of inhibiting the
expression or function of a cytochrome P450 polypeptide
involved in the metabolic conversion of nicotine to nornicotine in a plant, such as full-length polynucleotide or polypeptide sequences, truncated polynucleotide or polypeptide
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sequences, fragments of polynucleotide or polypeptide
sequences, variants of polynucleotide or polypeptide
sequences, sense-oriented nucleotide sequences, antisenseoriented nucleotide sequences, the complement of a sense- or
antisense-oriented nucleotide sequence, inverted regions of
nucleotide sequences, hairpins of nucleotide sequences,
double-stranded nucleotide sequences, single-stranded
nucleotide sequences, combinations thereof, and the like. The
term "polynucleotide sequence" includes sequences of RNA,
DNA, chemically modified nucleic acids, nucleic acid analogs, combinations thereof, and the like.
Inhibitory sequences are designated herein by the name of
the target gene product. Thus, a "cytochrome P450 inhibitory
sequence" refers to an inhibitory sequence that is capable of
inhibiting the expression of a cytochrome P450 polypeptide
that is involved in the metabolic conversion of nicotine to
nomicotine in a plant, for example, at the level of transcription and/or translation, or which is capable of inhibiting the
function of such a cytochrome P450 polypeptide. When the
phrase "capable of inhibiting" is used in the context of a
polynucleotide inhibitory sequence, it is intended to mean
that the inhibitory sequence itself exerts the inhibitory effect;
or, where the inhibitory sequence encodes an inhibitory
nucleotide molecule (for example, hairpin RNA, miRNA, or
double-stranded RNA polynucleotides ), or encodes an inhibitory polypeptide (i.e., a polypeptide that inhibits expression
or function of the target gene product), following its transcription (for example, in the case of an inhibitory sequence encoding a hairpin RNA, miRNA, or double-stranded RNA polynucleotide) or its transcription and translation (in the case of
an inhibitory sequence encoding an inhibitory polypeptide),
the transcribed or translated product, respectively, exerts the
inhibitory effect on the target gene product (i.e, inhibits
expression or function of the target gene product).
By "host cell" is meant a cell that comprises a heterologous
nucleic acid sequence of the invention. Though the nucleic
acid sequences of the invention, and fragments and variants
thereof, can be introduced into any cell of interest, of particular interest are plant cells, more particularly cells of a Nicotiana plant species, for example, the tobacco plant species and
varieties described herein below.
The use of the term "polynucleotide" is not intended to
limit the present invention to polynucleotides comprising
DNA. Those of ordinary skill in the art will recognize that
polynucleotides can comprise ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides. Such
deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. The polynucleotides of the invention also encompass all forms of
sequences including, but not limited to, single-stranded
forms, double-stranded forms, hairpins, stem-and-loop structures, and the like.
The term "variant" as used herein is intended to mean a
substantially similar sequence, and the term "native" polynucleotide or polypeptide is intended to mean a naturally
occurring nucleotide sequence or amino acid sequence,
respectively. By "fragment" is intended a portion of a polynucleotide or a portion of an amino acid sequence and hence
protein encoded thereby.
As used herein, the term "plant part" includes plant cells,
plant protoplasts, plant cell tissue cultures from which a
whole plant can be regenerated, plant calli, plant clumps, and
plant cells that are intact in plants or parts of plants such as
embryos, pollen, anthers, ovules, seeds, leaves, flowers,
stems, branches, fruit, roots, root tips, and the like. Progeny,
variants, and mutants of regenerated plants are also included

within the scope of the invention, provided that these comprise the introduced nucleic acid sequences of the invention.
By "phenotypic change" is intended a measurable change
in one or more cell functions. For example, plants having a
genetic modification at the genomic locus encoding a cytochrome P450 polypeptide of the invention can show reduced
or eliminated expression or activity of that cytochrome P450
polypeptide.
The term "introducing" is intended to mean presenting to
the plant the polynucleotide or polypeptide in such a manner
that the sequence gains access to the interior of a cell of the
plant.
The term "operably linked" is intended to mean a functional linkage between two or more elements. For example,
an operable linkage between a polynucleotide of interest and
a regulatory sequence (i.e., a promoter) is a functional link
that allows for expression of the polynucleotide of interest.
Operably linked elements may be contiguous or non-contiguous. When used to refer to the joining of two protein coding
regions, by operably linked is intended that the coding regions
are in the same reading frame.
The term "heterologous" according to the present invention when used in reference to a sequence is intended to mean
a sequence that originates from a foreign species, or, if from
the same species, is substantially modified from its native
form in composition and/or genomic locus by deliberate
human intervention. The term also is applicable to nucleic
acid constructs, also referred to herein as "polynucleotide
constructs" or "nucleotide constructs." In this manner, a "heterologous" nucleic acid construct is intended to mean a construct that originates from a foreign species, or, if from the
same species, is substantially modified from its native form in
composition and/or genomic locus by deliberate human intervention. Heterologous nucleic acid constructs include, but are
not limited to, recombinant nucleotide constructs that have
been introduced into a plant or plant part thereof, for example,
via transformation methods or subsequent breeding of a
transgenic plant with another plant of interest.
For example, a promoter operably linked to a heterologous
polynucleotide is from a species different from the species
from which the polynucleotide was derived, or, if from the
same/analogous species, one or both are substantially modified from their original form and/or genomic locus, or the
promoter is not the native promoter for the operably linked
polynucleotide. Furthermore, as used herein a chimeric gene
comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding
sequence.
The term "expression" as used herein refers to the biosynthesis of a gene product, including the transcription and/or
translation of said gene product. For example, for the purposes of the present invention, an expression cassette, as
described elsewhere herein, capable of expressing a polynucleotide that inhibits the expression of at least one cytochrome P450 polypeptide of the invention is an expression
cassette capable of producing an RNA molecule that inhibits
the transcription and/or translation of at least one cytochrome
P450 polypeptide. The "expression" or "production" of a
protein or polypeptide from a DNA molecule refers to the
transcription and translation of the coding sequence to produce the protein or polypeptide, while the "expression" or
"production" of a protein or polypeptide from an RNA molecule refers to the translation of the RNA coding sequence to
produce the protein or polypeptide.

10

15

20

25

30

35

40

45

50

55

60

65

US 9,187,759 B2
9

10

Cytochrome 450 Polynucleotides and Polypeptides, and Variants and Fragments Thereof
Compositions of the present invention include isolated
cytochrome P450 polynucleotides and polypeptides that are
involved in the metabolic conversion of nicotine to nomicotine in plants, including commercial varieties of tobacco
plants. In particular, compositions of the invention include
isolated polypeptides comprising the amino acid sequences
as shown in SEQ ID NOS:2, 4, 6, 8, 10, and 12, and isolated
polynucleotides comprising the nucleotide sequences as
shown in SEQ ID NOS: 1, 3, 5, 7, 9, and 11. The polynucleotides of the invention find use in inhibiting expression of
these cytochrome P450 polypeptides or variants thereof that
are involved in the metabolic conversion of nicotine to nornicotine in plants, particularly tobacco plants.
In this manner, the invention further provides expression
cassettes comprising all or a portion of the polynucleotide
sequence set forth in SEQ ID N0:1, 3, 5, 7, 9, or 11, a
complement or fragment thereof, or a sequence having substantial sequence identity to SEQIDN0:1, 3, 5, 7, 9, or 11, or
a complement or fragment thereof, operably linked to a promoter that is functional in a plant cell for use in expressing an
inhibitory RNA transcript that interferes with expression (i.e.,
transcription and/or translation) of cytochrome P450
polypeptides described herein. In some embodiments, the
expression cassettes comprise the nucleotide sequence as
shown in SEQ ID N0:13, 14, 15, or 16, a complement or
fragment thereof, or a sequence having substantial sequence
identity to SEQ ID N0:13, 14, 15, or 16, or a complement or
fragment thereof. Introduction of these expression cassettes
into a Nicotiana plant of interest, particularly a tobacco plant
of varieties commonly known as flue or bright varieties, Burley varieties, dark varieties, and oriental/Turkish varieties,
results in the production of tobacco plants having reduced
amounts of nomicotine and the nitrosamine, N'-nitrosonornicotine (NNN). Leaf and stem material from these transgenic
plants can be used to produce a variety of tobacco products
having reduced levels of nornicotine, and a concomitant
reduction in this carcinogenic nitrosamine metabolite.
The cytochrome P450 polynucleotides and encoded
polypeptides of the present invention represent a novel cytochrome P450 gene family, designated the 3D_C12 cytochrome 450 gene family, that is newly identified as having a
role in the metabolic conversion of nicotine to nomicotine in
tobacco plants. Suppression of the expression of their
encoded gene products in transgenic tobacco plants results in
a significant reduction in the accumulation of nomicotine in
the leaves of these transgenic plants. While not being bound
by theory, the metabolic role of these polypeptides may be a
direct one, i.e., directly catalyzing the N-demethylation reaction, or an indirect one, i.e., in the form of production of a
product that leads to the up-regulation of the nicotine demethylase activity of the leaf. Regardless of the mechanism,
any means by which expression and/or function of the
polypeptides encoded by members of this cytochrome P450
gene family are targeted for inhibition within a Nicotiana
plant will be effective in reducing nomicotine levels, and
levels of its carcinogenic metabolite, NNN, within leaves and
stems of these plants.
The cytochrome P450 genes of the invention were isolated
from tobacco lines of a Burley variety. The first of these
cytochrome P450 genes, designated 3D_C12, encodes an
mRNA transcript corresponding to nucleotides (nt) 1-1551 of
the eDNA sequence set forth in SEQ ID NO: 1, which codes
for the full-length 517-residue polypeptide set forth in SEQ
ID N0:2. The second member of this novel cytochrome P450
family, designated 3D_C12-1 0, encodes an mRNA transcript

corresponding to nt 1-1551 of the eDNA sequence set forth in
SEQ ID N0:3, which codes for the full-length 517-residue
polypeptide set forth in SEQ ID N0:4. The third of these
cytochrome P450 genes, designated 3D_C12-7, encodes an
mRNA transcript corresponding to nt 1-1551 of the eDNA
sequence set forth in SEQ ID N0:5, which codes for the
full-length 517 residue polypeptide set forth in SEQ ID N0:6.
The fourth member of the novel cytochrome P450 family,
designated 7D_A06, encodes an mRNA transcript corresponding to nt 1-1554 of the eDNA sequence set forth in SEQ
ID N0:7, which codes for the full-length 518-residue
polypeptide set forth in SEQ ID N0:8.
Two partial-length P450 gene sequences sharing high
sequence identity to the full-length members of the 3D_C12
cytochrome P450 gene family were also isolated from these
Burley tobacco lines. The first of these, designated 3D_C1215, encodes an mRNA transcript corresponding to the eDNA
sequence set forth in SEQ ID N0:9, which encodes the partial-length polypeptide set forth in SEQ ID NO: 10. The second partial-length P450 gene sequence, designated
131A_A02, encodes an mRNA transcript corresponding to
the eDNA sequence set forth in SEQ ID NO: 11, which
encodes the partial-length polypeptide set forth in SEQ ID
N0:12.
In one aspect, the cytochrome P450 genes of the present
invention are involved in the conversion of nicotine to nornicotine in a plant. In one aspect, the cytochrome P450 genes of
the present invention have nicotine demethylase activity.
An alignment of the members of the 3D_C12 cytochrome
P450 gene family is shown in FIGS. 3A-3G. The predicted
amino acid sequences for the four full-length clones are
aligned in FIG. 4. These sequences share high sequence identity with each other (at least 90% at both the nucleotide and
amino acid level (see Tables 2 and 3, Example 4 herein
below).
The invention encompasses isolated or substantially purified polynucleotide or protein compositions. An "isolated" or
"purified" polynucleotide or protein, or biologically active
portion thereof, is substantially or essentially free from components that normally accompany or interact with the polynucleotide or protein as fonnd in its naturally occurring environment. Thus, an isolated or purified polynucleotide or
protein is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or
substantially free of chemical precursors or other chemicals
when chemically synthesized. Optimally, an "isolated" polynucleotide is free of sequences (optimally protein encoding
sequences) that naturally flank the polynucleotide (i.e.,
sequences located at the 5' and 3' ends of the polynucleotide)
in the genomic DNA of the organism from which the polynucleotide is derived. For example, in various embodiments,
the isolated polynucleotide can contain less than about 5 kb,
4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or0.1 kb of nucleotide sequence
that naturally flank the polynucleotide in genomic DNA of the
cell from which the polynucleotide is derived. A protein that
is substantially free of cellular material includes preparations
of protein having less than about 30%, 20%, 10%, 5%, or 1%
(by dry weight) of contaminating protein. When the protein of
the invention or biologically active portion thereof is recombinantly produced, optimally culture medium represents less
than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of
chemical precursors or non-protein-of-interest chemicals.
Fragments of the disclosed cytochrome P450 polynucleotides and polypeptides encoded thereby are also encompassed by the present invention. Fragments of a polynucleotide may encode protein fragments that retain the biological
activity of the native protein and hence are involved in the
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metabolic conversion of nicotine to nornicotine in a plant.
Alternatively, fragments of a polynucleotide that are useful as
hybridization probes or PCR primers using methods
described below generally do not encode fragment proteins
retaining biological activity. Furthermore, fragments of the
disclosed nucleotide sequences include those that can be
assembled within recombinant constructs for use in gene
silencing with any method known in the art, including, but not
limited to, sense suppression/cosuppression, antisense suppression, double-stranded RNA (dsRNA) interference, hairpin RNA interference and intron-containing hairpin RNA
interference, amplicon-mediated interference, ribozymes,
and small interfering RNA or micro RNA, as described herein
below. Thus, fragments of a cytochrome P450 polynucleotide
sequence may range from at least about 20 nucleotides, about
50 nucleotides, about 70 nucleotides, about 100 nucleotides,
about 150 nucleotides, about 200 nucleotides, about 250
nucleotides, about 300 nucleotides, about 350 nucleotides,
about 400 nucleotides, and up to the full-length polynucleotide encoding the proteins of the invention, depending upon
the desired outcome. In one aspect, the fragments of a cytochrome P450 polynucleotide sequence can be a fragment of
between about 50 and about 400 nucleotides, between about
70 and about 350 nucleotides, between about 90 and about
325 nucleotides, between about 90 and about 300 nucleotides, between about 90 and about 27 5 nucleotides, between
about 100 and about 400 nucleotides, between about 100 and
about 350 nucleotides, between about 100 and about 325
nucleotides, between about 100 and about 300 nucleotides,
between about 125 and about 300 nucleotides, or between
about 125 and about 275 nucleotides in length. In some
embodiments, a fragment of a cytochrome P450 polynucleotide is about 50, about 60, about 70, about 80, about 90,
about100,about125,about150,about175,about200,about
225,about250,about275,about300,about325,about350,
about 400 nucleotides in length, and other such values
between about 70 and about 400 nucleotides. In one such
embodiment, a fragment of a cytochrome P450 polynucleotide of the invention is about 90 bp to about 110 bp in length,
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,
103, 104, 105, 106, 107, 108, 109, and 110 bp in length. In
another such embodiment, a fragment of a cytochrome P450
polynucleotide of the invention is about 290 to about 310 bp
in length, including 290, 291, 292, 293, 294, 295, 296, 297,
298,299,300,301,302,303,304,305,306,307,308,309,
and 310 bp in length.
A fragment of a cytochrome P450 polynucleotide of the
present invention that encodes a biologically active portion of
a cytochrome P450 polypeptide of the present invention will
encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 200,
250,300,350,400,450, or 500 contiguous amino acids, or up
to the total number of amino acids present in a full-length
cytochrome P450 polypeptide of the invention (e.g., 517 for
SEQ ID NOS: 2, 4, and 6; and 518 for SEQ ID N0:8), or will
encode at least 15, 25, 30, 50, 75, 100, 125, 150, or up to the
total number of amino acids present in a partial-length cytochrome P450 polypeptide of the invention (e.g., 173 for SEQ
ID N0:10; and 222 for SEQ ID N0:12). In one aspect, a
fragment of a cytochrome P450 polynucleotide of the invention encodes a polypeptide that comprises position 329 of the
encoded polypeptide sequence. In another aspect, the polynucleotide fragment encodes a fragment of a cytochrome
P450 polypeptide, where the polypeptide fragment comprises
the amino acids from position 225 through the amino acid at
about position 600 of SEQ ID N0:6. In one such embodiment, the polynucleotide fragment encodes a fragment of a
cytochrome P450 polypeptide, where the polypeptide frag-

ment comprises the amino acids from about position 239
through the amino acid at about position 402 of SEQ ID
N0:6. A biologically active portion of a cytochrome P450
polypeptide can be prepared by isolating a portion of one of
the cytochrome P450 polynucleotides of the present invention, expressing the encoded portion of the cytochrome P450
polypeptide (e.g., by recombinant expression in vitro), and
assessing the activity of the encoded portion of the cytochrome P450 polypeptide, i.e., the ability to promote conversion of nicotine to nomicotine, using assays known in the art
and those provided herein below.
Polynucleotides that are fragments of a cytochrome P450
nucleotide sequence of the present invention comprise at least
16, 20, 50, 75,100,150,200,250,300,350,400,450,500,
550, 600,650,700, 800, 900, 950, 1000, 1050, 1100, 1150,
1200,1250,1300,1350,1400,1450,1500,1550,1600,1650,
or 1700 contiguous nucleotides, or up to the number of nucleotides present in a full-length cytochrome P450 polynucleotide as disclosed herein (e.g., 539 for SEQ ID NO: 9; 666 for
SEQ ID NO: 11; 1733 for SEQ ID NOS: 1, 3, and 5; and 1727
for SEQ ID N0:7). Polynucleotides that are fragments of a
cytochrome P450 nucleotide sequence of the present invention comprise fragments from about 20 to about 1700 contiguous nucleotides, from about 50 to about 1600 contiguous
nucleotides, from about 75 to about 1500 contiguous nucleotides, from about 100 to about 1400 nucleotides, from about
150 to about 1300 contiguous nucleotides, from about 150 to
about 1200 contiguous nucleotides, from about 17 5 to about
1100 contiguous nucleotides, or from about 200 to about
1000 contiguous nucleotides from a cytochrome P450 polynucleotide as disclosed herein.
In one aspect, fragments of a cytochrome P450 polynucleotide comprise a polynucleotide sequence containing the
nucleotides from about position 700 to about position 1250 of
a cytochrome P450 coding sequence. In another aspect, fragments of a cytochrome P450 polynucleotide comprise a polynucleotide sequence containing the nucleotides from about
position 715 to about position 1210, or from about position
717 to about position 1207 of a cytochrome P450 coding
sequence disclosed herein.
In other embodiments of the invention, fragments of a
cytochrome P450 polynucleotide comprise a polynucleotide
sequence containing the nucleotides from about position 265
to about position 625 of a cytochrome P450 coding sequence
disclosed herein, or a complement thereof. In some of these
embodiments, the fragments of a cytochrome P450 coding
sequence disclosed herein comprise the nucleotides corresponding to about position 297 to about position 594 of the
P450 coding sequence set forth in SEQ ID N0:3 or SEQ ID
N0:5, or a complement thereof.
In yet other embodiments of the invention, fragments of a
cytochrome P450 polynucleotide comprise a polynucleotide
sequence containing the nucleotides from about position
1420 to about position 1580 of a cytochrome P450 coding
sequence disclosed herein, or a complement thereof. In some
of these embodiments, the fragments of a cytochrome P450
coding sequence disclosed herein comprise the nucleotides
corresponding to about position 1453 to about position 1551
of the P450 coding sequence set forth in SEQ ID NO: 1, or a
complement thereof.
Variants of the disclosed polynucleotides and polypeptides
encoded thereby are also encompassed by the present invention. Such naturally occurring variants include those variants
that share substantial sequence identity to the disclosed cytochrome P450 polynucleotides and polypeptides disclosed
herein as defined herein below. The compositions and methods of the invention can be used to target expression or func-
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tion of any naturally occurring cytochrome P450 that shares
substantial sequence identity to the disclosed cytochrome
P450 polypeptides and which possesses the relevant cytochrome P450 activity, i.e., involvement in the metabolic conversion of nicotine to nornicotine in plants. Such variants may
result from, for example, genetic polymorphism or from
human manipulation as occurs with breeding and selection.
Biologically active variants of a cytochrome P450 protein of
the invention, for example, variants of the polypeptide set
forth in SEQ ID N0:2, 4, 6, 8, 10, or 12, will have at least
about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99% or more sequence identity to the amino acid sequence for
the native protein as determined by sequence alignment programs and parameters described elsewhere herein, and are
characterized by their functional involvement in the metabolic conversion of nicotine to nornicotine in plants. A biologically active variant of a protein of the invention may differ
from that protein by as few as 1-15 amino acid residues, as
few as 10, as few as 9, as few as 8, as few as 7, as few as 6, as
few as 5, as few as 4, as few as 3, as few as 2, or as few as 1
amino acid residue.
Variants of a particular polynucleotide of the present invention include those naturally occurring polynucleotides that
encode a cytochrome P450 polypeptide that is involved in the
metabolic conversion of nicotine to nornicotine in plants.
Such polynucleotide variants can comprise a deletion and/or
addition of one or more nucleotides at one or more sites
within the native polynucleotide disclosed herein and/or a
substitution of one or more nucleotides at one or more sites in
the native polynucleotide. Because of the degeneracy of the
genetic code, conservative variants for polynucleotides
include those sequences that encode the amino acid sequence
of one of the cytochrome P450 polypeptides of the invention.
Naturally occurring variants such as these can be identified
with the use ofwell-knownmolecularbiology techniques, as,
for example, with polymerase chain reaction (PCR) and
hybridization techniques as outlined below. Variant polynucleotides also include synthetically derived polynucleotides, such as those generated, for example, by using sitedirected mutagenesis but which still share substantial
sequence identity to the naturally occurring sequences disclosed herein, and thus can be used in the methods of the
invention to inhibit the expression or function of a cytochrome P450 that is involved in the metabolic conversion of
nicotine to nornicotine, including the cytochrome P450
polypeptides set forth in SEQ ID NOS:2, 4, 6, and 8, and
polypeptides comprising the sequence set forth in SEQ ID
NO: 10 or 12. Generally, variants of a particular polynucleotide of the invention, for example, the sequence set forth in
SEQ ID N0:1, 3, 5, 7, 9, or 11, will have at least about 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more
sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters
described elsewhere herein.
Variants of a particular polynucleotide of the present invention (also referred to as the reference polynucleotide) can also
be evaluated by comparison of the percent sequence identity
between the polypeptide encoded by the reference polynucleotide and the polypeptide encoded by a variant polynucleotide. For example, isolated polynucleotides encoding a
polypeptide with a particular percent sequence identity to the
full-length polypeptide of SEQ ID N0:2, 4, 6, or 8, or the
partial-length polypeptide encoded by SEQ ID N0:9 or 11
are disclosed. Such polynucleotides can be used in the methods of the present invention to target expression of cyto-

chrome P450 polypeptides involved in the metabolic conversion of nicotine to nornicotine in plants, particularly tobacco
plants, thereby inhibiting accumulation of nornicotine and its
metabolite N'-nitrosonornicotine in the stems and leaves of
the genetically modified plant. Percent sequence identity
between any two polypeptides can be calculated using
sequence alignment programs and parameters described elsewhere herein. Where any given pair of polynucleotides of the
invention is evaluated by comparison of the percent sequence
identity shared by the two polypeptides they encode, the
percent sequence identity between the two encoded polypeptides is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99% or more sequence identity. In one aspect, a
variant polypeptide of the present invention includes a
polypeptide having a tryptophan at position 329 or an isoleucine at position 274 of the cytochrome P450 polypeptide, or
both a tryptophan at position 329 and an isoleucine at position
274.
Furthermore, the polynucleotides of the invention can be
used to isolate corresponding cytochrome P450 sequences
from other organisms, particularly other plants, more particularly other members of the Nicotiana genus. PCR, hybridization, and other like methods can be used to identifY such
sequences based on their sequence homology to the
sequences set forth herein. Sequences isolated based on their
sequence identity to the nucleotide sequences set forth herein
or to variants and fragments thereof are encompassed by the
present invention. Such sequences include sequences that are
orthologs of the disclosed sequences.
According to the present invention, "orthologs" are genes
derived from a common ancestral gene and which are found
in different species as a result of speciation. Genes found in
different species are considered orthologs when their nucleotide sequences and/or their encoded protein sequences share
at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99%, or greater sequence identity. Functions of orthologs are often highly conserved among
species. Thus, isolated polynucleotides that encode for a cytochrome P450 polypeptide that is involved in the nicotine-tonornicotine metabolic conversion and which hybridize under
stringent conditions to the cytochrome P450 sequences disclosed herein, or to variants or fragments thereof, are encompassed by the present invention. Such sequences can be used
in the methods of the present invention to inhibit expression
of cytochrome P450 polypeptides that are involved in the
metabolic conversion of nicotine to nornicotine in plants.
Using PCR, oligonucleotide primers can be designed for
use in PCR reactions to amplify corresponding DNA
sequences from eDNA or genomic DNA extracted from any
plant of interest. Methods for designing PCR primers and
PCR cloning are generally known in the art and are disclosed
in Sambrook eta!. (1989) Molecular Cloning: A Laboratory
Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.). Innis et a!., eds. (1990) PCR Protocols: A
Guide to Methods and Applications (Academic Press, New
York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999)
PCR Methods Manual (Academic Press, New York). Known
methods ofPCR include, but are not limited to, methods using
paired primers, nested primers, single specific primers,
degenerate primers, gene-specific primers, vector-specific
primers, partially mismatched primers, and the like.
Hybridization techniques involve the use of all or part of a
known polynucleotide as a probe that selectively hybridizes
to other corresponding polynucleotides present in a popula-
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tion of cloned genomic DNA fragments or eDNA fragments
(i.e., genomic or eDNA libraries) from a chosen organism.
Hybridization may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization
conditions" is intended conditions under which a probe will
hybridize to its target sequence to a detectably greater degree
than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and
will be different in different circumstances. By controlling
the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the
probe can be identified (homologous probing). Alternatively,
stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are
detected (heterologous probing). Generally, a probe is less
than about 1000 nucleotides in length, optimally less than 500
nucleotides in length.
Typically, stringent conditions will be those in which the
salt concentration is less than about 1.5 M Na ion, typically
about 0.01 to 1.0 M Na ion concentration (or other salts) at pH
7.0 to 8.3 and the temperature is at least about 30° C. Stringent
conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency
conditions include hybridization with a buffer solution of30
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl
sulphate) at 37° C., and a wash in 1x to 2xSSC (20xSSC=3.0
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary
moderate stringency conditions include hybridization in 40 to
45% formamide, 1.0 MNaCl, 1% SDS at 37° C., and a wash
in 0.5x to 1xSSC at 55 to 60° C. Exemplary high stringency
conditions include hybridization in 50% formamide, 1 M
NaCl, 1% SDS at 37° C., and a washin0.1xSSC at 60 to 65°
C. Optionally, wash buffers may comprise about 0.1% to
about 1% SDS. Duration of hybridization is generally less
than about 24 hours, usually about 4 to about 12 hours. The
duration of the wash time will be at least a length of time
sufficient to reach equilibrium.
In a specific embodiment, stringency conditions include
hybridization in a solution containing 5xSSC, 0.5% SDS,
5xDenhardt's, 0.45 flg/fll Poly ARNA, 0.45 flg/fll calf thymus
DNA and 50% formamide at 42° C., and at least one posthybridization wash in a solution comprising from about 0.01 x
SSC to about 1xSSC. The duration of hybridization is from
about 14 to about 16 hours.
Specificity is typically the function of post-hybridization
washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids,
the T m can be approximated from the equation of Meinkoth
and Wahl (1984) Anal. Biochem. 138:267-284: Tm=81.5°
C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-500/L; where
M is the molarity of monovalent cations, % GC is the percentage of guanosine and cytosine nucleotides in the DNA, %
form is the percentage of formamide in the hybridization
solution, and Lis the length of the hybrid in base pairs. The T m
is the temperature (under defined ionic strength and pH) at
which 50% of a complementary target sequence hybridizes to
a perfectly matched probe. T m is reduced by about 1o C. for
each 1% of mismatching; thus, Tm' hybridization, and/or
wash conditions can be adjusted to hybridize to sequences of
the desired identity. For example, if sequences with ;;:90%
identity are sought, the T m can be decreased 10° C. Generally,
stringent conditions are selected to be about so C. lower than
the thermal melting point (T m) for the specific sequence and
its complement at a defined ionic strength and pH. However,
severely stringent conditions can utilize a hybridization and/
or wash at 1, 2, 3, or4° C. lower than thethermalmeltingpoint
(Tm); moderately stringent conditions can utilize a hybridiza-

tion and/or wash at 6, 7, 8, 9, or 10° C. lower than the thermal
melting point (T m); low stringency conditions can utilize a
hybridization and/or wash at 11, 12, 13, 14, 15, or 20° C.
lower than the thermal melting point (Tm). Using the equation, hybridization and wash compositions, and desired T m'
those of ordinary skill will understand that variations in the
stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results
in a T m of less than 45° C. (aqueous solution) or 32° C.
(formamide solution), it is optimal to increase the sse concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in
Tijssen (1993) Laboratory Techniques in Biochemistry and
Molecular Biology-Hybridization with Nucleic Acid
Probes, Part I, Chapter 2 (Elsevier, N.Y.); andAusubel eta!.,
eds. (1995) Current Protocols in Molecular Biology, Chapter
2 (Greene Publishing and Wiley-Interscience, New York).
See Sambrook eta!. (1989) Molecular Cloning: A Laboratory
Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
Hybridization probes may be genomic DNA fragments,
eDNA fragments, RNA fragments, or other oligonucleotides,
and may be labeled with a detectable group such as 32 P, or any
other detectable marker. For example, probes for hybridization can be made by labeling synthetic oligonucleotides based
on the cytochrome P450 polynucleotides sequences of the
present invention. Methods for preparation of probes for
hybridization and for construction of eDNA and genomic
libraries are generally known in the art and are disclosed in
Sambrook et a!. (1989) Molecular Cloning: A Laboratory
Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
For example, the cytochrome P450 polynucleotide
sequences disclosed herein, or one or more portions thereof,
may be used as probes capable of specifically hybridizing to
corresponding cytochrome P450 polynucleotides and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are
unique among cytochrome P450 polynucleotide sequences,
including upstream regions 5' to the coding sequence and
downstream regions 3' to the coding sequence, and are optimally at least about 10 nucleotides in length, and most optimally at least about 20 nucleotides in length. Such probes
may be used to amplifY corresponding cytochrome P450
polynucleotides. This technique may be used to isolate additional coding sequences from a desired plant or as a diagnostic assay to determine the presence of coding sequences in a
plant. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see,
for example, Sambrook eta!. (1989) Molecular Cloning: A
Laboratory Manual (2d ed., Cold Spring Harbor Laboratory
Press, Plainview, N.Y.).
As used herein, with respect to the sequence relationships
between two or more polynucleotides or polypeptides, the
term "reference sequence" is a defined sequence used as a
basis for sequence comparison. A reference sequence may be
a subset or the entirety of a specified sequence; for example,
as a segment of a full-length eDNA or gene sequence, or the
complete eDNA or gene sequence.
As used herein, the term "comparison window" makes
reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in
the comparison window may comprise additions or deletions
(i.e., gaps) compared to the reference sequence (which does
not comprise additions or deletions) for optimal alignment of
the two polynucleotides. Generally, the comparison window
is at least 20 contiguous nucleotides in length, and optionally
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can be 30, 40, 50, 100, or longer. Those of skill in the art
understand that to avoid a high similarity to a reference
sequence due to inclusion of gaps in the polynucleotide
sequence a gap penalty is typically introduced and is subtracted from the number of matches.
Methods of alignment of sequences for comparison are
well known in the art. Thus, the determination of percent
sequence identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting
examples of such mathematical algorithms are the algorithm
ofMyers and Miller (1988) CABIOS 4: 11-17; the local alignment algorithm of Smith eta!. (1981 )Adv. Appl. Math. 2:482;
the global alignment algorithm of Needleman and Wunsch
(1970) J. Mol. Biol. 48:443-453; the search-for-local alignment method ofPearson and Lipman (1988) Proc. Nat!. A cad.
Sci. 85:2444-2448; the algorithm of Karlin and Altschul
(1990) Proc. Nat!. Acad. Sci. USA 872264, modified as in
Karlin and Altschul (1993) Proc. Nat!. Acad. Sci. USA
90:5873-5877.
The BLAST programs ofAltschul eta!. (1990) J. Mol. Biol.
215:403 are based on the algorithm of Karlin and Altschul
(1990) supra. BLAST nucleotide searches can be performed
with the BLASTN program, score=100, wordlength=12, to
obtain nucleotide sequences homologous to a nucleotide
sequence encoding a protein of the invention. BLAST protein
searches can be performed with the BLASTX program,
score=50, wordlength=3, to obtain amino acid sequences
homologous to a protein or polypeptide of the invention. To
obtain gapped alignments for comparison purposes, Gapped
BLAST (in BLAST 2.0) can be utilized as described in Altschul eta!. (1997) Nucleic Acids Res. 25:3389. Alternatively,
PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et a!. (1997) supra. When utilizing
BLAST, Gapped BLAST, PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for proteins) can be used (See
www.ncbi.nlm.nih.gov). Alignment may also be performed
manually by inspection.
The sequence identity/similarity values provided herein
were calculated using the BLASTX (Altschul et a!. (1997)
supra), Clustal W (Higgins eta!. (1994) Nucleic Acids Res.
22: 4673-4680), and GAP (University of Wisconsin Genetic
Computing Group software package) algorithms using
default parameters. The present invention also encompasses
the use of any equivalent program thereof for the analysis and
comparison of nucleic acid and protein sequences. By
"equivalent program" is intended any sequence comparison
program that, for any two sequences in question, generates an
aligrm1ent having identical nucleotide or amino acid residue
matches and an identical percent sequence identity when
compared to the corresponding alignment generated by
BLASTX, Clustal W, or GAP.
For purposes of the foregoing discussion of variant nucleotide and polypeptide sequences encompassed by the present
invention, the term "sequence identity" or "identity" in the
context of two polynucleotides or polypeptide sequences
makes reference to the residues in the two sequences that are
the same when aligned for maximum correspondence over a
specified comparison window. When percentage of sequence
identity is used in reference to proteins it is recognized that
residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues
are substituted for other amino acid residues with similar
chemical properties (e.g., charge or hydrophobicity) and
therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions,

the percent sequence identity may be adjusted upwards to
correct for the conservative nature of the substitution.
Sequences that differ by such conservative substitutions are
said to have "sequence similarity" or "similarity." Means for
making this adjustment are well known to those of skill in the
art. Typically this involves scoring a conservative substitution
as a partial rather than a full mismatch, thereby increasing the
percentage sequence identity. Thus, for example, where an
identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative
substitution is given a score between zero and 1. The scoring
of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain
View, Calif.).
The term "percentage of sequence identity" as used herein
means the value determined by comparing two optimally
aligned sequences over a comparison window, wherein the
portion of the polynucleotide sequence in the comparison
window may comprise additions or deletions (i.e., gaps) as
compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two
sequences. The percentage is calculated by determining the
number of positions at which the identical nucleic acid base or
amino acid residue occurs in both sequences to yield the
number of matched positions, dividing the number of
matched positions by the total number of positions in the
window of comparison, and multiplying the result by 100 to
yield the percentage of sequence identity.
When any two polypeptide sequences are optimally
aligned for comparison, it is recognized that residues appearing opposite of one another within the alignment occupy
positions within their respective polypeptides that correspond
to one another. Such positions are referred to herein as "corresponding positions" and the residues residing at corresponding positions are referred to as "corresponding residues" or residues that "correspond" to one another. Thus, for
example, where a polypeptide of interest is optimally aligned
to a reference polypeptide sequence having, for example, 10
residues, the residue within the polypeptide of interest
appearing opposite residue 5 of the reference sequence is
referred to as the "residue at the position corresponding to
residue 5" of the reference sequence.
In like mauner, when any two polynucleotide sequences
are optimally aligned for comparison, it is recognized that the
nucleotides appearing opposite of one another within the
alignment occupy positions within their respective polynucleotide positions that correspond to one another. Such
positions are referred to herein as "corresponding positions"
and the nucleotides residing at corresponding positions are
referred to as "corresponding nucleotides" or nucleotides that
"correspond" to one another. Thus, for example, where a
polynucleotide of interest is optimally aligned to a reference
polynucleotide sequence having, for example, 300 nucleotides, the nucleotide within the polynucleotide of interest
appearing opposite nucleotide 275 of the reference sequence
is referred to as the "nucleotide at the position corresponding
to nucleotide 275" of the reference sequence.
Where a region of nucleotides is being compared between
a polynucleotide of interest and a reference polynucleotide,
the nucleotides within these regions are said to "correspond"
to one another. Thus, for example, where a region of a reference polynucleotide sequence, for example, the polynucleotide sequence set forth in SEQ ID N0:5, resides from nucleotide position 265 to nucleotide position 625 of the reference
polynucleotide, and this region ofnucleotides is being compared to the corresponding region of nucleotides within an
optimally aligned polynucleotide sequence of interest, the
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nucleotides within the corresponding region of the polynucleotide of interest are referred to herein as "a region" of the
polynucleotide of interest that "corresponds to nucleotide
position 265 to nucleotide position 625" of the reference
sequence, in this case, SEQ ID N0:5.
Cytochrome P450 polynucleotide and polypeptide
sequences can be identified using the sequences provided
herein. Such methods include obtaining a polynucleotide or
polypeptide sequence at least 80%, 85%, 90%, 95%, 98%,
99% sequence identity with the polynucleotide sequence of
SEQ ID NO 1, 3, 5, 7, 9, or 11 or a complement or fragment
thereof, or a polypeptide sequence of SEQ ID N0:2, 4, 6, 7,
10, or 12. In one embodiment, the identified sequence contains or encodes for a tryptophan residue at position 329 and
an isoleucine residue at position 274.
In this manner, one aspect of the present invention is
directed to a method of screening for a nicotine demethylase
sequence. This method comprises obtaining a nucleic acid
sequence that has greater than about 90% sequence identity
with SEQ ID N0:3 or SEQ ID N0:5; and identifYing within
this nucleic acid sequence a codon sequence encoding for a
tryptophan residue at position 329 of the polypeptide encoded
by the nucleic acid sequence. In some embodiments, this
nucleic acid sequence also encodes an isoleucine at position
27 4 of the encoded polypeptide. Any suitable method known
in the art can be usedto identify the codon sequence encoding
the tryptophan or isoleucine residue. In one embodiment, the
codon sequence is identified by a method selected from the
group consisting of identifYing a single nucleotide polymorphism and RT-PCR. In some embodiments of this aspect of
the invention, the screening method identifies a nicotine demethylase that converts nicotine to nomicotine at a rate that is at
least about 5-fold greater than the conversion rate of the
nicotine demethylase encoded by SEQ ID N0:3 (polypeptide
set forth in SEQ ID N0:4) or SEQ ID N0:5 (polypeptide set
forth in SEQ ID N0:6). In particular embodiments, the nicotine demethylase identified with this screening method has a
conversion rate that is at least about 8-fold greater than the
conversion rate of the nicotine demethylase encoded by SEQ
ID N0:3 or SEQ ID N0:5.
In another aspect, the present invention provides a method
for screening for a nicotine demethylase having an isoleucine
at position 274 or a tryptophan at position 329 of the polypeptide. This method comprises obtaining a nucleic acid
sequence that has greater than about 90% sequence identity
with SEQ ID N0:3 or SEQ ID N0:5; and identifying a first
codon sequence encoding for an isoleucine residue at position
274 of the encoded polypeptide or a second codon sequence
encoding a tryptophan residue at position 329 of the encoded
polypeptide. As noted above, any suitable method known to
those of skill in the art can be used to identify these codons. In
one embodiment, either or both of the first and second codons
are identified by a method selected from the group consisting
of identifYing a single nucleotide polymorphism and RTPCR. In some embodiments of this aspect of the invention, the
screening method identifies a nicotine demethylase that converts nicotine to nornicotine at a rate that is at least about
5-fold greater than the conversion rate of the nicotine demethylase encoded by SEQ ID N0:3 (polypeptide set forth in
SEQ ID N0:4) or SEQ ID NO: 5 (polypeptide set forth in SEQ
ID N0:6). In particular embodiments, the nicotine demethylase identified with this screening method has a conversion
rate that is at least about 8-fold greater than the conversion
rate of the nicotine demethylase encoded by SEQ ID N0:3 or
SEQIDN0:5.
The present invention also provides transgenic plant cells,
plants, and seed comprising a nucleic acid molecule having a

promoter functional in a plant cell and a nucleic acid sequence
encoding a nicotine demethylase having an isoleucine residue
at position 274 and a tryptophan residue at position 329. In
some embodiments, the nucleic acid sequence encoding this
nicotine demethylase is derived from a sequence selected
from the group consisting of SEQ ID N0:3, SEQ ID N0:5,
and SEQ ID N0:7. These transgenic plant cells, plants, and
seed include, but are not limited to, Nicotiana plant cells,
Nicotiana plants, and seed of Nicotiana plants. In some
embodiments, theNicotiana plant cells, Nicotiana plants, and
seed of Nicotiana plants are from converter Nicotiana plants.
Expression Cassettes for Use in the Methods of the Invention
Compositions of the present invention further include
expression cassettes comprising inhibitory sequences
capable of inhibiting expression or function of a cytochrome
P450 polypeptide involved in the conversion of nicotine to
nornicotine in a Nicotiana plant or plant part thereof, where
the inhibitory sequences are operably linked to a promoter
that is functional in a plant cell. In this manner, expression
cassettes comprising all or part of the sequence set forth in
SEQ ID N0:1, 3, 5, 7, 9, or 11, a complement or fragment
thereof, or sequences sharing substantial sequence identity to
SEQ ID N0:1, 3, 5, 7, 9, 11, or a complement or fragment
thereof, operably linked to a promoter that is functional in a
plant cell are constructed for use in the gene-silencing methods of the present invention described herein below. Such
sequences are referred to herein as "inhibitory sequences" or
"inhibitory polynucleotide sequences" as they are capable of
being expressed as an RNA molecule that inhibits expression
(i.e, transcription and/or translation) of the target cytochrome
P450 polypeptide, for example, the polypeptide set forth in
SEQ ID N0:2, 4, 6, or 8 and variants thereof, or a polypeptide
comprising the sequence set forth in SEQ ID NO: 10 or 12 and
variants thereof, where the variant polypeptides have substantial sequence identity to these disclosed cytochrome P450
polypeptides and are involved in the metabolic conversion of
nicotine to nomicotine in a plant.
As noted above, such inhibitory sequences include fragment sequences of the target cytochrome P450 polynucleotides. For example, a fragment sequence can include any
portion of the cytochrome P450 sequence, including coding
and non-coding sequence (e.g., 5' UTR, intron, and 3' UTR
sequences), and can include fragments of between about 20
and about 400 nucleotides, between about 50 and about 400
nucleotides, between about 100 and about 400 nucleotides,
between about 125 and about 325 nucleotides, between about
125 and about 300 nucleotides, or between about 125 and
about 275 nucleotides.
In this marmer, such inhibitory sequences include, but are
not limited, sequences that comprise a fragment of a cytochrome P450 polynucleotide sequence ranging from at least
about 20 nucleotides, about 50 nucleotides, about 70 nucleotides, about 100 nucleotides, about 150 nucleotides, about
200 nucleotides, about 250 nucleotides, about 300 nucleotides, about 350 nucleotides, and up to the full-length polynucleotide encoding the proteins of the invention, depending
upon the desired outcome. In one aspect, the inhibitory
sequences comprise a fragment of a cytochrome P450 polynucleotide sequence that is between about 50 and about 400
nucleotides, between about 50 and about 350 nucleotides,
between about 70 and about 350 nucleotides, between about
90 and about 325 nucleotides, between about 90 and about
300 nucleotides, between about 90 and about 275 nucleotides, between about 100 and about 400 nucleotides,
between about 100 and about 350 nucleotides, between about
100 and about 325 nucleotides, between about 100 and about
300 nucleotides, between about 125 and about 300 nucle-
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otides, or between about 125 and about 275 nucleotides in
length. In some embodiments, the inhibitory sequences comprise a fragment of a cytochrome P450 polynucleotide
sequencethatisabout50,about60,about70,about80,about
90, about 100, about 125, about 150, about 175, about 200,
about225,about250,about275,about300,about325,about
350, about 400 nucleotides in length, and other such values
between about 50 and about 400 nucleotides. It is recognized
that the inhibitory sequence can also comprise a sequence that
is complementary to all or a part of the fragment of the
cytochrome P450 polynucleotide sequence.
In one such embodiment, the inhibitory sequences comprise a fragment of a cytochrome P450 polynucleotide of the
invention that is about 90 bp to about 110 bp in length,
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,
103, 104, 105, 106, 107, 108, 109, and 110 bp in length, and
can also comprise a sequence that is complementary to all or
a part of the fragment sequence. In another such embodiment,
a fragment of a cytochrome P450 polynucleotide of the invention is about 290 to about 310 bp in length, including 290,
291,292,293,294,295,296,297,298,299,300,301,302,
303, 304, 305, 306, 307, 308, 309, and 310 bp in length, and
can also comprise a sequence that is complementary to all or
a part of the fragment sequence.
In other embodiments of the invention, the inhibitory
sequence within an expression cassette of the invention comprises a polynucleotide sequence containing the nucleotides
from about position 265 to about position 625 of a cytochrome P450 coding sequence disclosed herein and sequence
that is fully or partially complementary thereto. In some of
these embodiments, the inhibitory sequence comprises the
nucleotides corresponding to about position 297 to about
position 594 of the P450 coding sequence set forth in SEQ ID
N0:3 or SEQ ID N0:5 and a sequence that is fully or partially
complementary thereto. In preferred embodiments, such
inhibitory sequences are expressed as a hairpin RNA as
described herein below.
In yet other embodiments of the invention, the inhibitory
sequence within an expression cassette of the invention comprises a polynucleotide sequence containing the nucleotides
from about position 1420 to about position 1580 of a cytochrome P450 coding sequence disclosed herein and a
sequence that is fully or partially complementary thereto. In
some of these embodiments, the inhibitory sequence comprises the nucleotides corresponding to about position 1453
to about position 1551 of the P450 coding sequence set forth
in SEQ ID NO: 1 and a sequence that is fully or partially
complementary thereto. In preferred embodiments, such
inhibitory sequences are expressed as a hairpin RNA as
described herein below.
It is recognized that expression cassettes of the present
invention encompass constructs in which a desired nucleic
acid sequence is operably linked to a promoter that is functional in a plant cell, particularly in the cell of a Nicotiana
plant. By "promoter" is intended a regulatory region of DNA
usually comprising a TATA box capable of directing RNA
polymerase II to initiate RNA synthesis at the appropriate
transcription initiation site for a particular polynucleotide
sequence. A promoter may additionally comprise other recognition sequences generally positioned upstream or 5' to the
TATA box, referred to as upstream promoter elements, which
influence the transcription initiation rate. It is also recognized
that expression cassettes of the present invention encompass
additional domains that modulate the level of expression, the
developmental timing of expression, or tissue type that
expression occurs in (e.g., Australian Patent No. AU-A77751/94 and U.S. Pat. Nos. 5,466,785 and 5,635,618). By

"functional" is intended the promoter, when operably linked
to an inhibitory sequence encoding an inhibitory nucleotide
molecule (for example, a hairpin RNA, double-stranded
RNA, miRNA polynucleotide, and the like), the promoter is
capable of initiating transcription of the operably linked
inhibitory sequence such that the inhibitory nucleotide molecule is expressed. The promoters can be selected based on
the desired outcome. The nucleic acids can be combined with
constitutive, tissue-preferred, or other promoters for expression in plants.
An expression cassette of the present invention may also
contain at least one additional gene to be cotransformed into
the plant. Alternatively, the additional gene(s) can be provided on multiple expression cassettes. Such an expression
cassette is provided with a plurality of restriction sites and/or
recombination sites for insertion of the cytochrome P450
inhibitory polynucleotide sequence to be under the transcriptional regulation of the regulatory regions. The expression
cassette may additionally contain selectable marker genes.
In this manner, an expression cassette of the present invention includes a transcriptional and translational initiation
region (i.e., a promoter) in the 5'-3' direction of transcription,
an inhibitory sequence as described elsewhere herein, and a
transcriptional and translational termination region (i.e., termination region) functional in a plant cell. The regulatory
regions (i.e., promoters, transcriptional regulatory regions,
and translational termination regions) and/or the inhibitory
sequence of the invention may be native/analogous to the host
cell or to each other. Alternatively, the regulatory regions
and/or the inhibitory sequence of the invention may be heterologous to the host cell or to each other. While heterologous
promoters can be used to express the inhibitory sequences of
the invention, native promoter sequences may also be used.
The termination region may be native with the transcriptional initiation region, may be native with the operably
linked inhibitory sequence of the invention, may be native
with the plant host, or may be derived from another source
(i.e., foreign or heterologous to the promoter, the inhibitory
sequence of interest, the plant host, or any combination
thereof). Convenient termination regions are available from
the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also
Guerineau et a!. (1991) Mol. Gen. Genet. 262:141-144;
Proudfoot (1991) Cell 64:671-674; Sanfacon et a!. (1991)
Genes Dev. 5:141-149; Mogen et a!. (1990) Plant Cell
2:1261-1272; Munroe eta!. (1990) Gene 91:151-158; Ballas
eta!. (1989)NucleicAcids Res. 17:7891-7903; and Joshi eta!.
(1987) Nucleic Acids Res. 15:9627-9639.
Expression cassettes of the present invention may additionally contain 5' leader sequences that can act to enhance translation. Translation leaders are known in the art and include:
picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein eta!. (1989)
Proc. Nat!. A cad. Sci. USA 86:6126-6130); potyvirus leaders,
for example, TEV leader (Tobacco Etch Virus) (Gallie eta!.
(1995) Gene 165(2):233-238), MDMV leader (Maize Dwarf
Mosaic Virus) (Virology 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP) (Macejak et a!.
(1991) Nature 353:90-94); untranslated leader from the coat
protein mRNA of alfalfa mosaic virus (AMY RNA 4)
(Jobling eta!. (1987) Nature 325:622-625); tobacco mosaic
virus leader (TMV) (Gallie eta!. (1989) in Molecular Biology
ofRNA, ed. Cech (Liss, New York), pp. 237 -256); and maize
chlorotic mottle virus leader (MCMV) (Lamme! eta!. (1991)
Virology 81:382-385). See also, Della-Cioppa eta!. (1987)
Plant Physiol. 84:965-968. Other methods known to enhance
translation can also be utilized.
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In preparing the expression cassette, DNA fragments of the
activated by salicylic acid. Other chemical-inducible promotinvention may be manipulated so as to provide for the DNA
ers of interest include steroid-responsive promoters (see, for
sequences in the proper orientation and, as appropriate, in the
example, the glucocorticoid-inducible promoter in Schena et
a!. (1991) Proc. Nat!. Acad. Sci. USA 88:10421-10425 and
proper reading frame. Adapters or linkers may be employed
to join the DNA fragments or other manipulations may be 5 McNellis eta!. (1998) Plant J. 14(2):247-257) and tetracycline-inducible promoters (see, for example, Gatz et a!.
involved to provide for convenient restriction sites, removal
of superfluous DNA, removal of restriction sites, or the like.
(1991) Mol. Gen. Genet. 227:229-237, and U.S. Pat. Nos.
For this purpose, in vitro mutagenesis, primer repair, restric5,814,618 and 5,789,156), herein incorporated by reference.
tion, annealing, resubstitutions, e.g., transitions and transverConstitutive promoters include, for example, the core prosions, may be involved.
1o mater of the Rsyn7 promoter and other constitutive promoters
disclosed in U.S. Pat. No. 6,072,050; the core CaMV 35S
The expression cassettes of the present invention can also
comprise a selectable marker gene for the selection of transpromoter (Odell eta!. (1985) Nature 313:810-812); ubiquitin
formed cells. Selectable marker genes are utilized for the
(Christensen eta!. (1989) Plant Mol. Biol. 12:619-632 and
selection of transformed cells or tissues. Marker genes
Christensen et a!. (1992) Plant Mol. Biol. 18:675-689);
include genes encoding antibiotic resistance, such as those 15 pEMU (Last eta!. (1991) Theon. Appl. Genet. 81:581-588);
MAS (Velten et a!. (1984) EMBO J. 3:2723-2730); ALS
encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring
promoter (U.S. Pat. No. 5,659,026), and the like. Other conresistance to herbicidal compounds, such as glufosinate
stitutive promoters include, for example, U.S. Pat. Nos.
ammonium, bromoxynil, imidazolinones, and 2,4-dichlo5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785;
rophenoxyacetate (2,4-D). Additional selectable markers 20 5,399,680; 5,268,463; 5,608,142; and 6,177,611.
Tissue-preferred promoters can be utilized to target expresinclude phenotypic markers such as ~-galactosidase and fluosion of an inhibitory polynucleotide sequence of the present
rescent proteins such as green fluorescent protein (GFP)
(Rouwendal eta!. (1997) Plant Mo. Biol. 33:989-999; Suet
invention within a particular plant tissue. Tissue-preferred
promoters include Yamamoto eta!. (1997)PlantJ. 12(2):255a!. (2004)BiotechnolBioeng 85:610-9 and Fetter eta!. (2004)
Plant Cell16:215-28), cyan florescent protein (CYP) (Bolte 25 265; Kawamata eta!. (1997) Plant Cell Physiol. 38(7):792eta!. (2004).1. Cell Science 117:943-54 andKato eta!. (2002)
803; Hansen eta!. (1997) Mol. Gen Genet. 254(3):337-343;
Russell eta!. (1997) Transgenic Res. 6(2): 157-168; Rinehart
Plant Physiol 129:913-42), and yellow fluorescent protein
(PhiYFP™ from Evrogen, see, Bolte et a!. (2004) J. Cell
eta!. (1996) Plant Physiol. 112(3):1331-1341; Van Camp et
Science 117:943-954). For additional selectable markers, see
a!. (1996) Plant Physiol. 112(2):525-535; Canevascini eta!.
generally, Yarranton (1992) Curr. Opin. Biotech. 3:506-511; 30 (1996) Plant Physiol. 112(2):513-524; Yamamoto et a!.
Christopherson et a!. (1992) Proc. Nat!. Acad. Sci. USA
(1994) Plant Cell Physiol. 35(5):773-778; Lam (1994)
89:6314-6318; Yao et a!. (1992) Cell 71:63-72; Reznikoff
Results Probl. Cell Differ. 20:181-196; Orozco eta!. (1993)
(1992) Mol. Microbial. 6:2419-2422; Barkley eta!. (1980) in
Plant Mol Biol. 23(6):1129-1138; Matsuoka eta!. (1993)
The Operon, pp. 177 -220; Hu eta!. (1987) Cell 48:555-566;
Proc Nat!. Acad. Sci. USA 90(20):9586-9590; and GuevaraBrown eta!. (1987) Cell49:603-612; Figge eta!. (1988) Cell 35 Garcia eta!. (1993) Plant J. 4(3):495-505.
52:713-722; Deuschle eta!. (1989) Proc. Nat!. Acad. Aci.
Of particular interest are leaf-preferred promoters that provide for expression predominately in leaf tissues. See, for
USA 86:5400-5404; Fuerst eta!. (1989) Proc. Nat!. A cad. Sci.
example, Yamamoto et a!. (1997) Plant J. 12(2):255-265;
USA 86:2549-2553; Deuschle eta!. (1990) Science 248:480483; Gossen (1993) Ph.D. Thesis, University of Heidelberg;
Kwon eta!. (1994) Plant Physiol. 105:357-67; Yamamoto et
Reines eta!. (1993) Proc. Nat!. Acad. Sci. USA 90:1917- 40 a!. (1994) Plant Cell Physiol. 35(5):773-778; Gator et a!.
1921; Labow et a!. (1990) Mol. Cell. Biol. 10:3343-3356;
(1993) Plant J. 3:509-18; Orozco eta!. (1993) Plant Mol.
Zambretti eta!. (1992) Proc. Nat!. Acad. Sci. USA 89:3952Biol. 23(6):1129-1138; Baszczynski eta!. (1988) Nucl. Acid
3956; Baimetal. (1991)Proc. Nat!. Acad. Sci. USA 88:5072Res. 16:4732; Mitra eta!. (1994) Plant Molecular Biology
5076; Wyborski et a!. (1991) Nucleic Acids Res. 19:464726:35-93; Kayaya et a!. (1995) Molecular and General
4653; Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 45 Genetics 248:668-674; and Matsuoka eta!. (1993)Proc. Nat!.
10:143-162; Degenkolb et a!. (1991) Antimicrob. Agents
A cad. Sci. USA 90(20):9586-9590. Senecence-regulated promoters are also of use, such as SAM22 (Crowell eta!. (1992)
Chemother. 35:1591-1595; Kleinschnidt et a!. (1988) BioPlant Mol. Biol. 18:459-466); SAG12 (Lohman eta!. (1994)
chemistry 27: 1094-1104; Bonin (1993) Ph.D. Thesis, University ofHeidelberg; Gossen eta!. (1992) Proc. Nat!. A cad. Sci.
Physiol. Plant. 92:322-328; Wingler et a!. (1998) Plant
USA 89:5547-5551; Oliva eta!. (1992) Antimicrob. Agents 50 Physiol. 116:329-335); SAG 13 (Gan and Amasino (1997)
Chemother. 36:913-919; Hlavka eta!. (1985) Handbook of
PlantPhysiol. 113:313-319; SAG15 (Gan (1995) "Molecular
Experimental Pharmacology, Vol. 78 (Springer-Verlag, BerCharacterization and Genetic Manipulation of Plant Seneslin); Gillet a!. (1988) Nature 334:721-724. Such disclosures
cence," Ph.D. Thesis, University of Wisconsin, Madison);
are herein incorporated by reference. The above list of selectSENT (Oh eta!. (1996) Plant Mol. Biol. 30:739-754; proable marker genes is not meant to be limiting. Any selectable 55 moter of a senescence-specific gene for expression of IPT
(Gan and Amasino 91995) Science 270: 1986-1988); and the
marker gene can be used in the present invention.
A number of promoters can be used in the practice of the
like (see, for example, Or: eta!. (1999) Plant Cell11:1073invention. Of particular interest are constitutive promoters,
1080 and McCabe eta!. (2001) Plant Physiol. 127:505-516).
inducible promoters, particularly chemical-inducible proMethods for Inhibiting Expression or Function of a Cytomoters, and tissue-preferred promoters, particularly leaf-pre- 60 chrome P450 Involved in the Conversion of Nicotine to Nornicotine
ferred promoters.
Methods of reducing the concentration, content, and/or
Chemical-inducible promoters can be used to inhibit the
expression of a cytochrome P450 that is involved in the metaactivity of a cytochrome P450 polypeptide of the present
bolic conversion of nicotine to nomicotine in a plant through
invention in a Nicotiana plant or plant part, particularly the
the application of an exogenous chemical regulator. Chemi- 65 leaf tissue, are provided. Many methods may be used, alone or
cal-inducible promoters are known in the art and include, but
in combination, to reduce or eliminate the activity of a cytoare not limited to, the tobacco PR-1a promoter, which is
chrome P450 polypeptide of the present invention. In addi-
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tion, combinations of methods may be employed to reduce or
eliminate the activity of two or more different cytochrome
P450 polypeptides.
In accordance with the present invention, the expression of
a cytochrome P450 polypeptide of the present invention is
inhibited if the protein level of the cytochrome P450 polypeptide is statistically lower than the protein level of the same
cytochrome P450 polypeptide in a plant that has not been
genetically modified or mutagenized to inhibit the expression
of that cytochrome P450 polypeptide, and where these plants
have been cultured and harvested using the same protocols. In
particular embodiments of the invention, the protein level of
the cytochrome P450 polypeptide in a modified plant according to the invention is less than 95%, less than 90%, less than
80%, less than 70%, less than 60%, less than 50%, less than
40%, less than 30%, less than 20%, less than 10%, less than
5%, less than 4%, less than 3%, less than 2%, or less than 1%
of the protein level of the same cytochrome P450 polypeptide
in a plant that is not a mutant or that has not been genetically
modified to inhibit the expression of that cytochrome P450
polypeptide and which has been cultured and harvested using
the same protocols. The expression level of the cytochrome
P450 polypeptide may be measured directly, for example, by
assaying for the level of the cytochrome P450 transcript or
cytochrome P450 polypeptide expressed in the Nicotiana
plant or plant part, or indirectly, for example, by measuring
the conversion of nicotine to nornicotine in the Nicotiana
plant or plant part. Methods for monitoring the expression
level of a protein are known in the art, and include, but are not
limited to, Northern blot analysis as discussed in the
examples herein below. Methods for determining the activity
of the targeted cytochrome P450 polypeptide in converting
nicotine to nornicotine are described elsewhere herein below,
and include, but are not limited to, alkaloid analysis using gas
chromatography, for example the procedures described in the
examples herein below.
In other embodiments of the invention, the activity of one
or more cytochrome P450 polypeptides is reduced or eliminated by transforming a plant or plant part with an expression
cassette comprising a polynucleotide encoding a polypeptide
that inhibits the activity of one or more cytochrome P450
polypeptides of the present invention. The activity of a cytochrome P450 polypeptide in converting nicotine to nornicotine in a Nicotiana plant or plant part is inhibited according to
the present invention if this conversion activity is statistically
lower than conversion activity of the same cytochrome P450
polypeptide in aNicotiana plant or plant part that has not been
genetically modified to inhibit the conversion activity of that
cytochrome P450 polypeptide and which has been cultured
and harvested using the same protocols. In particular embodiments, activity of a cytochrome P450 polypeptide in converting nicotine to nornicotine in a modified Nicotiana plant or
plant part according to the invention is inhibited if the activity
is less than 95%, less than 90%, less than 80%, less than 70%,
less than 60%, less than 50%, less than 40%, less than 30%,
less than 20%, less than 10%, less than 5%, less than 4%, less
than 3%, less than 2%, or less than 1% of the conversion
activity of the same cytochrome P450 polypeptide in a Nicotiana plant that that has not been genetically modified to
inhibit the expression of that cytochrome P450 polypeptide
and which has been cultured and harvested using the same
protocols. The activity of a cytochrome P450 polypeptide in
converting nicotine to nornicotine in a Nicotiana plant or
plant part is eliminated according to the invention when it is
not detectable by the assay methods described elsewhere
herein. Methods of determining the activity of a cytochrome
P450 polypeptide in converting nicotine to nornicotine in a

Nicotiana plant or plant part are described elsewhere herein,
and include the alkaloid analyses using gas chromatography
disclosed in the examples herein below.
In specific embodiments, a cytochrome P450 inhibitory
polynucleotide sequence described herein is introduced into a
Nicotiana plant or plant part. Subsequently, a Nicotiana plant
or plant part having the introduced inhibitory polynucleotide
sequence of the invention is selected using methods known to
those of skill in the art such as, but not limited to, Southern
blot analysis, DNA sequencing, PCR analysis, or phenotypic
analysis. A plant or plant part altered or modified by the
foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/
or activity of polypeptides of the present invention in the
plant. Plant forming conditions are well known in the art and
discussed briefly elsewhere herein.
In some embodiments, a transformed tobacco plant containing a cytochrome P450 inhibitory polynucleotide
sequence described herein has a reduced level of conversion
of nicotine to nornicotine. In particular embodiments, conversion of nicotine to nornicotine in a transformed tobacco
plant or plant part according to the invention is less than 95%,
less than 90%, less than 80% less than 70%, less than 60%,
less than 50%, less than 40%, less than 30%, less than 20%
less than 10%, less than 5%, less than 4%, less than 3%, less
than 2%, or less than 1% of the conversion in a tobacco plant
that that has not been genetically modified to inhibit the
expression of that cytochrome P450 polypeptide and which
has been cultured and harvested using the same protocols. In
some embodiments, the transformed tobacco plant is a converter tobacco plant. In some embodiments, the transformed
tobacco plant has a conversion rate lower than the rate
observed in commercial nonconverter tobacco plants.
It is also recognized that the level and/or activity of the
polypeptide may be modulated by employing a polynucleotide that is not capable of directing, in a transformed plant,
the expression of a protein or an RNA. For example, the
polynucleotides of the invention may be used to design polynucleotide constructs that can be employed in methods for
altering or mutating a genomic nucleotide sequence in an
organism. Such polynucleotide constructs include, but are not
limited to, RNA:DNA vectors, RNA:DNA mutational vectors, RNA:DNA repair vectors, mixed-duplex oligonucleotides, self-complementary RNA:DNA oligonucleotides,
and recombinogenic oligonucleobases. Such nucleotide constructs and methods of use are known in the art. See, U.S. Pat.
Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012; 5,795,972;
and 5,871,984; all of which are herein incorporated by reference. See also, WO 98/49350, WO 99/07865, WO 99/25821,
and Beetham et a!. (1999) Proc. Nat!. Acad. Sci. USA
96:8774-8778; herein incorporated by reference.
It is therefore recognized that methods of the present invention do not depend on the incorporation of the entire cytochrome P450 inhibitory polynucleotide into the genome, only
that the Nicotiana plant or plant part thereof is altered as a
result of the introduction of this inhibitory polynucleotide
into a cell. In one embodiment of the invention, the genome
may be altered following the introduction of the cytochrome
P450 inhibitory polynucleotide into a cell. For example, the
inhibitory polynucleotide, or any part thereof, may incorporate into the genome of the plant. Alterations to the genome
include, but are not limited to, additions, deletions, and substitutions of nucleotides into the genome. While the methods
of the present invention do not depend on additions, deletions,
and substitutions of any particular number of nucleotides, it is
recognized that such additions, deletions, or substitutions
comprise at least one nucleotide.
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It is further recognized that reducing the level and/or activpolypeptide that is involved in the metabolic conversion of
nicotine to nornicotine. In some embodiments, the inhibitory
ity of a cytochrome P450 sequence of the present invention
can be performed to elicit the effects of the sequence only
sequence is introduced by transformation of the plant or plant
during certain developmental stages and to switch the effect
part, such as a plant cell, with an expression cassette that
off in other stages where expression is no longer desirable.
expresses a polynucleotide that inhibits the expression of the
Control of cytochrome P450 expression can be obtained via
cytochrome P450 polypeptide. The polynucleotide may
the use of inducible or tissue-preferred promoters. Alternainhibit the expression of a cytochrome P450 polypeptide
tively, the gene could be inverted or deleted using site-specific
directly, by preventing translation of the cytochrome P450
polypeptide messenger RNA, or indirectly, by encoding a
recombinases, transposons or recombination systems, which
would also turn on or off expression of the cytochrome P450 10 polypeptide that inhibits the transcription or translation of an
sequence.
cytochrome P450 polypeptide gene encoding a cytochrome
P450 polypeptide. Methods for inhibiting or eliminating the
According to the present invention, changes in levels,
expression of a gene product in a plant are well known in the
ratios, activity, or distribution of cytochrome P450 polypeptides of the present invention, or changes inNicotiana plant or
art, and any such method may be used in the present invention
plant part phenotype, particularly reduced accumulation of 15 to inhibit the expression of cytochrome P450 polypeptides.
nornicotine and its carcinogenic metabolite, NNN, could be
In other embodiments, the activity of a cytochrome P450
measured by comparing a subject plant or plant part to a
polypeptide of the present invention may be reduced or elimicontrol plant or plant part, where the subject plant or plant part
nated by disrupting the gene encoding the cytochrome P450
and the control plant or plant part have been cultured and/or
polypeptide. The invention encompasses mutagenized plants
harvested using the same protocols. As used herein, a subject 20 that carry mutations in cytochrome P450 genes, where the
plant or plant part is one in which genetic alteration, such as
mutations reduce expression of the cytochrome P450 gene or
inhibit the activity of an encoded cytochrome P450 polypeptransformation, has been affected as to the cytochrome P450
polypeptide of interest, or is a Nicotiana plant or plant part
tide of the present invention.
In some embodiments of the present invention, a Nicotiana
that is descended from a Nicotiana plant or plant part so
altered and which comprises the alteration. A control plant or 25 plant or plant part is transformed with an expression cassette
plant part provides a reference point for measuring changes in
that is capable of expressing a polynucleotide that inhibits the
phenotype of the subject plant or plant part.
expression of a cytochrome P450 sequence. Such methods
The measurement of changes in phenotype can be meamay include the use of sense suppression/cosuppression,
sured at any time in a plant or plant part, including during
antisense suppression, double-stranded RNA (dsRNA) interplant development, senescence, or after curing. In other 30 ference, hairpin RNA interference and intron-containing
embodiments, the measurement of changes in phenotype can
hairpin RNA interference, amplicon-mediated interference,
be measured in plants grown under any conditions, including
ribozymes, and small interfering RNA or micro RNA.
from plants grown in a growth chamber, greenhouse, or in a
For cosuppression, an expression cassette is designed to
field. In one embodiment, changes in phenotype can be meaexpress an RNA molecule corresponding to all or part of a
sured by determining the nicotine to nornicotine conversion 35 messenger RNA encoding a cytochrome P450 polypeptide of
rate. In a preferred embodiment, conversion can be measured
interest (for example, a cytochrome P450 polypeptide comby dividing the percentage of nornicotine (as a percentage of
prising the sequence set forth in SEQ ID N0:2, 4, 6, 8, 10, or
the total tissue weight) by the sum of the percentage nicotine
12 or a sequence having substantial sequence identity to SEQ
ID N0:2, 4, 6, 8, 10, or 12) in the "sense" orientation. Over
and nornicotine (as percentages of the total tissue weight) and
40 expression of the RNA molecule can result in reduced expresmultiplying by 100.
According to the present invention, a control plant or plant
sion of the native gene. Multiple plant lines transformed with
part may comprise a wild-type Nicotiana plant or plant part,
the cosuppression expression cassette are then screened to
i.e., of the same genotype as the starting material for the
identify those that show the greatest inhibition of cytochrome
P450 polypeptide expression.
genetic alteration that resulted in the subject plant or plant
part. A control plant or plant part may also comprise a Nic- 45
The polynucleotide used for cosuppression may correotiana plant or plant part of the same genotype as the starting
spond to all or part of the sequence encoding a cytochrome
P450 polypeptide or the present invention, all or part of the 5'
material but that has been transformed with a null construct
and/or 3' untranslated region of a cytochrome P450 polypep(i.e., with a construct that has no known effect on the trait of
interest, such as a construct comprising a selectable marker
tide transcript, or all or part of both the coding sequence and
gene). Alternatively, a control plant or plant part may com- 50 the untranslated regions of a transcript encoding a cytoprise a Nicotiana plant or plant part that is a non-transformed
chrome P450 polypeptide. In some embodiments where the
segregant among progeny of a subject plant or plant part, or a
polynucleotide comprises all or part of the coding region for
Nicotiana plant or plant part genetically identical to the suba cytochrome P450 polypeptide of the present invention, the
expression cassette is designed to eliminate the start codon of
ject plant or plant part but that is not exposed to conditions or
stimuli that would induce suppression of the cytochrome 55 the polynucleotide so that no protein product will be tranP450 gene of interest. Finally, a control plant or plant part
scribed.
may comprise the subject plant or plant part itself under
Cosuppression may be used to inhibit the expression of
plant genes to produce plants having undetectable protein
conditions in which the cytochrome P450 inhibitory
sequence is not expressed. In all such cases, the subject plant
levels for the proteins encoded by these genes or may also be
or plant part and the control plant or plant part are cultured 60 used to inhibit the expression of multiple proteins in the same
and harvested using the same protocols.
plant (e.g., Brain eta!. (2002) Plant Cell14:1417-1432; U.S.
As described elsewhere herein, methods are provided to
Pat. No. 5,942,657). Methods for using cosuppression to
reduce or eliminate the activity and/or concentration of a
inhibit the expression of endogenous genes in plants are
cytochrome P450 polypeptide of the present invention by
described in Flavell eta!. (1994) Proc. Nat!. Acad. Sci. USA
introducing into a Nicotiana plant or plant part a cytochrome 65 91:3490-3496; Jorgensen et a!. (1996) Plant Mol. Biol.
P450 inhibitory polynucleotide sequence that is capable of
31:957-973; Johansen and Carrington (2001) Plant Physiol.
inhibiting expression or function of a cytochrome P450
126:930-938; Brain eta!. (2002) Plant Cell 14: 1417-1432;
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Stoutjesdijk eta!. (2002) Plant Physiol. 129:1723-1731; Yu et
a!. (2003) Phytochemistry 63:753-763; and U.S. Pat. Nos.
5,034,323, 5,283,184, and 5,942,657; each of which is herein
incorporated by reference. The efficiency of cosuppression
may be increased by including a poly-dT region in the expression cassette at a position 3' to the sense sequence and 5' of the
polyadenylation signal. See, U.S. Patent Publication No.
20020048814, herein incorporated by reference. Typically,
such a nucleotide sequence has substantial sequence identity
to the sequence of the transcript of the endogenous gene,
optimally greater than about 65% sequence identity, more
optimally greater than about 85% sequence identity, most
optimally greater than about 95% sequence identity (e.g.,
U.S. Pat. Nos. 5,283,184 and 5,034,323; herein incorporated
by reference).
In some embodiments of the invention, inhibition of the
expression of the cytochrome P450 polypeptide of the present
invention may be obtained by antisense suppression. For antisense suppression, the expression cassette is designed to
express an RNA molecule complementary to all or part of a
messenger RNA encoding the cytochrome P450 polypeptide.
Over expression of the antisense RNA molecule can result in
reduced expression of the native gene. Accordingly, multiple
plant lines transformed with the antisense suppression
expression cassette are screened to identify those that show
the greatest inhibition of cytochrome P450 polypeptide
expression.
The polynucleotide for use in antisense suppression may
correspond to all or part of the complement of the sequence
encoding the cytochrome P450 polypeptide, all or part of the
complement of the 5' and/or 3' untranslated region of the
cytochrome P450 polypeptide transcript, or all or part of the
complement ofboth the coding sequence and the untranslated
regions of a transcript encoding the cytochrome P450
polypeptide. In addition, the antisense polynucleotide may be
fully complementary (i.e., 100% identical to the complement
of the target sequence) or partially complementary (i.e., less
than 100% identical to the complement of the target
sequence) to the target sequence. Antisense suppression may
be used to inhibit the expression of multiple proteins in the
same plant (e.g., U.S. Pat. No. 5,942,657). Furthermore, portions of the antisense nucleotides may be used to disrupt the
expression of the target gene. Generally, sequences of at least
50 nucleotides, 100 nucleotides, 200 nucleotides, 300, 400,
450, 500, 550, or greater may be used. Methods for using
antisense suppression to inhibit the expression of endogenous
genes in plants are described, for example, in Liu eta!. (2002)
Plant Physiol. 129:1732-1743 and U.S. Pat. Nos. 5,759,829
and 5,942,657, each of which is herein incorporated by reference. Efficiency of antisense suppression may be increased
by including a poly-dT region in the expression cassette at a
position 3' to the antisense sequence and 5' of the polyadenylation signal. See, U.S. Patent Publication No. 20020048814,
herein incorporated by reference.
For dsRNA interference, a sense RNA molecule like that
described above for cosuppression and an antisense RNA
molecule that is fully or partially complementary to the sense
RNA molecule are expressed in the same cell, resulting in
inhibition of the expression of the corresponding endogenous
messenger RNA.
Expression of the sense and antisense molecules can be
accomplished by designing the expression cassette to comprise both a sense sequence and an antisense sequence for the
target cytochrome P450 sequence. Alternatively, separate
expression cassettes may be used for the sense and antisense
sequences. Multiple plant lines transformed with the dsRNA
interference expression cassette or expression cassettes are

then screened to identify plant lines that show the greatest
inhibition of expression of the targeted cytochrome P450
polypeptide. Methods for using dsRNA interference to inhibit
the expression of endogenous plant genes are described in
Waterhouse et a!. (1998) Proc. Nat!. Acad. Sci. USA
95:13959-13964, Liu eta!. (2002) Plant Physiol. 129:17321743, and WO 99/49029, WO 99/53050, WO 99/61631, and
WO 00/49035; each of which is herein incorporated by reference.
Amplicon expression cassettes comprise a plant virus-derived sequence that contains all or part of the target gene but
generally not all of the genes of the native virus. The viral
sequences present in the transcription product of the expression cassette allow the transcription product to direct its own
replication. The transcripts produced by the amplicon may be
either sense or antisense relative to the target sequence (i.e.,
the messenger RNA for a cytochrome P450 polypeptide that
is involved in the metabolic conversion of nicotine to nornicotine). Methods of using amplicons to inhibit the expression
of endogenous plant genes are described, for example, in
Angell and Baulcombe (1997) EMBO J. 16:3675-3684,
Angell and Baulcombe (1999) Plant J. 20:357-362, and U.S.
Pat. No. 6,646,805, each of which is herein incorporated by
reference.
In additional embodiments of the present invention, the
polynucleotide expressed by the expression cassette of the
invention is catalytic RNA or has ribozyme activity specific
for the messenger RNA of a cytochrome P450 polypeptide
described herein. Thus, the polynucleotide causes the degradation of the endogenous messenger RNA, resulting in
reduced expression of the cytochrome P450 polypeptide.
This method is described, for example, in U.S. Pat. No. 4,987,
071, herein incorporated by reference.
In further embodiments of the invention, inhibition of the
expression of one or more cytochrome P450 polypeptides
may be obtained by RNA interference (RNAi) by expression
of a gene encoding a micro RNA (miRNA). miRNAs are
regulatory agents consisting of about 22 ribonucleotides.
miRNA are highly efficient at inhibiting the expression of
endogenous genes. See, for example Javier et a!. (2003)
Nature 425: 257-263, herein incorporated by reference.
For miRNA interference, the expression cassette is
designed to express an RNA molecule that is modeled on an
endogenous miRNA gene. The miRNA gene encodes an
RNA that forms a hairpin structure containing a 22-nucleotide sequence that is complementary to another endogenous
gene (target sequence). For suppression of cytochrome P450
polypeptide expression, the 22-nucleotide sequence is
selected from a cytochrome P450 polypeptide transcript
sequence and contains 22 nucleotides encoding this cytochrome P450 polypeptide sequence in sense orientation and
21 nucleotides of a corresponding antisense sequence that is
complementary to the sense sequence. miRNA molecules are
highly efficient at inhibiting the expression of endogenous
genes, and the RNA interference they induce is inherited by
subsequent generations of plants.
In still other embodiments of the invention, inhibition of
the expression of one or more cytochrome P450 polypeptides
by RNAi may be obtained by hairpin RNA (hpRNA) interference or intron-containing hairpin RNA (ihpRNA) interference. These methods are highly efficient at inhibiting the
expression of endogenous genes. See, Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38 and the references
cited therein.
For hpRNA interference, the expression cassette is
designed to express an RNA molecule that hybridizes with
itself to form a hairpin structure that comprises a single-
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stranded loop region and a base-paired stem. The base-paired
stem region comprises a sense sequence corresponding to all
or part of the endogenous messenger RNA encoding the gene
product whose expression is to be inhibited, in this case, a
cytochrome P450 polypeptide described herein, and an antisense sequence that is fully or partially complementary to the
sense sequence. Alternatively, the base-paired stem region
may correspond to a portion of a promoter sequence controlling expression of the gene encoding the cytochrome P450
polypeptide to be inhibited. Thus, the base-paired stem region
of the molecule generally determines the specificity of the
RNA interference. hpRNA molecules are highly efficient at
inhibiting the expression of endogenous genes, and the RNA
interference they induce is inherited by subsequent generations of plants. See, for example, Chuang and Meyerowitz
(2000) Proc. Nat!. Acad. Sci. USA 97:4985-4990; Stoutjesdijk et a!. (2002) Plant Physiol. 129:1723-1731; and Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38. Methods for using hpRNA interference to inhibit or silence the
expression of genes are described, for example, in Chuang
and Meyerowitz (2000) Proc. Nat!. Acad. Sci. USA 97:49854990; Stoutjesdijk et a!. (2002) Plant Physiol. 129:17231731; Waterhouse and Helliwell (2003) Nat. Rev. Genet.
4:29-38; Pandolfini eta!. BMC Biotechnology 3:7, and U.S.
Patent Publication No. 2003017 5965; each of which is herein
incorporated by reference. A transient assay for the efficiency
of hpRNA constructs to silence gene expression in vivo has
been described by Panstruga et a!. (2003) Mol. Biol. Rep.
30:135-140, herein incorporated by reference.
For ihpRNA, the interfering molecules have the same genera! structure as for hpRNA, but the RNA molecule additionally comprises an intron that is capable ofbeing spliced in the
cell in which the ihpRNA is expressed. The use of an intron
minimizes the size of the loop in the hairpin RNA molecule
following splicing, and this increases the efficiency of interference. See, for example, Smith et a!. (2000) Nature 407:
319-320. In fact, Smith et a!. show 100% suppression of
endogenous gene expression using ihpRNA-mediated interference. Methods for using ihpRNA interference to inhibit the
expression of endogenous plant genes are described, for
example, in Smith eta!. (2000) Nature 407:319-320; Wesley
et a!. (2001) Plant J. 27:581-590; Wang and Waterhouse
(2001) Curr. Opin. Plant Biol. 5:146-150; Waterhouse and
Helliwell (2003) Nat. Rev. Genet. 4:29-38; Helliwell and
Waterhouse (2003) Methods 30:289-295, and U.S. Patent
Publication No. 20030180945, each of which is herein incorporated by reference.
In one such embodiment, RNAi is accomplished by
expressing an inhibitory sequence that comprises a first
sequence of a cytochrome P450 polynucleotide of the invention that is about 90 bp to about 110 bp in length, including 90,
91,92,93,94,95,96,97,98,99,100, 101,102,103,104,105,
106, 107, 108, 109, and 110 bp in length, and a second
sequence that is complementary to all or a part of the first
sequence. In another such embodiment, the inhibitory
sequence comprises a first sequence of a cytochrome P450
polynucleotide of the invention that is about 290 to about 310
bp in length, including 290,291,292,293,294,295,296,297,
298,299,300,301,302,303,304,305,306,307,308,309,
and 310 bp in length, and a second sequence that is complementary to all or a part of the fragment sequence.
In other embodiments of the invention, RNAi is accomplished by expressing an inhibitory sequence that comprises
a first polynucleotide sequence containing the nucleotides
from about position 265 to about position 625 of a cytochrome P450 coding sequence disclosed herein and a second
sequence that is fully or partially complementary thereto. In

some of these embodiments, the inhibitory sequence comprises as the first polynucleotide sequence the nucleotides
corresponding to about position 297 to about position 594 of
the P450 coding sequence set forth in SEQ ID N0:3 or SEQ
ID N0:5 and the second sequence is the complement (i.e.,
antisense sequence) of this first sequence. The inhibitory
sequence can optionally comprise an intron sequence linked
between the first and second sequences. Any intron known to
those of skill in the art can be used in this manner. In some
embodiments, the intron is from the soybean omega-6 fatty
acid desaturase (FAD) (see GenBank Accession No.
DQ672337, and Example 7 herein below). In one such
embodiment, the intron comprises about 151 nucleotides that
comprise nucleotides 100-247 of the soybean omega-6 fatty
acid desaturase polynucleotide shown in GenBankk Accession No. DQ672337. Examples of other introns include, but
are not limited to, the intron nucleotide sequences of alcohol
dehydrogenase (adh1) genes. Expression of this inhibitory
sequence produces an intron-containing hairpin RNA that
strongly interferes with expression of the cytochrome P450
polypeptides disclosed herein. In this manner, Nicotiana
plants that are normally converters of nicotine to nornicotine
that are transformed with an expression cassette comprising
such an inhibitory sequence advantageously have a nicotine
to nomicotine conversion rate that, surprisingly, is even lower
than that observed for Nicotiana plants that are nonconverters
of nicotine to nornicotine.
In yet other embodiments of the invention, RNAi is accomplished by expressing an inhibitory sequence that comprises
a first polynucleotide sequence containing the nucleotides
from about position 1420 to about position 1580 of a cytochrome P450 coding sequence disclosed herein and a
sequence that is fully or partially complementary thereto. In
some of these embodiments, the inhibitory sequence comprises as the first polynucleotide sequence the nucleotides
corresponding to about position 1453 to about position 1551
of the P450 coding sequence set forth in SEQ ID NO: 1 and the
second sequence is the complement (i.e., antisense sequence)
of this first sequence. The inhibitory sequence can optionally
comprise an intron sequence linked between the first and
second sequences. Any intronknown to those of skill in the art
can be used in this manner, as noted herein above. Expression
of this inhibitory sequence produces a hairpin RNA (or
intron-containing hairpin RNA when the intron is present)
that also interferes with expression of the cytochrome P450
polypeptides disclosed herein.
The expression cassette for hpRNA interference may also
be designed such that the sense sequence and the antisense
sequence do not correspond to an endogenous RNA. In this
embodiment, the sense and antisense sequence flank a loop
sequence that comprises a nucleotide sequence corresponding to all or part of the endogenous messenger RNA of the
target gene. Thus, it is the loop region that determines the
specificity of the RNA interference. See, for example, WO
02/00904, herein incorporated by reference.
Transcriptional gene silencing (TGS) may be accomplished through use of hpRNA constructs wherein the
inverted repeat of the hairpin shares sequence identity with
the promoter region of a gene to be silenced. Processing of the
hpRNA into short RNAs that can interact with the homologous promoter region may trigger degradation or methylation
to result in silencing (Aufsatz eta!. (2002) Proc. Nat!. A cad.
Sci. 99 (Suppl. 4):16499-16506; Mette eta!. (2000) EMBOJ.
19(19):5194-5201 ).
In further embodiments, a polynucleotide may be utilized
that encodes a zinc finger protein that binds to a gene encoding a cytochrome P450 polypeptide, resulting in reduced
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expression of the gene. In particular embodiments, the zinc
finger protein binds to a regulatory region of a cytochrome
P450 polypeptide gene. In other embodiments, the zinc finger
protein binds to a messenger RNA encoding a cytochrome
P450 polypeptide and prevents its translation. Methods of
selecting sites for targeting by zinc finger proteins have been
described, for example, in U.S. Pat. No. 6,453,242, and methods for using zinc finger proteins to inhibit the expression of
genes in plants are described, for example, in U.S. Patent
Publication No. 20030037355; each of which is herein incorporated by reference.
In other embodiments of the invention, the polynucleotide
encodes an antibody that binds to at least one cytochrome
P450 polypeptide, and reduces the activity of a cytochrome
P450 polypeptide of the present invention. In another
embodiment, the binding of the antibody results in increased
turnover of the antibody-cytochrome P450 polypeptide complex by cellular quality control mechanisms. The expression
of antibodies in plant parts and the inhibition of molecular
pathways by expression and binding of antibodies to proteins
in plant parts are well known in the art. See, for example,
Conrad and Sonnewald (2003) Nature Biotech. 21:35-36,
incorporated herein by reference.
In other embodiments, the activity of a cytochrome P450
polypeptide of the present invention is reduced or eliminated
by disrupting the gene encoding the cytochrome P450
polypeptide. The gene encoding the cytochrome P450
polypeptide may be disrupted by any method known in the
art, for example, by transposon tagging or by mutagenizing
plants using random or targeted mutagenesis and selecting for
plants that have reduced cytochrome P450 activity.
Transposon tagging may be used to reduce or eliminate the
activity of one or more cytochrome P450 polypeptides of the
present invention. Transposon tagging comprises inserting a
transposon within an endogenous cytochrome P450 gene to
reduce or eliminate expression of the cytochrome P450
polypeptide.
In this embodiment, the expression of one or more cytochrome P450 polypeptides is reduced or eliminated by inserting a transposon within a regulatory region or coding region
of the gene encoding the cytochrome P450 polypeptide. A
transposon that is within an exon, intron, 5' or 3' untranslated
sequence, a promoter, or any other regulatory sequence of a
cytochrome P450 polypeptide gene may be used to reduce or
eliminate the expression and/or activity of the encoded cytochrome P450 polypeptide.
Methods for the transposon tagging of specific genes in
plants are well known in the art. See, for example, Maes eta!.
(1999) Trends Plant Sci. 4:90-96; Dharmapuri and Santi
(1999) FEMS Microbial. Lett. 179:53-59; Meissner et a!.
(2000) Plant J. 22:265-274; Phogat et a!. (2000) J. Biosci.
25:57-63; Walbot (2000) Curr. Opin. Plant Biol. 2:103-107;
Gai eta!. (2000) Nucleic Acids Res. 28:94-96; Fitzmaurice et
a!. (1999) Genetics 153:1919-1928).
Additional methods for decreasing or eliminating the
expression of endogenous genes in plants are also known in
the art and can be similarly applied to the instant invention.
These methods include other forms of mutagenesis, such as
ethyl methanesulfonate-induced mutagenesis, deletion
mutagenesis, and fast neutron deletion mutagenesis used in a
reverse genetics sense (with PCR) to identify plant lines in
which the endogenous gene has been deleted. For examples
of these methods see Ohshima eta!. (1998) Virology 243:472481; Okubara eta!. (1994) Genetics 137:867-874; and Quesada eta!. (2000) Genetics 154:421-436; each of which is
herein incorporated by reference. In addition, a fast and
automatable method for screening for chemically induced

mutations, TILLING (Targeting Induced Local Lesions In
Genomes ), using denaturing HPLC or selective endonuclease
digestion of selected PCR products is also applicable to the
instant invention. See McCallum eta!. (2000) Nat. Biotechno!. 18:455-457, herein incorporated by reference.
Mutations that impact gene expression or that interfere
with the function of the encoded cytochrome P450 protein
can be determined using methods that are well known in the
art. Insertional mutations in gene exons usually result in nullmutants. Mutations in conserved residues can be particularly
effective in inhibiting the metabolic function of the encoded
protein. Conserved residues of plant cytochrome P450
polypeptides suitable for mutagenesis with the goal to eliminate activity of a cytochrome P450 polypeptide in converting
nicotine to nornicotine in a Nicotiana plant or plant part have
been described (See, for example, FIGS. 3 and 4). Such
mutants can be isolated according to well-known procedures.
In another embodiment of this invention, dominant
mutants can be used to trigger RNA silencing due to gene
inversion and recombination of a duplicated gene locus. See,
for example, Kusaba eta!. (2003) Plant Cell15:1455-1467.
While a number of sequences are recognized in the practice
of the invention, in particular SEQ ID N0:3 and SEQ ID
N0:5 find particular use. While not bound by any particular
mechanisms of action, it is believed that these sequences
encode a nicotine demethylase that catalyzes the oxidative
N -demethy lation of nicotine to nornicotine. Thus, methods to
specifically inhibit these coding sequences and not other
P450 sequences may be beneficial to the recombinant plant.
That is, strategies that would lead to inhibition of gene function of this individual locus may prove to be superior to those
that inhibit the entire gene family. The P450 enzymes are
involved in many mechanisms in the plant, the inhibition of
which may prove deleterious or detrimental to the growth and
development of the plant or may negatively impact factors
such as the disease defense capabilities of the plant. Likewise,
because the Nicotiana plant P450 enzymes have been implicated in plant metabolites such as phenylpropanoid, alkaloids, terpenoids, lipids, cyanogenic glycosides, glucosinolates, and a host of other chemical entities, disruption of p450
activity may alter components involved in tobacco flavor,
texture, or other properties that would impact the commercial
usefulness of the plant. Therefore, the use of the methods
discussed above to inhibit expression in a marmer that specifically targets the coding sequence of SEQ ID N0:3 or SEQ
ID N0:5 may be preferred, including targeted mutational
strategies, such as chimeraplasty. See, for example, Stewart et
a!. (2000) Biotechniques 29(4): 838-843; Graham et a!.
(2002) Biochim Biophys Acta 1587 (1 ): 1-6, herein incorporated by reference.
The protein encoded by the eDNA designated 3D_C12-1 0
(SEQ ID N0:4) differs from 3D_C12-7 (SEQ ID N0:6) at
only two amino acid residues immediately following the start
methionine. The codons corresponding to these amino acids
were contained within the PCR primer used to generate the
3D_C12-7 eDNA. Thus, the original mRNA template from
which 3D_C12-7 was amplified may be the same as that
corresponding to the 3D_C12-10 gene, with the PCRprimer
sequences mediating the changes observed in the second and
third amino acid sequence. Regardless, the encoded protein
products would function identically. The location of the two
amino acids that differ between the predicted proteins is in the
N-terminal signal sequence that merely serves to anchor the
protein to the endoplasmic reticulum membrane and therefore would not be expected to influence the catalytic properties of the enzyme.
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In another embodiment of the invention, the compositions
of the invention find use in screening methods to identify
nonconverter plants for use in breeding programs. In this
manner, the nucleotide sequences of the invention can be used
to screen native germplasms for nonconverter plants having a
stable mutation in one or more p450 genes identified herein.
These nonconverter plants identified by the methods of the
invention can be used to develop breeding lines.
In addition to the nucleotide sequences encoding P450
coding sequences, compositions of the invention include an
intron sequence in the 3D_C12-10 sequence that can be used
in screening methods. While not bound by any mechanism of
action, the 3D_C12-7/3D_C12-10 gene(s) may represent the
only member(s) of the 3D_C12 family involved in the metabolic conversion of nicotine to nornicotine (and as stated
previously there is a good likelihood that the 3D_C12-7 and
3D_C12-10 cDNAs originated from a single unique genetic
locus). For certain applications it would be useful to have a
means of diagnostically differentiating this specific member
of the 3D_C12 gene family from the rest of the closely related
sequences within this family. For example, it is possible that
within the naturally existing tobacco germplasm (or in
mutagenized populations), accessions may exist in which this
gene is naturally dysfunctional and may therefore may be
valuable as a permanently nonconverter resource. A method
to specifically assay for such genotypes (e.g. deletion
mutants, rearrangements, and the like) could serve as a powerful tool. To obtain such a tool, the sequence alignment
shown in FIGS. 3A-3G was used to design PCR primers in
regions possessing polymorphisms among the members. One
primer combination (5' primer shown in SEQ ID N0:25 and
3' primer shown in SEQ ID N0:26) using sequences specific
to 3D_C12-10 yields two particularly useful results: (1) all
PCR products amplified from tobacco genomic DNA gave
that same unique product (as determined by DNA sequence
analysis); and (2) the presence of a 992 bp intron was revealed
that is located between the primer sequences (FIG. 7; intron
shown in SEQ ID N0:24).
When any eDNA corresponding to a member of the
3D_C12 family is used as a hybridization probe in a Southern
blotting assay of tobacco genomic DNA, a complex pattern is
observed. This is expected, given that there are multiple,
closely related members of this gene family. Because the
intron regions of genes are typically less conserved than
exons, it is predicted that the use of an intron-specific probe
would reduce this complexity and better enable one to distinguish the gene(s) corresponding to the 3D_C12-7/3D_C1210 gene from the other members of the family. Indeed, the
pro be corresponding to the sequence shown in FIG. 7 resulted
in a Southern blotting pattern with greatly reduced complexity. The use of a 3D_C12-10 intron-specific probe, and/or the
PCR primers used to generate the fragment shown in FIG. 7,
therefore provide powerful tools in assays to determine
whether any naturally occurring, or mutagenized, tobacco
plants possess deletions or rearrangements that may render
the gene inactive. Such a plant can then be used in breeding
programs to create tobacco lines that are incapable of converting.
Transformed Plants, Plant Parts, and Products Having
Reduced Nornicotine and NNN Content
The cytochrome P450 polynucleotides of the invention,
and variants and fragments thereof, can be used in the methods of the present invention to inhibit expression or function
of cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in a plant. In this manner,
inhibitory sequences that target expression or function of a
cytochrome P450 polypeptide disclosed herein are intra-

duced into a plant or plant cell of interest. In some embodiments the expression cassettes described herein are introduced into a plant of interest, for example, a Nicotiana plant
as noted herein below, using any suitable transformation
methods known in the art including those described herein.
The methods of the invention do not depend on a particular
method for introducing a sequence into a plant or plant part,
only that the desired sequence gains access to the interior of at
least one cell of the plant or plant part. Methods for introducing polynucleotide sequences into plants are known in the art
and include, but are not limited to, stable transformation
methods, transient transformation methods, and virus-mediated methods.
Transformation protocols as well as protocols for introducing heterologous polynucleotide sequences into plants vary
depending on the type of plant or plant cell targeted for
transformation. Suitable methods of introducing polynucleotides into plant cells of the present invention include microinjection (Crossway eta!. (1986) Biotechniques 4:320-334),
electroporation (Shillito eta!. (1987) Meth. Enzymol. 153:
313-336; Riggs et a!. (1986) Proc. Nat!. Acad. Sci. USA
83:5602-5606), Agrobacterium-mediated transformation
(U.S. Pat. Nos. 5,104,310, 5,149,645, 5,177,010, 5,231,019,
5,463,174, 5,464,763, 5,469,976, 4,762,785, 5,004,863,
5,159,135, 5,563,055, and 5,981,840), direct gene transfer
(Paszkowski eta!. (1984) EMBO J. 3:2717 -2722), and ballistic particle acceleration (see, for example, U.S. Pat. Nos.
4,945,050, 5,141,131, 5,886,244, 5,879,918, and 5,932,782;
Tomes eta!. (1995) in Plant Cell, Tissue, and Organ Culture
Fundamental Methods, ed. Gamborg and Phillips (SpringerVerlag, Berlin); McCabe eta!. (1988) Biotechnology 6:923926). Also see Weissinger et a!. (1988) Ann. Rev. Genet.
22:421-477; Christon eta!. (1988) Plant Physiol. 87:671-674
(soybean); McCabe eta!. (1988) Bio/Technology 6:923-926
(soybean); Finer and McMullen (1991) In Vitro Cell Dev.
Biol. 27P: 175-182 (soybean); Singhet a!. (1998) Theor. Appl.
Genet. 96:319-324 (soybean); De Wet eta!. (1985) in The
Experimental Manipulation ofOvule Tissues, ed. Chapman et
a!. (Longman, N.Y.), pp. 197-209 (pollen); Kaeppler eta!.
(1990) Plant Cell Reports 9:415-418 and Kaeppler et a!.
(1992) Theor. Appl. Genet. 84:560-566 (whisker-mediated
transformation); D'Halluin eta!. (1992) Plant Cell 4:14951505 (electroporation); all of which are herein incorporated
by reference.
Any plant tissue that can be subsequently propagated using
clonal methods, whether by organogenesis or embryogenesis,
may be transformed with a recombinant construct comprising
a cytochrome P450 inhibitory sequence, for example, an
expression cassette of the present invention. By "organogenesis" in intended the process by which shoots and roots are
developed sequentially from meristematic centers. By
"embryogenesis" is intended the process by which shoots and
roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes. Exemplary
tissues that are suitable for various transformation protocols
described herein include, but are not limited to, callus tissue,
existing meristematic tissue (e.g., apical meristems, axillary
buds, and root meristems) and induced meristem tissue (e.g.,
cotyledon meristem and hypocotyl meristem), hypocotyls,
cotyledons, leaf disks, pollen, embryos, and the like.
As used herein, the term "stable transformation" is
intended to mean that the nucleotide construct of interest
introduced into a plant integrates into the genome of the plant
and is capable of being inherited by the progeny thereof
"Transient transformation" is intended to mean that a
sequence is introduced into the plant and is only temporally
expressed or is only transiently present in the plant.
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In specific embodiments, the inhibitory sequences of the
invention can be provided to a plant using a variety of transient transformation methods. The inhibitory sequences of
the invention can be transiently transformed into the plant
using techniques known in the art. Such techniques include
viral vector systems and the precipitation of the polynucleotide in a manner that precludes subsequent release of the
DNA. Thus, the transcription from the particle-bound DNA
can occur, but the frequency with which it is released to
become integrated into the genome is greatly reduced. Such
methods include the use of particles coated with polyethyenlimine (PEl; Sigma #P3143).
In other embodiments, the inhibitory sequence of the
invention may be introduced into plants by contacting plants
with a virus or viral nucleic acids. Generally, such methods
involve incorporating an expression cassette of the invention
within a viral DNA or RNA molecule. It is recognized that
promoters for use in the expression cassettes of the invention
also encompass promoters utilized for transcription by viral
RNA polymerases. Methods for introducing polynucleotides
into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See,
for example, U.S. Pat. Nos. 5,889,191, 5,889, 190, 5,866, 785,
5,589,367, 5,316,931, and Porta eta!. (1996) Molecular Biotechnology 5:209-221; herein incorporated by reference.
Transformed cells may be grown into Nicotiana plants in
accordance with conventional methods. See, for example,
methods disclosed in Vasil and Hildebrandt (1965) Science
150:889; Negaard and Hoffman (1989) Biotechniques 7(8):
808-812. These plants may then be grown, and either pollinated with the same transformed line or different lines, and
the resulting progeny having expression of the desired phenotypic characteristic identified, i.e., reduced expression of
one or more cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine, and thus reduced
content of nornicotine, and a concomitant reduced content of
its nitrosamine metabolite, NNN, in the plant, particularly in
the leaf tissues. Two or more generations may be grown to
ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested
to ensure expression of the desired phenotypic characteristic
has been achieved. In this manner, the present invention provides transformed seed (also referred to as "transgenic seed")
having a polynucleotide of the invention, for example, an
expression cassette of the invention, stably incorporated into
their genome.
The compositions and methods of the invention can be
used to reduce the nornicotine content, particularly in the
leaves and stems, of any plant of the genus Nicotiana including, but not limited to, the following species: acuminata,
ajfinis, alata, attenuate, bigelovii, clevelandii, excelsior, forgetiana, glauca, glutinosa, langsdorjfii, longiflora, obtusifolia, palmeri, paniculata, plumbaginifolia, qudrivalvis,
repanda, rustica, suaveolens, sylvestris, tabacum, tomentosa,
trigonophylla, and x sanderae. The present invention also
encompasses the transformation of any varieties of a plant of
the genus Nicotiana, including but not limited to Nicotiana
acuminata multiflora, Nicotiana alata grand flora, Nicotiana
bigelovii quadrivalvis, Nicotiana bigelovii wallacei, Nicotiana obtusifolia obtusifolia, Nicotiana obtusifolia plameri,
Nicotiana quadrivalvis bigelovii, Nicotiana quadrivalvis
quadrivalvis, Nicotiana quadrivalvis wallacei, andNicotiana
trigonophylla palmeri, as well as varieties commonly known
as flue or bright varieties, Burley varieties, dark varieties, and
oriental/Turkish varieties.
The transgenic plants of the genus Nicotiana as described
herein are suitable for conventional growing and harvesting

techniques, such as cultivation in manure rich soil or without
manure, bagging the flowers or no bagging, or topping or no
topping. The harvested leaves and stems may be used in any
traditional tobacco product including, but not limited to, pipe,
cigar and cigarette tobacco, and chewing tobacco in any form
including leaf tobacco, shredded tobacco, or cut tobacco.
Thus the present invention provides a Nicotiana plant,
particularly leaf tissues of these plants, comprising an expression cassette of the invention and a reduced amount of nornicotine and N'-nitrosonornicotine. As used herein, the term "a
reduced amount" or "a reduced level" is intended to refer to an
amount of nornicotine and/or N'-nitrosonornicotine in a
treated or transgenic plant of the genus Nicotiana or a plant
part or tobacco product thereof that is less than what would be
found in a plant of the genus Nicotiana or a plant part or
tobacco product from the same variety of tobacco, processed
(i.e., cultured and harvested) in the same manner, that has not
been treated or was not made transgenic for reduced nornicotine and/or N'-nitrosonornicotine. The amount of nornicotine may be reduced by about 10% to greater than about 90%,
including greater than about 20%, about 30%, about 40%,
about 50%, about 60%, about 70%, and about 80%.
The term "tobacco products" as used herein include, but
are not limited to, smoking materials (e.g., cigarettes, cigars,
pipe tobacco), snuff, chewing tobacco, gum, and lozenges.
The present invention also encompasses a range of tobacco
product blends that can be made by combining conventional
tobacco with differing amounts of the low nornicotine and/or
N'-nitrosonornicotine tobacco described herein. In further
embodiments, the plant or plant part of the genus Nicotiana as
described above is cured tobacco.
In some embodiments of the present invention, the tobacco
product reduces the carcinogenic potential of tobacco smoke
that is inhaled directly with consumption of a tobacco product
such as cigars, cigarettes, or pipe tobacco, or inhaled as secondary smoke (i.e., by an individual that inhales the tobacco
smoke generated by an individual consuming a tobacco product such as cigars, cigarettes, or pipe tobacco). The cured
tobacco described herein can be used to prepare a tobacco
product, particularly one that undergoes chemical changes
due to heat, comprising a reduced amount of nornicotine
and/or N'-nitrosonornicotine in the smoke stream that is
inhaled directly or inhaled as secondary smoke. In the same
manner, the tobacco products of the invention may be useful
in the preparation of smokeless tobacco products such as
chewing tobacco, snuff, and the like.
The tobacco products obtained from the transgenic tobacco
plants of the present invention thus find use in methods for
reducing the carcinogenic potential of these tobacco products, and reducing the exposure of humans to the carcinogenic nitrosamine NNN, particularly for individuals that are
users of these tobacco products.
The following examples are offered by way of illustration
and not by way of limitation.
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The following materials and protocols were utilized in the
experiments described herein below.
Plant Materials
All plant materials utilized in these experiments were provided by Dr. Earl Wernsman, Department of Crop Science,
North Carolina State University. DH 91-1307-46(NC) and
DH91-1307-46(Con) are near-isogenic doubledhaploidBurley lines (nonconverter and converter, respectively) recovered
from the same maternal haploid plant. Burley lines DH
98-326-3 (nonconverter) and DH 98-326-1 (converter), and
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DH 98-325-5 (nonconverter) and DH 98-325-6 (converter)
represent two additional pairs of near-isogenic lines. SC58 is
a flue-cured tobacco variety, nonconverter individuals of
which are designated SC58(czer)· SC58(CzCr) is a nearisogenic stable converter line that originated though the intragression of the single dominant converter locus (Cr) found in
the tobacco progenitor species N. tomentosiformis into SC58
(Mann eta!. (1964) Crop Sci. 4:349-353. After eight additional backcrosses to SC58, the near-isogenic SC58(CzCr)
line was created and subsequently maintained via self-fertilization.
All plants were maintained in growth chambers or greenhouses using standard potting soil and fertilizer. For the
microarray studies, the metabolism of nicotine to nornicotine
was accelerated by excising individual leaves and inserting
their petioles into a solution of0.1% ethephon or 1% sodium
bicarbonate. The leaves were then placed in a growth chamber (27° C.) for 5 to 7 hours to facilitate the entry of the
ethephon or sodium bicarbonate solutions throughout the
transpirational stream. The treated leaves were placed in
small plastic storage bags after being lightly sprayed with
water (to maintain high humidity) and cured for three days at
30° C. in the dark. To enhance the nicotine to nornicotine
conversion in the transgenic plants generated in this study,
detached leaves were dipped into a solution of 0.2% ethephon, dried, and cured in plastic storage bags for seven days at
room temperature in the dark.
eDNA Libraries and Expressed Sequence Tags
Total cellular RNA was isolated from senescing leaf tissue
of Burley lines DH 91-1307-46(NC) and DH 91-1307-46
(Con) using the TRizol® reagent according to the manufacturer's protocol (Invitrogen). PolyA+RNA was isolated from
total RNA using the MessageMaker system (Invitrogen), and
eDNA was subsequently synthesized and cloned into the
lambda ZAP II phage vector using the ZAP-eDNA Synthesis
and Gigapack III Gold Cloning Kit (Stratagene ). Aliquots of
the phage libraries were converted to pB!uescript-based plasmid libraries following the mass excision protocol outlined
by Stratagene.
Thousands of colonies from both the converter and nonconverter libraries were grown on selective solid media and
picked into 384-well plates containing Luria broth (with
ampicillin) in 10% glycerol to facilitate long term storage of
the clones at -80° C. Over 11,000 clones from each library
were transferred from the 384-well plates to 96-well growth
blocks and grown in selective media. Plasmids were isolated
in 96-well format using the R.E.A.L. Preparation Kit
(Qiagen) with the aid of a BioRobot 3000 Workstation
(Qiagen). To generate the ESTs, the plasmid clones were
sequenced using the T3 primer (Qiagen) and BigDye® Terminator system (Applied Biosystems) according to the BigDye® cycle sequencing protocol. Performa® DTR 96-well
plates (Edge Biosystems) were used to remove the unincorporated dye from the sequencing reactions prior to loading
the samples onto a Perkin Elmer Prism 3700 96-Capillary
Automated DNA Sequencer.
Preparation of DNA Chips
To obtain DNAs suitable for spotting onto glass slides, the
M13 forward and reverse sequencing primers (Qiagen) were
used as PCR primers to amplifY eDNA inserts from the plasmids containing cDNAs represented in the EST databases.
Plasmid clones were subjected to PCR in 96-well format
using an Applied Biosystems Gene Amp 9700 model thermocycler. The resulting PCR products were processed
through Millipore Multiscreen™ PCR or Montage™
PCRf196 purification systems. The resulting products were
transferred into 384-well plates containing equal volumes of

DSMO. The final DNA concentrations were estimated to be
equal to or greater than 0.1 mg/ml. The DNAs were subsequently spotted onto amino silane-coated slides (Corning®
GAPS II) using anAffymetrix GMS 417 array printer. DNAs
were immobilized to the slide surface by UV crosslinking
(-120 mJ/m 2 ), followed by baking at 75° C. for two hours.
Microarray Hybridization and Analysis
The amino allyl dUTP-based indirect method of dye incorporation described by "The Institute of Genome Research"
(http://pga.tigr.org/protocols.html) was used to label nonconverter and converter RNAs with Cy3 and Cy3 fluorescent
dyes (Amersham Biosciences ). Briefly, 20 flg of total RNA
was reverse transcribed in a 30 fll volume containing 400 units
of SuperScript II RT (Invitrogen), 6 ng random hexamer
primers, 0.5 mM each of dATP, dCTP, and dGTP, 0.3 mM
dTTP, and 0.2 mM amino allyl dUTP (Sigma) in first strand
synthesis buffer (Invitrogen). Reactions were incubuted for 6
to 14 hours at 42° C., followed by hydrolysis of the RNA with
NaOH. The resulting first strand eDNA molecules were colunm purified (Qiagen) and washed with phosphate buffer.
Coupling reactions of the NHS-ester Cy3 or Cy5 fluorescent
dyes to the eDNA occurred during incubation in 0.05 M
sodium carbonate buffer (pH 9.0) and 25% DMSO at room
temperature for 1.5 hours.
Microarray slides were prehybridized in a solution of
5xSSC, 0.1% SDS, and 1% BSA at 42° C. for 45 minutes,
rinsed gently with dH 2 0 and isopropanol, and dried by low
speed centrifugation. The Cy3- and Cy5-labeled cDNAs were
column purified (Qiagen), combined, and hybridized to the
DNA slides in a solution containing 5xSSC, 0.5% SDS,
5xDenhardt's, 0.45 flg/fll Poly ARNA, 0.45 flg/fll calf thymus
DNA, and 50% formamide. The slides were incubated with
the hybridization solution for 14 to 16 hours at 42° C. Posthybridization washes consisted of sequential 4-minute incubations with the following solutions: 1xSSC, 0.2% SDS;
0.1xSSC, 0.2% SDS; 0.1xSSC, and a final 10 second rinse
with 0.01xSSC.
The microarrays were subsequently scanned using ScanArray 2.1 (GSI Lumonics) or ScanArray Express (PerkinElmer). Sequential scanning for Cy5 and Cy3 fluorescence
was performed at a maximal resolution of 10 grn/pixel, and
laser power and PMT gain adjusted to provide reliable and
equivalent signal strengths. The acquired array images were
quantified for signal intensity with QuantArray™ analysis
software (PerkinElmer), using the histogram-based method.
Total intensities were used as quantification output fields, and
the acquired data sets were saved as Unicode, tab-delimited
text files. Importation of the text files into Microsoft Excel
enabled the subsequent calculation ofCy5/Cy3 and Cy3/Cy5
ratios, the statistic we employed for the identification of candidate genes.
Cloning Full-Length andAdditional Members of the 3D_C 12
Gene Family
To clone the entire coding region of3D_C12 and 7D_A06
a modified 5'-RACE strategy was employed using a pB!uescript II vector-specific forward primer (BlueSK;
5'-CGCTCTAGAACTAGTGATC-3'; SEQ ID NO: 17) and a
set of gene-specific reverse primers. Two 3D_C12-specific
reverse primers were designed, one of which is complementary to the downstream portion of the 3' nntranslated region
(5'-TTTTTGGGACAATCAGTCAA-3'; SEQ ID NO: 18) and
the other complementary to a sequence within the coding
region (5'-GTTAGATTTATCGTACTCGAATT-3'; SEQ ID
N0:19). For the former primer, the first five Ts are complementary to the polyA tail of the transcript. A 7D_A06-specific
reverse primer (5'-TTCATTTCAAATTATTTTATGCACCA3'; SEQ ID N0:20) was also designed, and is complementary
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to a segment in the 3' untranslated region of this gene. PCR
reactions contained 10 ng of converter tobacco leaf eDNA
library (within the pB!uescript vector) as template, 2 f.LM
concentration of each primer, 350 f.LM of each dNTP, and 1.5
mM MgC1 2 in a final reaction volume of 50 f.LL. Amplification
was initiated by the addition of 2.5 units of UniPol enzyme
mix using conditions described by the manufacturer (Roche).
After an initial denaturation step at 94 o C. for 4 minutes, the
samples were subjected to 30 cycles of denaturation at 94 o C.
for 15 seconds, annealing at 57° C. for 30 seconds, and
extension at 72° C. for 90 seconds. A final extension step at
72o C. for 10 minutes was includedattheendofthe 30 cycles.
The amplicons were ligated into the pGEM Easy T/A vector
(Promega), and 10 randomly selected clones from each
amplification were subjected to DNA sequence analysis.
Nucleic acid and predicted protein sequences of the various
members of the 3D_C12 gene family were analyzed and
compared using the BLASTX (Altschul eta!. (1997) Nucleic
Acids Res. 25:3389-3402), ClustalW (Higgins eta!. (1994)
Nucleic Acids Res. 22:4673-4680) and GAP (University of
Wisconsin Genetic Computing Group software package)
algorithms.
The above described strategy was effective in identifying
full-length sequence information for 3D_C12 and 7D_A06.
In addition, PCR amplifications using the PCR primer internal to the 3D_C 12 coding region gave rise to partial-sequence
information for the unique 3D_C12-15 eDNA. In an attempt
to obtain full-length sequence information for 3D_C 12-15, a
gene-specific primer complementary to the 5' terminus of its
coding region ( 5'-ATGGTTTTTCCCATAGAAGCC-3'; SEQ
ID N0:21) was used in conjunction with a pB!uescript-specific reverse primer (5'-TCGAGGTCGACGGTATC-3'; SEQ
ID N0:22). Although a full-length 3D_C12-15 eDNA was
not recovered, this amplification resulted in the isolation of
3D_C12-7, which proved to be another unique member of the
3D_C12 gene family.
Transgenic Plant Analysis
The RNAi-based gene silencing constructs were
assembled in a version of the pKYL80 cloning vector
(Schardl eta!. (1987) Gene 61:1-11) that was engineered to
contain a 151-bp fragment of the soybean FAD3 gene intron
between the Xhol and Sad restriction sites of the polylinker
(pKYLX80I). To create a construct in which the FAD3 intron
was flanked by a sense and antisense fragment of3D_C12, a
99-bp region located immediately upstream of the stop codon
ofthe3D_C12 eDNA (FIGS. 3A-3G)was cloned between the
Hindiii-Xhol and Sacl-Xbal restriction sites of pKYLX80I in
its sense and antisense orientation, respectively. The resulting
Hindiii-Xbal fragment containing the 3D_C12 sense arm,
FAD3 intron, and 3D_C12 antisense arm was subcloned into
the pKYLX71 plant binary expression vector (Maiti et a!.
(1993) Proc. Nat!. Acad. Sci. USA 90:6110-6114) between
the 35S CaMV promoter and a rubisco small subunit terminat or.
Overexpression constructs were created by replacing the
3-glucuronidase ORF of the plant binary expression vector
pBI121 (Clontech) with the full-length coding regions of the
3D_C12, 7D_A06, and 3D_C12-7 cDNAs. This placed the
tobacco P450s under the transcriptional control of the 35S
CaMV promoter. The pBI121- and pKYLX71-based constructs were transformed into Agrobacterium tumefaciens
strain LBA 4404 and introduced into tobacco cultivars Petite
Havana and DH98-325-6 (converter), respectively, using
established protocols (Horsch eta!. (1985) Science 227:12291231).

Northern Blot Analysis
Total cellular RNAs were isolated from tobacco leaves
using the TRIZOL® method as described by the manufacturer (Invitrogen). Five to ten micrograms of RNA were size
fractionated on a 1.2% agarose gel prepared in TBE buffer.
RNA immobilization, probe labeling, and signal detection
were carried out using the DIG nucleic acid labeling and
detection kits according to the manufacturer's instructions
(Roche). Alternatively, probes were synthesized using 32 PdCTP according to protocols accompanying the Random
Primed DNA Labeling kit (Roche).
Alkaloid Analysis
Tobacco leaves were harvested and air dried in an oven at
65° C. for 2 days.A 100mg sample of crushed, dried leaf was
addedto0.5 ml of2 NNaOHina20mL scintillation vial. The
sample was mixed and allowed to incubate for 15 minutes at
room temperature. Alkaloids were extracted by the addition
of 5 mL of extraction solution [0.04% quinoline (wt/vol)
dissolved in methyl-t-butyl ether] and gently rotated on a
linear shaker for 3 hours. Following phase separation, an
aliquot of the organic phase was transferred to a sample vial.
Samples were analyzed using a PerkinElmer Auto system XL
gas chromatograph equipped with a flame ionization detector,
a 4 mm split/splitless glass liner, and a 30 mx0.53 mm ID
DB-5 colunm. Chromatographic conditions were as follows:
detector temperature: 250° C.; injector temperature: 250° C.;
helium flow rate at 120° C.: 20 mL/min; injection volume: 2
f.LL; column conditions: 120° C., hold 1 minute, 120-280° C.
at 30° C./minute ramping rate, hold at 280° C. for 2 minutes.
Alkaloid composition was determined by the TotalChrome
Navigator software using a calibration curve.
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Generation of EST Databases
RNAs isolated from senescing leaves of the converter
genotype DH 91-1307-46(Con) and its near-isogenic nonconverter counterpart DH 91-1307 -46(NC) were used to generate eDNA libraries. High-throughput automated DNA
sequencers were initially used to generate single-run
sequence information (ESTs) for 11,136 randomly chosen
cDNAs from the converter library. The local alignment search
tool BLASTX (Altschul eta!. (1990) J. Mol. Biol. 215:403410) was used to compare the predicted protein sequence of
each tobacco eDNA with the nonredundant protein database
curated by the National Center for Biotechnology Information of the National Library of Medicine and National Institutes of Health. Subsequently, a similar annotated EST database was generated by conducting sequencing runs on 11,904
cDNAs selected from the nonconverter library.
Example 2
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Microarray Analyses of Converter CDNA Library
Methods
Upon completion of the EST database generated from the
converter eDNA library, the inserts from 4992 clones were
amplified by PCR and spotted onto glass slides. Given the
possibility that the nicotine demethylase enzyme may be
catalyzed by an enzyme of the P450 class of oxidative
enzymes, special attention was given to library entries that
were predicted by BLASTX analysis to encode P450s.
From visual inspection of the BLASTX results, it was
estimated that 31 unique P450 genes were represented in the
database. When selecting specific 96-well plates to be
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included on the microarray, care was taken to ensure that all
unique P450 genes would be included among the 4992
cDNAs selected.
RNAs isolated from the near-isogenic Burley genotypes
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter),
and DH 98-325-5 (nonconverter) and DH 98-325-6 (converter) were used to generate Cy3- and Cy5-labeled cDNAs.
To maximize the metabolic conversion of nicotine to nornicotine in converter genotypes, detached leaves were treated
with sodium bicarbonate or ethephon prior to curing, treatments that have been shown to accelerate nomicotine production in converter plants while having no effect in nonconverter
individuals (Fannin and Bush (1992) Med. Sci. Res. 20:867868; Shi eta!. (2003) J. Agric. Food Chern. 51:7679-7683).
To minimize the variability inherent with microarray
experiments, reciprocal experiments were conducted simultaneously. In this manner, DH 98-325-5 RNA was labeled
with Cy5 and DH 98-325-6 RNA was labeled with Cy3, and
then in a reciprocal experiment DH 98-325-5 RNA was
labeled with Cy3 and DH 98-325-6 RNA was labeled with
Cy5 (collectively referred to as Exp. 2.1). Similarly, DH
98-326-3 and DH 98-326-1 RNAs were labeled with Cy3 and
Cy5, respectively, in one experiment, and then the same
RNAs were labeled with Cy5 and Cy3, respectively, in a
reciprocal experiment (collectively referred to as Exp. 2.2).
Even when conducted reciprocally, the results of any given
microarray experiment are likely to include "false positives,"
representing genes that are differentially regulated between a
specific genotypic pair and/or uniquely in response to a specific treatment, as opposed to differences directly associated
with the conversion phenomenon. To define the set of candidate genes that are most likely to be upregulated due to the
conversion process, cDNAs were identified that met the following criteria: for any set of reciprocal experiments (i.e.,
Exp. 2.1, or Exp. 2.2), the hybridization intensity of a given
eDNA had to be at least 2-fold higher with the converter probe
than nonconverter probe in at least one of the hybridizations,
and not less than 1.5-fold higher in the reciprocal experiment.
Experiment 2.1-Leaves from near-isogenic lines DH
98-325-5 and DH 98-325-6 were treated with ethephon and
cured for 3 days at 30° C. Alkaloid analysis revealed that
virtually all of the nicotine had been metabolized to nomicotine in the DH 98-325-6leaf during this period while minimal
nomicotine was observed in the DH 98-325-5 leaf. RNAs
from the DH 98-325-5 nonconverter plant were labeled with
the Cy3 fluorescent dye, and RNAs extracted from a DH
98-325-6 (converter) leaf were labeled with Cy5. The Cy3and Cy5-labeledcDNAs were incubated together on the same
DNA chip and allowed to hybridize overnight.
Experiment 2.2-Amicroarray analysis similar to Exp. 2.1
was conducted using the DH 98-326-3 (nonconverter) and
DH 98-326-1 (converter) near-isogenic lines. In these experiments, leaves from each genotype were treated with 1%
sodium bicarbonate and cured for 3 days at 30° C. At the end
of the treatment period, nicotine was the predominant alkalaid in the DH 98-326-3 leaf, while nearly all of the alkaloid
in the DH 98-326-1 leaf was nornicotine. As described for
Exp. 2.1, these experiments were reciprocally conducted.
Results
In both Experiment 2.1 and Experiment 2.2, the great
majority of the 4992 cDNAs spotted on the glass slides
showed no substantial differences in their hybridization
intensities to the competing Cy3- and Cy5-labeled probes.
Of the 4992 cDNAs spotted on the glass slides, only five
showed at least 2-fold higher expression in one hybridization
and not less than 1.5-fold in the reciprocal hybridization for
both Exp. 2.1 and Exp. 2.2. These entries were designated

3D_C12, 7D_A06, 27C_C12, 33A_D06, and 34D_F06.
BLASTX analysis of the partial sequence information for
3D_C12 and 7D_A06 found in our EST database predicted
that the cDNAs encode two closely related P450 enzymes.
27C_C12 and 33A_D06 were predicted to encode glycinerich cell wall proteins, displaying over 90% sequence identity
to small tobacco glycine-rich proteins found in GenBank
(e.g., Accession No. AAK57546). Clone 34D_F06 was found
to contain a double eDNA insert, one insert showing homology to serine/threonine protein kinases, and the other showing high sequence identity to the same glycine-rich cell wall
proteins as the 27C_C12 and 33A D06 cDNAs.
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Upon completion of the EST database from the nonconverter library (generated from senescing leaves of genotype
DH 91-1307-46 (NC) ), another set of microarray experiments
was initiated. For this next generation of microarrays, the goal
was to produce glass slides containing the complete nonredundant set of genes represented in both libraries.
To obtain an estimate of the number of unique genes that
are represented in the database, clustering analysis was conducted to identifY ESTs predicted to be represented multiple
times in the database (contigs) versus those predicted to be
represented only once (singletons) (Huang and Madan (1999)
Genome Res. 9:868-877). Due to the nature of the clustering
algorithms, sequences showing high, but imperfect, sequence
identities are clustered into the same contig. The total set of
predicted unique genes, or unigenes, within a database is
calculated as the sum of the contigs and singletons. Clustering
analysis of the combined converter and nonconverter databases predicted 2246 contigs and 4717 singletons for a total of
6,963 unigenes. Inserts from all singletons and an individual
from each contig were amplified by PCR and spotted onto
glass slides, resulting in a gene chip containing the complete
6,963 unigene set.
In addition to creating a new DNA chip, the genetic materials used to generate hybridization probes also differed from
those used in Example 2. SC58 is a flue-cured tobacco variety,
nonconverter individuals of which are designated SC58
(crer)· SC58(CrCr) is a near-isogenic stable converter line
that originated though the introgression of the single dominant converter locus (Cr) found in the tobacco progenitor
species N. tomentosiformis into SC58 (Mann eta!. (1964)
Crop Sci. 4:349-353). After eight additional backcrosses to
SC58, the near-isogenic SC58(CrCr) line was created and
subsequently maintained via self-fertilization. The conversion phenotype of SC58(CrCr) plants is unique with respect
to standard converter tobacco lines in that the metabolism of
nicotine to nornicotine in the leaf does not require senescence
or curing. Plants possessing the Cr converter locus from N.
tomentosiformis contain nomicotine as the predominant alkaloid even in green leaf tissue (Wemsman and Matzinger
(1968) Tab. Sci. 12:226-228).
RNAs isolated from green leaf tissue of SC58(CrCr) and
SC58(CrCr) were labeled with Cy3 and Cy5, respectively,
and simultaneously hybridized to a DNA chip containing the
entire 6,963 unigene set of cDNAs. The fluorescent dyes were
reversed to produce the probes for a reciprocal experiment as
described in Exps. 2.1 and 2.2 of Example 2.
Results
Results were evaluated using the same criteria as in
Example 2, i.e., individual cDNAs were identified that
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showed at least 2-fold enhanced hybridization to the labeled
SC58(CzCr) versus SC58(czer) cDNAs in one experiment
and at least 1.5-fold enhancement in the reciprocal assay.
Results were compared to those from Exp. 2.1 and Exp. 2.2
in Example 2 above. Enhanced hybridization of converter
RNAs to cDNAs encoding members of the same closely
related P450 family was the only result shared by all three
microarray experiments using the defined criteria. 131
A_A02 is the name of the eDNA that was spotted onto the
6963-member unigene chip that is representative of the
closely-related P450 gene family that includes 3D_C12 and
7D_A06 (3D_C12 and 7D_A06 themselves were not spotted
on the unigene slide). No other cDNAs on the array in
Example 3, which included representatives of the contigs
containing the glycine-rich protein-encoding 27C_C12 and
33A_D06 and 34D_F06 cDNAs, scored positive by the
defined criteria and also scored positive in Exp. 2.1 or Exp.
2.2 of Example 2 above, regardless of whether the results
were compared individually or collectively.

sequenced when generating the EST database described elsewhere herein (and spotted onto the microarrays) were not
full-length cDNAs. To obtain a full-length sequence, primers
were generated corresponding to regions in the 3' flanking
region and in the interior of the coding regions that were
sufficiently polymorphic to distinguish between 7D_A06 and
3D_C12. These gene-specific primers were used in combination with primers specific to the cloning site of pB!uescript II
to amplifY cDNAs from the converter eDNA library in an
attempt to obtain sequence that would include the complete 5'
ends of the 3D_C12 and 7D_A06 reading frames.
This strategy led to the determination of the DNA sequence
corresponding to the complete coding regions of3D_C12 (nt
1-1551 of SEQ ID N0:1; predicted amino acid sequence
shown in SEQ ID N0:2) and 7D_A06 (nt 1-1554 of SEQ ID
N0:7; predicted amino acid sequence shown in SEQ ID
NO:S) (FIGS. 3A-3G and 4). GAP analyses of the 3D_C12
and 7D_A06 DNA and predicted protein sequences showed
that they share 93.4% DNA sequence identity and 92.3%
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TABLE 1
Microarray results of members oftbe 3D_C12 gene family
Experiment 2.1

eDNA
3D C12
7D_A06

Experiment 2.1 (reciprocal)

Cy3

Cy5

Cy5/Cy3

Cy3

Cy5

Cy5/Cy3

reading

reading

ratio

reading

reading

ratio

15514.14
15238.23

25928.95
37196.19

1.67
2.44

19355.85
13651.03

9507.87
8121.04

2.04
1.68

Experiment 2.2

3D C12
7D_A06

Experiment 2.2 (reciprocal)

Cy3

Cy5

Cy5/Cy3

Cy5/Cy3

reading

ratio

Cy3
reading

Cy5

reading

reading

ratio

12756.43
7571.06

28669.28
19180.94

2.25
2.53

32198.81
42408.85

16166.13
18440.17

1.99
2.30

Example 3

131A_A02

Example 3 (reciprocal)

Cy3

Cy5

Cy5/Cy3

Cy3

Cy5

Cy5/Cy3

reading

reading

ratio

reading

reading

ratio

11138.96

19638.82

1.76

36963.45

10085.25

3.67

Combined Results
The combined results of micro array experiments described
above defined members of a closely related P450 gene family,
hereafter referred to as the 3D_C12 family, to be the best
candidates for playing a direct role in the metabolic conversion of nicotine to nornicotine in converter tobacco plants.
The hybridization results of the members of this P450 family
in each of the three microarray experiments are shown in
Table 1. The results of the microarrays were independently
confirmed using Northern blotting assays. As shown in FIG.
2, an approximately 2-fold higher signal was observed in
senescing, cured converter leaves compared to their nonconverter counterparts when RNA blots were incubated with a
radiolabeled 7D_A06 hybridization probe.
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identity at the protein level (Tables 2 and 3). Initial BLASTX
analysis against the nonredundant GenBank database
revealed that 3D_C12 and 7D_A06 share greatest sequence
homology to CYP82E1, a tobacco P450 gene of unknown
function that is upregulated in response to fungal elicitors
(Takemoto eta!. (1999) Plant Cell Physiol. 40:1232-1242).
The CYP82E1 protein is 66.9% and 67.5% identical to the
predicted amino acid sequences of3D_C12 (SEQ ID N0:2)
and 7D_A06 (SEQ ID NO:S), respectively, and the CYP82E1
DNA sequence is 72.1% and 73.5% identical to the respective
coding sequences for 3D_C12 (nt 1-1551 of SEQ ID N0:1)
and 7D_A06 (nt 1-1554 of SEQ ID N0:7).
TABLE2

Example 4
60

Nucleotide sequence identities between members oftbe 3D_C12 gene
famil.

Sequence Analysis of the 3D_C12 Gene Family
Once microarray experiments defined 3D_C12 and
7D_A06 as potentially being involved in the conversion process, obtaining complete DNA sequence information for
these genes became the next step in their characterization.
The original 3D_C12 and 7D_A06 clones that were

7D_A06
3D_C12-7
65 3D_C12-10
3D_C12-

3D C12

7D_A06

3D_C127

3D C1210

93.4**
93.7
93.7
95.5

94.0
94.4
92.6

99.7
93.1

92.8

3D_C1215*
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TABLE 2-continued

(SEQ ID N0:5) (FIGS. 3A-3G), and at only two amino acids
positions from the predicted 3D_C 12-7 protein product (SEQ
ID N0:6) (FIG. 4).
With the completion of the nonconverter EST database,
another member of the 3D_C12 gene family was revealed.
The partial DNA sequence of 131A_A02 (SEQ ID NO: 11;
predicted amino acid sequence set forth in SEQ ID N0:12)
that is found in this database is 98.0% identical to the corresponding sequence of 3D_C12, and 94.0% identical to the
same region of 7D_A06 (FIGS. 3A-3G and Table 2). As
described in the previous section, 131A_A02 is a member of
the 3D_C12 gene family that was represented on the comprehensive unigene chip used in microarray assays as described
elsewhere herein.

Nucleotide sequence identities between members oftbe 3D_C12 gene
famil.

3D_C12

7D_A06

3D C127

3D C1210

3D C1215*

98.0

94.0

93.4

93.1

93.1

15*
131A_A02*

*partial sequences
**numbers indicate percentages
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TABLE3
Predicted amino acid sequence identities between full-lengtb members of
tbe 3D C12 gene family.
3D C12

7D_A06

3D C12-7

92.3*
92.8
92.5

94.8
94.4

99.6

7D_A06
3D C12-7
3D C12-10

15

Example 5
Transgenic Plant Analysis of Members ofthe
3D_C12 Gene Family
20

**numbers indicate percentages

In addition to enabling the acqmsJtJon of full-length
sequence information for the 3D_C12 and 7D_A06 cDNAs,
the above described PCR amplifications yielded additional
products that were closely related to, yet clearly distinct from,
the 3D_C12 and 7D_A06 eDNA sequences. Using a primer
directed against a sequence interior to the 3D_C12 eDNA, in
combination with a primer specific to pB!uescript II, a unique
sequence designated 3D_C12-15 (FIGS. 3A-3G; SEQ ID
N0:9; predicted amino acid sequence shown in SEQ ID
N0:10) was amplified in addition to the expected 3D_C12
product. 3D_C12-15 is 95.5% identical to the corresponding
DNA sequence of3D_C12 and 92.6% identical to the same
region of7D_A06 (Table 2).
Because the 3D_C12-15 fragment represented an additional, distinct member of the 3D_C12 gene family, an
attempt was made to obtain a full-length eDNA sequence of
this gene. A PCR primer specific to the first seven codons of
the 3D_C12-15 reading frame was used in combination with
a pB!uescript II-specific primer in an amplification reaction
using our converter eDNA library as template. Sequence
analysis of several independent amplification products failed
to reveal a full-length 3D_C12-15 gene. Instead, a new member of this family was recovered, designated 3D_C12-7
(FIGS. 3A-3G; coding sequence set forthasnt 1-1551 of SEQ
ID N0:5). Across the full-length nucleotide sequence shown
in SEQ ID N0:5, 3D_C12-7 shares 93.7% nucleotide
sequence identity with 3D_C12 (across SEQ ID N0:1),
94.0% nucleotide sequence identity with 7D_A06 (across
SEQ ID N0:7), and 93.1% identity over the corresponding
region of fragment 3D_C12-15 (SEQ ID N0:9) (Table 2).
The predicted amino acid sequence of 3D_C12-7 (SEQ ID
N0:6) is 92.8% identical to the 3D_C12 protein (SEQ ID
N0:2), and 94.8% identical to the 7D_A06 protein (SEQ ID
N0:8) (Table 3).
Two additional members of the 3D_C12 family were also
identified. A gene designated 3D_C12-10 (FIGS. 3A-3G;
coding sequence set forth as nt 1-1551 of SEQ ID N0:3;
predicted amino acid sequence set forth in SEQ ID N0:4) was
recovered from an amplification reaction using a PCR primer
complementary to a sequence in the 3' flanking region of
3D_C 12 together with a Bluescript II -specific primer (and the
converter library as template). 3D_C12-10 differs at only five
nucleotide positions from the 3D_C12-7 nucleotide sequence

25

30

35

40

45

50

55

60

65

To determine whether members of the 3D_C12 family of
cytochrome P450 genes are involved in the metabolic conversion of nicotine to nomicotine, transgenic plants were
generated using constructs designed to either enhance or
inhibit gene expression. To test the effects of down-regulating
gene activity, an RNA interference (RNAi) strategy was
employed. A 99-bp region of 3D_C12 located immediately
upstream of the stop codon (FIGS. 3A-3G), was used to create
a construct that would form a dsRNA hairpin within the plant
cell. Such dsRNA structures are known to activate an RNAi
silencing complex that leads to the degradation of both transgene RNAs and endogenous RNAs that are identical or highly
homologous to the sequence found in the dsRNA (Wesley et
a!. (2001) Plant J. 27: 581-590; Waterhouse & Helliwell
(2002) Nat. Gen. Rev. 4: 29-38).
Given that each member of the 3D_C12 characterized as
described herein shares over 90% DNA sequence identity, an
RNAi construct synthesized against one member was
expected to silence the entire gene family. Specifically, the
RNAi construct generated against the 3D_C12 sequence
shares sequence identities of 90/99 and 91/99 with the
7D_A06 and 3D_C12-7 cDNAs, respectively, over this
region (FIGS. 3A-3G). The 3D_C12/RNAi construct (also
referred to in Example 7 as the 3D_Cl2Ri99 construct) was
cloned downstream of the constitutive 35S promoter of cauliflower mosiac virus (CaMV) and introduced into the strong
converter Burley tobacco line DH 98-325-6 using Agrobacterium-mediated transformation.
A hallmark of RNAi-mediated silencing is the marked
reduction in steady-state transcript accumulation of the gene
whose activity has been down-regulated. To confirm that gene
silencing of the 3D_C12 gene family had occurred in the
plants showing low nomicotine phenotypes, a Northern blot
analysis was conducted using RNAs isolated from three of the
transgenic plants possessing 3D_C12/RNAi constructs and
displaying low nomicotine phenotypes, two individuals
transformed with the 3D_C12/RNAi construct yet still showing high levels of nomicotine, and one of the vector-only
control plants.
To assess the affects of overexpression of gene activity, the
cDNAs from the three members of the 3D_C12 gene family
for which we first obtained full-length sequence information
(3D_C12, 7D_A06, and 3D_C12-7) were cloned in their
sense orientations downstream of the 35S CaMV promoter.
These constructs were subsequently introduced into N.
tabacum cultivar Petite Havana using Agrobacterium-mediated transformation. The Petite Havana line is commonly
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used by researchers because of its shorter stature and abbreviated generation time in relation to commercial tobacco
cultivars. The converter/nonconverter status of the Petite
Havana cultivar is unknown, but the alkaloid assays of the
present application clearly showed that the plants in our possession were strong converters.
Although the host plants in these experiments were converters, the present strategy was to conduct alkaloid assays on
green, non-cured tissue, where minimal nornicotine accumulates in converter and nonconverter plants alike (and the 3 5 S
CaMV promoter is very active). In fact, a nonconverter line
was purposely chosen because tissue culturing, as required
when conducting Agrobacterium-mediated transformation,
is known to enhance the frequency of genetic conversion and
would thus potentially complicate interpretation of results
(e.g., assessing whether a novel phenotype was solely attributable to the transgene as opposed to being the result of the
plant having undergone genetic conversion).
Results
Given the high degree of variability typically observed
among independent transgenic plants transformed with the
same transgene construct, 10 independently transformed
individuals were selected to assess the effects of the 3D_C12/
RNAi construct on the metabolic conversion of nicotine to
nomicotine. Leaves from each of the 10 3D_C12/RNAi individuals, in addition to two control plants transformed with the
pBI121 vector alone, were treated with ethephon and cured
for seven days. Alkaloid analysis of these materials is shown
in Table 4.

struct displayed minimal nicotine to nornicotine conversion,
with conversion percentages ranging from 2.8 to 7.0 percent.
The other three 3D_C12/RNAi lines displayed alkaloid contents similar to the vector-only control plants. Concentrations
of the minor alkaloids anabasine and anatabine did not appear
to be significantly influenced by the presence or absence of
the 3D_C12/RNAi transgene (Table 4).
Although the eDNA insert of the 3D_C12-7 gene was used
as the specific hybridization probe, at the hybridization and
wash conditions used in this experiment, cross-hybridization
to the entire 3D_C12 gene family would be expected. As
shown in FIG. 5, a strong hybridization signal was detected in
each plant showing a high nomicotine phenotype, and minimal hybridization was detected in the plants transformed with
the 3D_C12/RNAi construct that showed a low nornicotine
phenotype. We thus conclude that the effective silencing of
the 3D_C12 gene family inhibits the metabolic conversion of
nicotine to nomicotine in tobacco.
Alkaloid analysis of the Petite Havana transgenic plants is
shown in Table 5. Four independently transformed plants
containing the 35S:3D_C12 and 35S:3D_C12-7 constructs
were tested along with seven independent 35S:7D_A06 individuals and three plants independently transformed with the
pBI121 control vector. As expected, the green, non-cured
leaves of the three vector-only control plants contained minimal amounts of nomicotine. Likewise, all plants transformed
with the 35S:3D_C12 and 35S:7D_A06 constructs showed
minimal metabolic conversion of nicotine to nomicotine. A
very different phenotype, however, was observed with plants
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TABLE4
Alkaloid analysis ofDH 98-325-6 plants independently transformed with the 3D_C12/RNAi
construct (and pBI121 vector control). Leaves were treated with ethephon and cured for
seven da s.

Sample
3D_C12 RNAi (1)
3D_C12 RNAi (2)
3D_C12 RNAi (3)
3D_C12 RNAi (4)
3D_C12 RNAi (5)
3D_C12 RNAi (6)
3D_C12 RNAi (7)
3D_C12 RNAi (8)
3D_C12 RNAi (9)
3D- C12RNAi
(10)
vector control (3)
vector control (11)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

3.149
2.569
2.175
3.517
1.085
0.025
0.027
2.268
2.197
2.434

0.100
0.193
0.064
0.125
0.868
2.260
1.867
0.128
0.133
0.112

0.012
0.009
0.007
0.012
0.009
0.011
0.011
0.009
0.008
0.009

0.159
0.110
0.080
0.139
0.119
0.122
0.122
0.102
0.099
0.110

2.8
7.0
2.9
3.4
44.4
98.9
98.6
5.3
5.7
4.4

1.811
0.290

1.1735
2.090

O.G18
0.013

0.170
0.143

48.9
87.8

*percentage of leaf dry weight
**[% nornicotine/(% nicotine+ nornicotine)] x 100
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Typical ofline DH 98-325-6, ethephon treatment and curing resulted in substantial nomicotine production in the two
control plants (48.9% and 87.8% conversion of nicotine to
nomicotine). In dramatic contrast, seven of the ten independent transgenic plants possessing the 3D_C12/RNAi con-

transformed with 35S:3D_C12-7. All four plants independently transformed with this construct contained nornicotine
as the predominant alkaloid in the green, nontreated leaf;
nicotine to nomicotine conversion percentages ranged from
94.6 to 98.6.
TABLES

Alkaloid analysis of individual Petite Havana plants transformed with 3D_C12, 3D_C12-7,
7D_A06 constructs or the pBI121 vector control. Green leaves were harvested and analyzed
without treatment or curing.

Sample
vector control (2)
vector control (8)
vector control (10)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

0.673
0.605
0.694

0.018
0.014
0.017

0.006
0.005
0.004

O.G18
0.016
O.G18

2.6
2.3
2.4
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TABLE 5-continued
Alkaloid analysis of individual Petite Havana plants transformed with 3D_C12, 3D_C12-7,
7D_A06 constructs or the pBI121 vector control. Green leaves were harvested and analyzed
without treatment or curing.

Sample
35S:3D_C12 (1)
35S:3D_C12 (2)
35S:3D_C12 (3)
35S:3D_C12 (4)
35S:3D_C12-7 (1)
35S:3D_C12-7 (2)
35S:3D_C12-7 (3)
35S:3D_C12-7 (4)
35S:7D_A06 (1)
35S:7D_A06 (2)
35S:7D_A06 (4)
35S:7D_A06 (5)
35S:7D_A06 (6)
35S:7D_A06 (7)
35S:7D_A06 (8)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

0.706
0.814
0.630
0.647
0.005
0.006
0.017
0.010
0.761
0.507
0.653
0.643
0.521
0.716
0.701

0.005
0.022
0.010
0.010
0.347
0.255
0.300
0.384
0.011
0.009
0.015
0.013
0.007
0.015
0.027

0.006
0.007
0.003
0.004
0.002
0.002
0.002
0.002
0.005
0.003
0.006
0.004
0.004
0.005
0.004

0.020
0.017
0.012
0.011
0.012
0.009
0.010
O.G15
O.G18
0.007
O.G15
O.G18
0.014
0.020
O.G18

0.7
2.6
1.6
1.5
98.6
97.4
94.6
97.5
1.4
1.7
2.2
2.0
1.3
2.1
3.7

*percentage of leaf dry weight
**[% nornicotine/(% nicotine+ nornicotine)] x 100
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Cosuppression of the 3D_C12 Gene Family
In addition to the major conclusion that the 3D_C12-7 gene
was capable of mediating nicotine to nornicotine conversion,
one additional observation stood out in the alkaloid analyses
of the Petite Havana transgenic plants. The alkaloid results
reported in Table 5 together with additional alkaloid assays

30

35S:3D_C12 (1) and two vector-only control plants. As
shown in Table 6, ethephon treatment and curing resulted in
over 97% nicotine to nomicotine conversion in the two control plants whereas similarly treated 35S:3D_C12 (1) leaves
displayed negligible conversion (0.6%). Leaves from five
other plants expressing either35S:3D_C12 and35S:7D_A06
transgenes were also subjected to ethephon treatment and
curing. In each case a high nomicotine phenotype was
observed, similar to the vector-only control plants (data not
shown).
TABLE6

Alkaloid analysis of35S:3D_C12 (1) and pBI121 vector controls plants. Leaves were
treated with ethephon cured for seven days.

Sample
vector control (8)
vector control (10)
35S:3D_C12 (1)

%

%

%

%

%

Nicotine*

Nornicotine*

Anabasine*

Anatabine*

Conversion**

0.009
0.008
1.185

0.425
0.560
0.007

n.d.
n.d.
n.d.

0.011
0.025
0.020

97.9
98.6
0.6

*percentage of leaf dry weight
**[% nornicotine/(% nicotine+ nornicotine)] x 100
n.d., not detected

conducted independently (data not shown) consistently
showed one of the plants transformed with the 35S:3D_C12
construct (35S:3D_C12(1)) as having less nornicotine in the
green, nontreated leaf than any other plant in this study. This
may be the result of co suppression of the 3D_C12 gene family in this specific plant, a phenomenon frequently observed
in transgenic plants even when a trans gene is expressed in its
sense orientation (Fagard and Vaucheret (2000) Annu. Rev.
Plant Physiol. Plant Mol. Biol. 51: 167-194).
If plant 35S:3D_C12 (1) was truly displaying a co suppression phenotype, this phenotype would be expected to be
maintained even upon ethephon treatment and curing of the
leaves, similar to the low nornicotine phenotypes conferred
by the 3D_C 12/RNAi construct in the converter genotype D H
98-325-6 as described above. To test this prediction, alkaloid
profiles were determined on ethephon treated, cured leaves of

50

55

60

65

Finally, Northern blot assays were conducted on select
plants representing each of the Petite Havana transgenic
genotypes (FIG. 6). Using a 3D_C12-7 eDNA as a hybridization probe, minimal signal was detected with RNAs isolated from green, nontreated leaves of the vector-only control
plant. In contrast, hybridization was easily detected in RNA
samples from all four independent transgenic plants possessing the 35S:3D_C12-7 construct. A strong hybridization signal was similarly observed using RNAs from all other transgenic plants tested that were transformed with the 35S:
3D_C12 and 35S:7D_A06 constructs, with the exception of
the low nomicotine containing plant 35S:3D_C12 (1).
Overall results of the Northern blotting assays show that
the 35S CaMV promoter was generally effective in mediating
a high level of gene expression for each of the three members
of the 3D_C12 gene family tested in this study. Failure to
detect a hybridization signal in plant 35S:3D_C12 (1) is con-
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a-tubulin gene was used as an internal standard. 3D_C12-7
eDNA concentration was determined from the transcriptspecific calibration curve and normalized to the internal stanExample 7
dard. Fold-induction was calculated by dividing the normals ized fluorescence values of the converter by the nonconverter
samples. Melting-curve analysis was used to confirm the
Additional Characterization and Suppression of
Additional3D_C12 Genes
purity of PCR products as described in Ririe eta!. (1997)
Anal. Biochem. 245:154-160. Two plants were sampled per
A second RNAi construct was prepared using polynucletreatment and amplifications were repeated three times.
otide sequences from the 3D_C12-7 sequence. The assembly 10 TaqMan® Chemistry
of the 3D_C12-7/RNAi expression cassette followed the
Total RNA was isolated from tobacco lines using TRizol
same basic steps as those outlined for 3D_C12/RNAi above.
reagent. Purified RNA was treated with RNase-free DNase
Briefly, a 298-bp sense and antisense strand of the 3D_C12-7
(TURBO DNA-free™). First strand eDNA was synthesized
eDNA (SEQ ID N0:5) corresponding to the region between
using 10 flg of total RNA and the High Capacity eDNA
nucleotide positions 297 and 594 of the coding sequence 15 Archive Kit (Applied Biosystems, Foster City, Calif.). The
(positions 1-1551 of SEQ ID N0:5) were ligated into the
RT-PCR mixture contained 1xTaqMan® Universal PCR
pKYLX801 vector downstream and upstream of the 151-bp
Master Mix (Applied Biosystems, Foster City, Calif.), 400
soybean omega-6 fatty acid desaturase intron (see GenBank
nM of each primer (E4TmFwd and E4TmRev), 250 nM TaqAccession No. DQ6n337), respectively. The primers
Man® minor groove binder (MGB) probe (E4MGB), 2 ng of
(E4SFwd and E4SRev) used for the isolation of the 298-bp 20 eDNA, and nuclease-free water (Afonina eta!. (2002) Rioregion
by
sense
and
antisense
arms
were
techniques 32:940-949). The primer and probe sequences
were 5'-CGGTAATCGGCCATCTTTTC-3' (E4TmFwd
5'-AAGCTTTGACGCCATTTTTTCCAATCG-3' (SEQ ID
N0:27),
and
5'-CTCGAGTTTTCCAGCGATCATCT(SEQ ID N0:31)), 5'-CCGAGTTTTCGAGCTAATGGA-3'
(E4TmRev(SEQ ID N0:32)), and 5'-CAATGACGAACGTCAC-3' (SEQ ID N0:28), respectively. The RNAi cassette
was excised from pKYL801 and placed between a strong 25 GCGACAG-3' (MGB probe(SEQ ID N0:33)). RT-PCR was
CaMV35S 2 promoter and a rubisco small subunit terminator
performed in anABI 7500 Real-Time System (Applied Bioof the binary plant expression vector, pKYLX71 (see FIG. 8).
systems, Foster City, Calif.) set to the following protocol: 50°
C. for 2 min; 95° C. for 10 min; 40 cycles of95° C. for 15 sec,
In the discussions below, this RNAi construct is referred to as
the 3D_C12-7-Ri298 construct.
60° C. for 1 min. Glyceraldehyde-3-phosphate dehydrogeTransgenic tobacco plants were generated via Agrobacte- 30 nase (G3PDH) was used as the endogenous control to norrium-mediated transformation following the procedures promalize the amount of eDNA template in the reactions. Foldvided above. Briefly, transformed burley tobacco plants were
change was determined by dividing the normalized
fluorescence values of each sample by those obtained from a
regenerated from calli on Murashige-Skoog (MS) medium
supplemented with 100 mg/L kanamycin and plant hormones
nonconverter or uncured control sample. For each treatment,
in a growth room maintained at 25° C. under a 16 hr/8 hr 35 RNA was isolated from three independent plants and amplifications were repeated 3 times per RNA sample.
light/dark cycle. Calli were transferred to fresh selection
media every 2-3 weeks until shoots appeared. Small shoots
Northern and Southern Blot Analyses
Total RNA was isolated from cured tobacco leaves using
were transferred to rooting media to allow root development
the TRizol reagent according to the manufacturer's instrucfor 2 weeks. Fully regenerated plants were transferred to a
greenhouse and grown under standard conditions.
40 tions (Invitrogen, Life Technologies). Total RNA samples
SYBR® Green I Chemistry
were separated on 1.2% TBE agarose gel, and transferred to
positively charged nylon membranes by electro blotting with
Total RNA was isolated from cured leaves of converter and
nonconverter burley tobacco plants using the TRizol®
2xTBE buffer. Membranes were UV crosslinked and washed
in 2xSSC for 5 min. Northern blot hybridization, washing,
reagent (Invitrogen, Life Technologies, Carlsbad, Calif.).
Purified RNA was treated with RNase-free DNase (TURBO 45 and detection were carried out using the digoxigenin (DIG)
DNA-free™, Ambion, Austin, Tex.). First strand eDNA was
System as described by the manufacturer (Roche Diagnostics
synthesized using 5 flg of total RNA and the StrataScript®
Corp., Indianapolis, Ind.). The 1.8 kb full-length ORF of the
3D_C12-7 eDNA was labeled with DIG and used as a probe.
First-Strand Synthesis System (Stratagene, Cedar Creek,
Tex.). Relative quantitative RT-PCR was employed for deterGenomic DNA was extracted with DNAzol® (Invitrogen,
miningthe abundanceofthe3D_C12-7 eDNA using SYBR® so Life Technologies) from green tobacco leaves according to
manufacturer's protocol. After incubation with FcoR1 or
Green I fluorescence chemistry Morrison et a!. (1998) Biotechniques 24:954-962.
Nco! restriction enzymes overnight, 15 flg of the digested
DNA was separated on 0.7% TBE agarose gel, depurinated
A calibration curve was generated with a serial dilution of
the 3D_C 12-7 eDNA cloned into the pGEM®-T Easy vector
with 0.25 M HCI for 10 min, and denaturated with 0.5 N
(Promega Corporation, Madison, Wis.). The RT-PCRmixture 55 NaOH for 30 minutes. DNA was blotted overnight by capillary transfer onto positively charged nylon membranes
contained 2.5 mM MgCI 2 , 125 f.LM each dNTP, 0.5 f.LM each
(Roche Diagnostics Corp.) and hybridized at 65° C. overnight
primer, 0.5xSYBR® Green I, 0.5 flg eDNA (or 1 fll reference
plasmid), and 1.25 U Platinum Taq polymerase (Invitrogen
with a 515-bp DIG-labeled fragment of the neomycin phosLife Technologies). The sequences of the allele-specific
photransferase II (NPT II) gene. Hybridization, washing, and
3D_C12-7 primers (E4SyFwdandE4SyRev)were 5'-ACGT- 60 detection were performed according to the protocols supplied
with the DIG System. The primers used for the amplifications
GATCCTAAACTCTGGTCTG-3' (E4SyFwd (SEQ ID
N0:29)) and 5'-GCCTGCACCTTCCTTCATG-3' (E4SyRev
of the Northern and Southern hybridization probes were
(SEQ ID N0:30)). RT-PCR was performed in a BioRad iCyE4FIFwsd (5'-ATGGTTTTTCCCATAGAAGCC-3' (SEQ ID
cler thermocycler (BioRad Laboratories, Hercules, Calif.) set
N0:34)), E4FIRev (5'-TTTTTGGGACAATCAGTCAAT-3'
to the following protocol: 95° C. for 2 min; 35 cycles of 95° 65 (SEQ ID N0:35)), KanFwd (5'-TGAATGAACTGCAGC. for 30 sec, 55° C. for 30 sec no C. for 50 sec, followed by
GACGAG-3' (SEQ ID N0:36)), and KanRev (5'-AATATfinal extension at no C. for 5 min. A 165-bp fragment of the
CACGGGTAGCCAACG-3' (SEQ ID N0:37)).

sistent with the interpretation that the 3D_C12 gene family
has been silenced via co suppression in this individual.
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Alkaloid Analysis
Tobacco leaves were harvested and air dried in an oven at
50° C. for 2 days. A 100 mg sample of crushed, dried leaf is
added to 0.5 ml of2 N NaOH in a 20 ml scintillation vial. The
sample was mixed and allowed to incubate for 15 minutes at
room temperature. Alkaloids were extracted by the addition
of 5 ml of extraction solution [0.04% quinoline (wt/vol) dissolved in methyl-t-butyl ether] and gently rotated on a linear
shaker for 3 hours. Following phase separation, an aliquot of
the organic phase was transferred to a sample vial. Samples
were analyzed using a PerkinElmer Autosystem XL (PerkinElmer, Boston, Mass.) gas chromatograph equipped with a
flame ionization detector, a 4 mm split/splitless glass liner and
a 30 mx0.53 mm ID DB-5 column. Chromatographic conditions were as follows: detector temperature: 250° C.; injector
temperature: 250° C.; helium flow at 120° C.: 20 ml/min;
injection volume: 2 fll; colunm conditions: 120°, hold 1 min,
20-280° C. at 30° C./min ramping rate, hold at 280° C. for 2
min. Alkaloid composition was determined by the TotalChrome Navigator software using a calibration curve. Means
of the alkaloid measurements were separated according to
Fisher's Protected LSD (PROC MIXED).
Plants
Double haploid burley tobacco lines DH 98-325-5 (325-5;
nonconverter) and DH98-325-6 (325-6; converter) described
above were used in all experiments, except for the fluorogenic
5' nuclease (TaqMan®) chemistry-based RT-PCR assays
where the isogenic DH 91-1307-46 (nonconverter) and DH
91-1307-46 (converter) lines were used. All plants were
grown in a controlled environment greenhouse equipped with
supplemental lighting providing, a 14 hr/10 hr light/dark
cycle.
For curing, tobacco leaves were collected from converter
and nonconverter plants about 1 month before flowering and
treated by dipping each leaf twice for 10 sec, into 2% ethephon and dried for 2 hours. Leaves were cured for up to two
weeks in plastic bags, under dark conditions, until they turned
yellow. Cured leaves were used for the Northern and alkaloid
analyses. Samples of cured leaves subjected to GC analysis
were dried at 50° C. for 2 days. For Southern analysis, green
tobacco leaves of adult plants were used. To produce T 1
generation transgenic plants, primary transformants (T0 )
were self-pollinated, and the harvested T 1 seed was screened
by germinating seedlings on MS-agar plates containing 100
mg/L kanamycin for 6 weeks. Survivors were transplanted to
soil and grown in a greenhouse as described above. Plants
were fertilized with Peter's Professional All Purpose Plant
Food (20-20-20; Spectrum Brands Inc., Madison, Wis.) once
a week.
RT-PCR Analysis of3 D_ C 12-7 Expression in Converter and
Nonconverter Tobacco
To further characterize the role of 3D_C12-7 in nicotine
N-demethylation, experiments were performed to demonstrate that the regulation of3D_C12-7 expression is consistent with the levels of nicotine N-demethylation activity
observed in converter versus nonconverter tobacco.
To determine the rate of3D_C12-7 mRNA accumulation
in converter and nonconverter tobacco, an allele-specific realtime RT-PCR strategy was employed. Because RT-PCR
involves the detection and measurement of the amplification
products of a PCR template, the use of allele-specific primers
allows the quantification of a single isoform among a group of
highly homologous sequences. For accurate quantification of
the 3D_C 12-7 transcript, two different segments of the
3D_C12-7 coding region were amplified and both SYBR®
Green and TaqMan® chemistries were used to generate fluorescence signals. RT-PCR analysis using the SYBR® Green I

chemistry revealed an 80-fold increase in the levels of the
3D_C12-7 transcript in the cured leaves of converter versus
nonconverter tobacco. A single peak melting curve and gel
electrophoretic analyses of the amplicons confirmed the
homogeneity of the PCR products.
In the TaqMan® chemistry-based RT-PCR experiment,
3D_C12-7 transcript levels were quantified in untreated and
ethephon-treated converter and nonconverter tobacco leaves
that were cured for 0, 1 or 5 days. Low levels of3D_C12-7
transcripts were detected in the uncured leaves or following a
1-day curing period regardless of conversion type or ethephon treatment. Similarly, base line levels of3D_C12-7 transcription were observed in converter or nonconverter leaves
that were cured for 5 days without ethephon treatment. In
contrast, a 7.5-fold increase in 3D_C12-7 transcript accumulation was detected in the cured leaves of converter versus
nonconverter tobacco, and a 70-fold increase was observed in
the uncured versus cured leaves of a converter tobacco variety
when ethephon treatment preceded the 5-day curing period.
While not intending to be limited by any particular theory,
these results suggest that 3D_C12-7 is a major contributor to
nicotine N-demethylation and is strongly inducible by ethylene in senescing tobacco leaves.
Suppression of Nicotine to Nornicotine Conversion by the
3D_C12-Ri99 and 3D_C12-7-Ri298 Constructs
To compare the extent to which 3D_C12 and 3D_C12-7
mediate the suppression of nornicotine production, converter
and nonconverter burley tobacco plants were transformed
with the two gene silencing vectors. Ten (10) transgenic
plants were regenerated per RNAi construct. About 80% of
tobacco plants overexpressing either the 99-bp or 298-bp
inverted repeat showed reduced nornicotine levels compared
to the empty vector controls (Tables 7 and 8). In the nonconverter genotype, 3D_C12-Ri99 and 3D_C12-7-Ri298
expression reduced nicotine to nornicotine conversion by
about 1.8-fold (2.0%) and 3.0-fold (1.2%), respectively, in
comparison to the rate of conversion detected in the vector
controls (3 .6%) (Table 7). Among the silenced nonconverter
plants, the lowest conversion level of 0.9% was achieved
using the 3D_C12-7-Ri298 construct (Table 7).
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TABLE 7

45

Alkaloid analysis ofnonconvertor burley tobacco plants transformed witb
tbe 3D C12-Ri99 or 3D C12-7-Ri298 construct.
Linec

% Nicotined

% Nornicotined

% Conversione

1.693
1.435
2.095
2.868
0.947
2.357
2.599
0.796
2.178
3.162
2.013
0.748

0.034
0.031
0.043
0.053
0.025
0.043
0.043
0.020
0.039
0.061
0.039
0.012

2.0
2.1
2.0
1.8
2.6
1.8
1.6
2.4
1.8
1.9
2.0a
0.3

1.806
1.948
2.061
2.704
2.652
1.074
2.041
0.550

0.020
0.207
0.020
0.040
0.023
O.G15
0.024
0.008

1.1
1.4
1.0
1.5
0.9
1.3
1.2b
0.2

3D-C12-Ri99

50

2
4

7
55
9
10
MEAN
STE
3D C12-7-Ri298
60
4

65

9
MEAN
STE
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TABLE 7 -continued

TABLE 8-continued

Alkaloid analysis ofnonconvertor burley tobacco plants transformed witb
tbe 3D C12-Ri99 or 3D C12-7-Ri298 construct.

Alkaloid analysis of convertor burley tobacco plants transformed witb tbe
3D C12-Ri99 or 3D C12-7-Ri298 construct.

% Nicotined

% Nornicotined

% Conversione

Linec

% Nicotined

% Nornicotined

4

0.060
0.114
0.119

1.419
1.267
1.303

95.9
91.7
91.6

MEAN
STE

0.150
0.093

1.628
0.498

92.1c
2.3

% Conversione

Vector Controlg

2
4

MEAN
STE

0.052
0.038
0.058
0.072
0.060
0.044
0.054
0.011

1.206
1.265
1.752
1.230
1.777
1.536
1.461
0.240

4.2
2.9
3.2
5.6
3.3
2.8
3.6c
1.0

aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C.
bOf the plants transformed with an RNAi construct, only silenced individuals are shown.
Alkaloid data represent the means of 2 measurements.
'Numbers represent independently transformed individuals.
«'percentage of leaf dry weight.
e[% nornicotine/(% nicotine+% nornicotine )] x 100; values followed by different letters are
J~f~~~~~Jar~~:~;t according to Fisher's Protected LSD (0.05).

10

aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C.
bOfthe plants transformed with an RNAi construct, only silenced individuals are shown.
15

dPercentage of leaf dry weight.
e[% nornicotine/(% nicotine+% nornicotine )] x 100; values followed by different letters are
significantly different according to Fisher's Protected LSD (0.05).
fsTE, standard error
20

8Tobacco plants transformed with only pKYLX71 vector were used as controls.

Relative to nonconverter tobacco, nornicotine accumulation was suppressed even more dramatically in the silenced
individuals of the strong converter plants (Table 8). Using
3D_C12-Ri99 constructs, nicotine conversion was reduced to
levels as low as 4.5% in 3D_C12-Ri 99-transformed 325-6
tobacco plants in sharp contrast to the 325-6 control plants
exhibiting about 98% conversion rates; Table 8). However,
using the 3D_C 12-7-Ri298 construct even greater reductions
in nicotine conversion were obtained (Table 8). Four
3D_C12-7-Ri298-transformed individuals converted as low
as 0.8% of their nicotine to nornicotine, and the arithmetic
mean across the 9 silenced transformants was 0.9% conversion. All silenced plants were morphologically indistinguishable from both the empty vector and wild-type controls (data
not shown).
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30

35

TABLES
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe
3D C12-Ri99 or 3D C12-7-Ri298 construct.
% Nicotined

% Nornicotined

% Conversione

3.419
2.569
2.175
3.517
2.268
2.197
2.434
2.654
0.573

0.100
0.193
0.064
0.125
0.128
0.133
0.112
0.122
0.039

2.8
7.0
2.9
3.4
5.3
5.7
4.4
4.5a
1.6

2.043
3.427
2.603
2.427
2.106
1.412
3.328
1.493
2.065
2.323
0.669

0.020
0.026
0.020
0.030
0.021
O.G15
0.028
O.G15
O.G18
0.021
0.005

1.0
0.8
0.8
1.2
1.0
1.1
0.8
1.0
0.8
0.9b
0.1

0.126
0.330

1.550
2.604

40

3D C12-Ri99
45
2
4
9
10
MEAN
STF
3D C12-7-Ri298b

<Numbers represent independently transformed individuals.

gTobacco plants transformed with onlypKYLX71 vector were used as controls.

To test the heritability of nornicotine suppression in the
3D_C12-7-Ri298-transformed plants, a set of 3D_C12-7Ri298-transformed converter and nonconverter lines that displayed the lowest levels of nicotine conversion were
advanced to the T 1 generation (Table 9). Because segregation
of the transgene( s) occurs in the T 1 progeny, transgenic individuals were identified by selecting seedlings capable of
growing on kanamycin-containing media. Nine kanamycinresistant progenies of each selected T 0 -generation 3D_C127 -Ri298 transformant and four kanamycin-resistant individuals from each selected vector control line were analyzed for
alkaloid content. The rate of nicotine conversion did not differ
significantly between the primary 3D_C12-7-Ri298 transformants and their T 1 progeny, indicating high heritability of the
nornicotine suppression trait (see Tables 7, 8, and 9). However, advancing the "nonconverter" vector control line by a
single generation increased the nicotine to nornicotine conversion rate from 4.2% to an average value of 11.6%, illustrating the high degree of instability of the conversion locus in
transgenic plants lacking the 3D_C12-7-Ri298-specific
RNAi construct (Tables 7 and 9). Overall, these results show
that RNAi-mediated silencing of the 3D_C12 gene subfamily
is a highly effective means of lowering nornicotine production in bothnonconverter and strong converter tobacco plants.
TABLE9
Alkaloid analysis ofT,-generation 3D C12-7-Ri298 transformants.

50
Line

% Nicotinec

% Nornicotinec

% Conversiond

DH98-325-5 (nonconverter)
3D _Cl2-7-Ri298#3

2

7
9
10
MEAN
STE
Vector Controlh,i

2

92.5
88.8

55

60

Mean
STE
3D C12-7-Ri298#5

1.764
0.456

0.024
0.004

1.4a
0.3

Mean
STE
3D C12-7-Ri298#8

1.500
0.306

0.020
0.006

1.3a
0.3

Mean
STE
Vector Control#! e

1.772
0.409

0.020
0.003

1.2a
0.3

1.466
0.713

0.203
0.161

11.6b
9.7

65 Mean
STE
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TABLE 9-continued

expression of this P450 family in converter tobacco lines
inhibited the metabolism of nicotine to nornicotine to levels
similar to that observed in nonconverter plants. Furthermore,
sense expression of several individuals of this closely related
gene family identified one member, designated 3D_C12-7, as
playing a direct role in the metabolic conversion of nicotine to
nornicotine. Overexpression of 3D_C12-7 using a strong
constitutive promoter caused a dramatic increase in nornicotine production and accumulation in non-cured green leaves
of transgenic tobacco plants, a tissue where nicotine is normally the predominant alkaloid in converter and nonconverter
plants alike. Given that the cytochrome P450 family member
designated 3D_C12-10 differs from 3D_C12-7 at only two
amino acid residues immediately following the start methionine and within theN-terminal signal sequence, it is predicted
that these encoded products function identically.
The contrast in alkaloid phenotypes between the 35S:
3D_C12 (1) plant and vector-only control plants was most
dramatic in leaves that had been ethephon treated and cured
(0.6% conversion versus >97% conversion; Table 6). However, it is noteworthy that the nornicotine content of the cosuppressed 35 S :3D_C 12 (1) plant was reduced even in green,
nontreated leaves where the high nornicotine phenotype is
typically not manifest in converter or nonconverter tobacco
lines. The green, nontreated leaves of line 35S:3D_C12 (1)
showed only 0.7% nicotine to nornicotine conversion,
whereas every other plant in this experiment showed conversion percentages ranging from 1.3 to 3.7 (Table 5). This result
suggests that the inhibition of gene expression of the 3D_C 12
family may prove to be effective in the further lowering of
nornicotine levels even in tobacco lines where genetic conversion isn't typically a major problem (such as flue-cured
tobaccos) or in the nonconverter individuals in lines that are
prone to genetic conversion (such as Burley tobaccos).
Southern blotting assays using members of the 3D_C12
gene family as hybridization probes gives very complex
banding patterns, suggesting that more members of this gene
family may exist even beyond those that have been identified
and characterized herein (data not shown). The hypothesis
that the 3D_C12 gene family is comprised of additional members is further supported by the recent publication of 75
full-length tobacco P450 cDNAs of unknown function (U.S.
Patent Application Publication 20040162420). Within this
list of P450s are additional cDNAs that would, based on the
work described herein, be placed within the 3D_C12 family
in view of their display of over 90% amino acid sequence
identity to the protein sequences shown in FIG. 4.
With respect to the specific molecular function of the
3D_C12-7 gene or the nearly identical family member
3D_C12-10, it is possible that it encodes the actual nicotine
demethylase enzyme which catalyzes the oxidative N-demethylation of nicotine to nornicotine (FIG. 1). Alternatively,
the 3D_C12-7 encoded enzyme or nearly identical3D_C1210 encoded enzyme may produce a product that leads to the
up-regulation of the nicotine demethylase activity of the leaf,
as opposed to directly catalyzing the N-demethylation reaction.
In addition, an allele-specific RT-PCR was employed to
compare 3D-C12-7 expression between converter and nonconverter plants (Example 7). An approximately 80-fold
increase in 3D-C12-7 expression in converter versus nonconverter plants was identified using the SYBR® Green-chemistry RT-PCR assay. A 7.5-fold up-regulation was identified
by the TaqMan® chemistry-based RT-PCR experiment.
While the DH 91-1307-46 tobacco variety used in the TaqMan® chemistry-based RT-PCR experiment exhibits low to
moderate levels of nicotine conversion, the DH98-325-5 non-

Alkaloid analysis ofT,-generation 3D C12-7-Ri298 transformants.

Line

% Nicotinec

% Nornicotinec

% Conversiond

DH98-325-6 (converter)
3D C12-7-Ri298#2
Mean
STE
3D C12-7-Ri298#8

1.970
0.536

0.019
0.004

l.Oa
0.3

Mean
STE
3D C12-7Ri298#10

1.623
0.300

0.022
0.002

1.3a
0.2

Mean
STE
Vector Control#2e

1.419
0.515

0.017
0.004

1.3a
0.3

Mean
STE

0.028
0.006

1.170
0.234

97.6c
0.5

10

15

aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C.
~eans and standard errors (STE) represent 9 and 4 T 1 progenies of the 3D_Cl2-7-Ri298
construct and empty vector-transformed (vector control) lines, respectively.
"Percentage of leaf dry weight.
d[% nornicotine/(%nicotine +% nornicotine)] x 100; values followed by different letters are
significantly different according to Fisher's Protected LSD (0.015).
eTobacco plants transformed with only pKYLX71 vector were used as controls.

Furthermore, transforming tobacco with the 3D_C12-7298 construct conferred a 3.6-fold reduction in nicotine conversion relative to typical nonconverter control plants without
affecting plant growth and development.
To demonstrate that the down-regulation of nornicotine
production in 3D_C12-7-298-transformed tobacco was concomitant with a reduction of the 3D_C12 gene subfamily
transcripts, a 3D_C12-7 eDNA probe was hybridized to the
total RNA isolated from cured leaves of nonconverter and
converter plants. A weak hybridization signal was generated
by the RNA isolated from 3D_C12-7-Ri298 transformants
displaying low nornicotine content in contrast to the strong
signal produced by the RNA extracted from plasmid control
or wild-type plants. These results indicate that the downregulation of nicotine conversion was a result of RNAi -mediated gene silencing of the nicotine N -demethylase gene(s ).
Determination ofTransgene Copy Number
To determine whether the integration of multiple 3D_C127-Ri298 copies were required for producing transplants displaying very low nicotine N-demethylase activity, Southern
analysis was performed on selected individuals exhibiting
<1.5% nornicotine accumulation. The number of transgenes
varied widely among these plants including individuals containing 1 copy (325-5, lines 5 & 8; 325-6, lines 2 & 8), 5
copies (325-6, line 10), and 6 copies (325-5, line 6) of the
3D_C12-7-Ri298 construct using Southern blot analysis of
genomic DNA digested with the EcoRI restriction enzyme.
Trans gene copy number was confirmed using Nco I digested
DNA (data not shown). These results indicate that the integration of a single 3D_C12-7-Ri298 construct into the
genome of a strong converter tobacco is sufficient for suppressing nornicotine production to very low levels.
General Conclusions
The analyses outlined in Examples 1-6 above resulted in
the discovery of a closely related P450 gene family, designated the 3D_C12 family, whose collective steady-state transcript levels were significantly elevated in converter tobacco
plants that were actively metabolizing nicotine to nornicotine
in comparison to their nonconverter counterparts. Transgenic
plant analysis demonstrated that the suppression of gene
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60
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converter plants used in the SYBR® Green-based RT-PCR
assay consistently convert a very low percentage of their
nicotine to nomicotine. Expression of the 3D-C 12-7 gene was
induced at least 7-fold by ethylene in senescing leaves of
converter tobacco plants.
An additional RNAi construct, 3D_C12-7-Ri298, was prepared based on a region of the 3D_C12-7 polynucleotide that
corresponds to nucleotide positions 297 through 594 of SEQ
ID N0:5. Expression of this RNAi construct allows for the
suppression of nomicotine production in a strong converter
tobacco line below the levels normally found in nonconverter
plants. The expression cassette of the 3D_C12-7-Ri298 construct encoded an intron-spliced hairpin RNA in which the
stem region was engineered from this 298-bp fragment of the
3D_C12-7 eDNA inserted as an inverted repeat. The loop of
the hairpin was created by placing a 151-bp intronofthe FAD
gene between the two sides of the palindromic sequences. An
arm length of 298-bp was used for the inverted repeats.
3D_C12-7-Ri298-transformed plants accumulated less
nomicotine than those harboring the 3D_C12-Ri99 construct
(Tables 7 and 8). No correlation was found between the number of copies of the 3D_C12-7-Ri298 construct and nomicotine production (Tables 7 and 8). The 3D_C12-7-Ri298

expression cassette enabled the production of tobacco with a
conversion rate as low as 0.8%, which is below the 3-5% rate
detected in burley lines used by seed producers. Such dramatic reduction in nomicotine production by targeting this
particular region of the 3D_C12-7 polynucleotide is an unexpected result. Also, suppression of nornicotine production
showed a high degree of heritability in the T 1 progeny of the
primary transformants (Table 9). Suppression of nornicotine
production in these transgenic plants yielded no obvious differences in growth and development when compared to wildtype plants.
All publications and patent applications mentioned in the
specification are indicative of the level of those skilled in the
art to which this invention pertains. All publications and
patent applications are herein incorporated by reference to the
same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in
some detail by way of illustration and example for purposes
of clarity of understanding, it will be obvious that certain
changes and modifications may be practiced within the scope
of the appended claims.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 37
<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 1
LENGTH, 1733
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1551)

<400> SEQUENCE, 1
atg gtt ttt ccc ata gaa gee ttt gta gga eta gta ace ttc aca ttt
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa ccc

96

Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttt
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

cac ttc aat aac gac ggc gac gac cgt cca tta get ega aaa etc gga

192

His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
gac tta get gat aaa tac ggc ccc gtt ttc act ttt egg eta ggt ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

ccc ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95

288

tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc

336

Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110
gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac gga

384

Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
cct tac tgg ega aaa aat cgt aaa tta gtc att cag gaa gtt etc tct
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140

432
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63
-continued
get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att caa
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln
145

150

155

160

acg age att aag aat tta tac act ega att aat gga aat tcg agt acg
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr
165

170

185

200

215

230

235

245

250

265

280

295

310

315

325

330

345

360

375

390

395

405

410

1248

415

cgc gat cct aaa etc ttg tea aat cct gat aag ttc gat cca gag aga
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg
420

1200

400

cac att cct aaa gag act aga tta ttc gca aac gtc atg aaa ctg cag
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln

425

1296

430

ttc ate get ggt gat att gac ttc cgt ggt cac cac tat gag ttt ate
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile
440

1344

445

cca ttt ggt tct gga aga ega tct tgt ccg ggg atg act tat gca ttg
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
455

1152

380

ttg tta gta cca cat gaa aat gta aag gat tgt gtt gtt agt gga tat
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr

450

1104

365

etc caa get att gtt aaa aag gtg tta ega tta tat cca cca gga cct
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro

435

1056

350

ggt aag gat aga tgg gta gaa gag agt gat att aag gat tta gta tac
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr

385

1008

335

aat caa aat gee ttg atg aaa gca caa gaa gag ata gac aca aaa gtt
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340

960

320

gac aca gtt get ctt cac ata aat tgg gga atg aca tta ttg ata aac
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn

370

912

300

gat act gtc att aaa gca aca gtt ttt agt ttg gtc ttg gat gca gca
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala

355

864

285

gtg ctt tea aaa ttg agt aaa gaa tat ctt gat gaa ggt tac tct cgt
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg

305

816

270

aaa atg gag gtt ggt gca gaa ggg aat gaa caa gat ttc att gat gtg
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val

290

768

255

gat tct gtt ttt cag aac tgg tta gag gaa cat att aat aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

720

240

gat ttt caa ggt cat att aag gca atg aaa agg aca ttt aag gat ata
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile

275

672

220

gaa ttt gta tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225

624

205

gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt tta tea atg
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met
210

576

190

aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195

528

175

ata aat eta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

480

460

1392
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66
-continued

caa gtg gaa cac eta aca atg gca cat tta ate cag ggt ttc aat tac

1440

Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480
aaa act cca aat gac gag gee ttg gat atg aag gaa ggt gca ggc ata
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495

1488

ace ata cgt aag gta aat cca gtg gaa ttg ata ata acg cct cgc ttg
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu
500
505
510

1536

gca cct gag ctt tac taaaacctaa gatctttcat cttggttgat cattgtttaa
Ala Pro Glu Leu Tyr
515

1591

tactcctaga tgggtattca tttacctttt ttcaattaat tgcatgtacg agctttttta

1651

atttggtata tttgtaacaa taagtaaaga atgattgtgc taatatataa agatttgcag

1711

aagataattg actgattgtc cc

1733

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 517
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 2
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln
145
150
155
160
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr
165
170
175
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met
210
215
220
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255

US 9,187,759 B2
67

68
-continued

Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260
265
270
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275
280
285
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg
290
295
300
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305
310
315
320
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn
325
330
335
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340
345
350
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355
360
365
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro
370
375
380
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr
385
390
395
400
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405
410
415
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg
420
425
430
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile
435
440
445
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu
500
505
510
Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 3
LENGTH, 1733
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1551)

<400> SEQUENCE, 3
atg ctt tct ccc ata gaa gee att gta gga eta gta ace ttc aca ttt

48

Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc

96

Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttc
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

cac ttc aat gac gac ggc gac gac cgt cca tta get ega aaa etc gga
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gac aaa tac ggc ccc gtt ttc act ttt egg eta ggc ctt

240
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70
-continued

Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65

70

75

80

ccc ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
85

90

288

95

tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc

336

Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100

105

110

gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115

120

384

125

cct tac tgg ega aaa aat ega aaa tta gtt att cag gaa gtt etc tee

432

Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130

135

140

get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa

480

Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145

150

155

160

gcg age att aag aat tta tat act ega att gat gga aat tcg agt acg
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165

170

175

ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

185

200

215

230

235

245

250

265

280

864

285

gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
295

912

300

gat act gtc att aaa gca acg gtg ttt agt ttg gtc ttg gat gca gca
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305

816

270

aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val

290

768

255

gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

720

240

gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile

275

672

220

gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225

624

205

gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210

576

190

aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195

528

310

315

320

gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325

960

330

1008

335

aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt

1056

Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340

345

350

ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355

360

365

etc caa get att gtt aaa gaa gtg tta ega tta tat cca cca gga cct

Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370

375

1104

380

1152
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ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385
390
395
400

1200

cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405
410
415

1248

cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420
425
430

1296

ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435
440
445

1344

ccg ttt ggt tct gga aga ega tct tgt cca ggg atg act tat gca ttg
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460

1392

caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac

1440

Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480
aga act cca aat gac gag ccc ttg gat atg aag gaa ggt gca ggc ata
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495

1488

act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500
505
510

1536

gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa
Ala Pro Glu Leu Tyr
515

1591

tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta

1651

atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag

1711

aagataattg actgattgtc cc

1733

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH, 517
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 4
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160
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Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165

170

175

Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

185

190

Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195

200

205

Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210

215

220

Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225

230

235

240

Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245

250

255

Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

265

270

Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275

280

285

Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
290

295

300

Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305

310

315

320

Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325

330

335

Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340

345

350

Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355

360

365

Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370

375

380

Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385

390

395

400

His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405

410

415

Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420

425

430

Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435

440

445

Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450

455

460

Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465

470

475

480

Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485

490

495

Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500

Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 5
LENGTH, 1733
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1551)

505

510
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<400> SEQUENCE, 5
atg gtt ttt ccc ata gaa gee att gta gga eta gta ace ttc aca ttt
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc

96

Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttc
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

cac ttc aat gac gac ggc gac gac cgt cca tta get ega aaa etc gga
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gac aaa tac ggc ccc gtt ttc act ttt egg eta ggc ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

ccc ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
85
90
95

288

tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110

336

gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125

384

cct tac tgg ega aaa aat ega aaa tta gtt att cag gaa gtt etc tee
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130
135
140

432

get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160

480

gcg age att aag aat tta tat act ega att gat gga aat tcg agt acg
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175

528

ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190

576

aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205

624

gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210
215
220

672

gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240

720

gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255

768

gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260
265
270

816

aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275
280
285

864

gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
290
295
300

912

gat act gtc att aag gca acg gtg ttt agt ttg gtc ttg gat gca gca

960
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Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305
310
315
320
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325
330
335

1008

aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt

1056

Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340
345
350
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355
360
365

1104

etc caa get att gtt aaa gaa gtg tta ega tta tat cca cca gga cct

1152

Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370
375
380
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385
390
395
400

1200

cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405
410
415

1248

cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420
425
430

1296

ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435
440
445

1344

ccg ttt ggt tct gga aga ega tct tgt cca ggg atg act tat gca ttg
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450
455
460

1392

caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac

1440

Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465
470
475
480
aga act cca aat gac gag ccc ttg gac atg aag gaa ggt gca ggc ata
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495

1488

act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500
505
510

1536

gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa
Ala Pro Glu Leu Tyr
515

1591

tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta

1651

atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag

1711

aagatgattg actgattgtc cc

1733

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 517
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE,
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
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50

55

60

Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65

70

75

80

Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe
85

90

95

Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100

105

110

Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115

120

125

Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser
130

135

140

Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145

150

155

160

Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165

170

175

Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180

185

190

Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195

200

205

Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210

215

220

Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225

230

235

240

Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245

250

255

Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu
260

265

270

Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val
275

280

285

Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg
290

295

300

Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala
305

310

315

320

Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn
325

330

335

Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val
340

345

350

Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr
355

360

365

Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro
370

375

380

Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr
385

390

395

400

His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln
405

410

415

Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg
420

425

430

Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile
435

440

445

Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu
450

455

460

Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr
465

470

475

480
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Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile
485
490
495
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu
500
505
510
Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 7
LENGTH, 1727
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (1554)

<400> SEQUENCE, 7
atg gtt ttt ccg gta gaa gee att gta ggg eta gtg ace ttc aca ttt
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc ttc tac ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc

96

Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
tta cca ccg aaa ate ccg gga gga tgg ccg gta ate ggc cat ctt ttc
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

tac ttc gat gac gac ggc gac gac cgt cca tta get ega aaa etc gga
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60

192

gac tta get gac aaa tac gga ccc gtt ttc act ttt egg eta ggc ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

ccc ctt gtg tta gtt gta age agt tac gaa get ata aaa gat tgt ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95

288

tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc

336

Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110
gaa tac ctt ggc tac aaa aat gee atg eta ttt ttg gca aat tac gga
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125

384

tct tac tgg ega aaa aat cgt aaa tta att att cag gaa gtt etc tct
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser
130
135
140

432

get agt cgt etc gaa aaa ttc aaa cac gtg aga ttc gee aga att caa

480

Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160
acg age att aag aat tta tac act ega att gat gga aat tcg agt acg
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175

528

ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190

576

aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205

624

gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210
215
220

672

gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val

720
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225

230

235

240

gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245

250

255

gat tct gtt ttt cag aat tgg tta gag gaa cat att aag aaa aga gaa
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu
260

265

280

295

310

315

325

330

345

360

375

390

395

405

410

425

440

1344

445

ate ccg ttt ggt tct gga aga cgc tct tgt ccg ggg atg act tat gca
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala
455

1392

460

ttg caa gtg gaa cac eta aca atg gca cat ttg ate cag ggt ttc aat
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn
470

475

485

490

1488

495

ata act ata cgt aag gta aat cct gtg aaa gtg ata att acg cct cgc
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg
505

1440

480

tac aga act cca act gat gag ccc ttg gat atg aaa gaa ggt gca ggc
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly

500

1296

430

aga ttc ate get cgt gat att gac ttt cat ggt cag cac tat gag tat
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr

465

1248

415

caa cgt gat cct aaa etc tgg tea aat cct gat aag ttc aat cca gag
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu
420

1200

400

tat cac att cct aaa gga act aga eta ttc gca aat gta atg aaa eta
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu

450

1152

380

cct ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly

435

1104

365

tac etc caa get att gtt aaa gaa gtg tta ega tta tat cca ccg gga
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly

385

1056

350

gtt ggt aag gat aga tgg gta gaa gag agt gat att aag gat ttg gta
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val

370

1008

335

aac aat caa aat gee ttg aag aaa gca caa gaa gag ata gac aca aaa
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys
340

960

320

gca gac aca gtt get ctt cac ata aat tgc gga atg gca tta ttg ata
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile

355

912

300

cgc gat act gtc ata aaa gca aca gta ttt agt ttg gtc ttg gat gca
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala
305

864

285

gtg gtg ctt tea aaa atg agt aat gaa tat ctt ggc gaa ggt tac tct
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser
290

816

270

aaa ata atg gag gtt ggt aca gaa ggg aat gaa caa gat ttt ata gat
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp
275

768

1536

510

ttg gca cct gag ctt tat taaaatctaa gatgtttcat cttggttgat
Leu Ala Pro Glu Leu Tyr

1584

515

cattgtttaa tactcctaga tgggtattca tctacctttt ttcaattagt tgtcggtacg

1644

tattttttta atttggtaag tttgtaataa taagtaaaga aggattgtgc taatatataa

1704

tggtgcataa aataattgaa atg

1727
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<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH, 518
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 8
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly
115
120
125
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser
130
135
140
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln
145
150
155
160
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr
165
170
175
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val
180
185
190
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln
195
200
205
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met
210
215
220
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val
225
230
235
240
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile
245
250
255
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu
260
265
270
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp
275
280
285
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser
290
295
300
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala
305
310
315
320
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile
325
330
335
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys
340
345
350
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val
355
360
365
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly
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370

375

380

Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly
385
390
395
400
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu
405
410
415
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu
420
425
430
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr
435
440
445
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala
450
455
460
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn
465
470
475
480
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly
485
490
495
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg
500
505
510
Leu Ala Pro Glu Leu Tyr
515

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 9
LENGTH, 539
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (539)

<400> SEQUENCE, 9
atg gtt ttt ccc ata gaa gee ttt gta gga eta gta ace ttc aca ttt
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15

48

etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa ccc

96

Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttt
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45

144

cac ttc aat aac gac ggc gac gac cgt cca tta get ega aaa etc gga

192

His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
gac tta get gat aaa tac ggc ccc gtt ttc act ttt egg eta ggt ctt
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80

240

ccc ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95

288

tct aca aat gat gee att ttc tee aat cgt cca get ttt ctt tat ggc
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110

336

gaa tac ctt ggc tac agt aat gee atg eta ttt tga caa aat acg gac
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe
Gln Asn Thr Asp
115
120
125

384

ctt act ggc gaa aaa ata gaa aat tag tea ttc agg aag ttc tct gtg
Leu Thr Gly Glu Lys Ile Glu Asn
Ser Phe Arg Lys Phe Ser Val
130
135
140

432

eta gtc gtc tcg aaa aat tga age acg tga gat ttg gtg aaa ttc aga
Leu Val Val Ser Lys Asn
Ser Thr
Asp Leu Val Lys Phe Arg
145
150
155

480
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ega gca tta aga att tat aca etc gaa ttg atg gaa att ega gta ega
Arg Ala Leu Arg Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg
160
165
170

528

taa ate taa ca

53 9

Ile

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH, 173
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 10
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe
1
5
10
15
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro
20
25
30
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe
35
40
45
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly
50
55
60
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu
65
70
75
80
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe
85
90
95
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly
100
105
110
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp Leu
115
120
125
Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val Leu Val
130
135
140
Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg Arg Ala Leu Arg
145
150
155
160
Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg Ile
165
170

<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 11
LENGTH, 666
TYPE, DNA
ORGANISM, Nicotiana sp.
FEATURE,
NAME/KEY, CDS
LOCATION, (1) ... (666)

<400> SEQUENCE, 11
atg gtt ttt ccc ata gaa gee att gta gga gca gta ace eta att aca
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr
1
5
10
15

48

ttt etc tta tac ttc eta tgt aca aaa aaa tct caa aaa cat tea aag

96

Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys
20
25
30
ccc tta cca acg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu
35
40
45

144

ttc cac ttc aat aac gac ggc gac gac cgt cca ttt get ega aaa etc

192

Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu
50
55
60
gga gac tta get gat aaa tac ggc ccc gtt ttc act ttt egg eta ggt
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly
65
70
75
80

240
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ctt ccc ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys
85
90
95

288

ttc tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac

336

Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr
100
105
110
ggc gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac

384

Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr
115
120
125
gga cct tac tgg ega aaa aat cgt aaa tta gtc att cag gaa gtt etc
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu
130
135
140

432

tct get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att

480

Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile
145
150
155
160
caa acg age att aag aat tta tac act ega att aat gga aat tcg agt

528

Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser
165
170
175
acg ata aat eta agt gat tgg tta gaa gaa ttg aat ttt ggt ctg ate
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile
180
185
190

576

gtg aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu
195
200
205

624

caa gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val
210
215
220

666

<210>
<211>
<212>
<213>

SEQ ID NO 12
LENGTH, 222
TYPE, PRT
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 12
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr
1
5
10
15
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys
20
25
30
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu
35
40
45
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu
50
55
60
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly
65
70
75
80
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys
85
90
95
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr
100
105
110
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr
115
120
125
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu
130
135
140
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile
145
150
155
160
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser
165
170
175
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile
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180

185

190

Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu
195
200
205
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val
210
215
220

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 13
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from
SEQ ID N0,1

<400> SEQUENCE, 13
gacgaggcct tggatatgaa ggaaggtgca ggcataacca tacgtaaggt aaatccagtg

60

gaattgataa taacgcctcg cttggcacct gagctttac

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 14
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from
SEQ ID N0,3

<400> SEQUENCE, 14
gacgagccct tggatatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg

60

gaactgataa tagcgcctcg cctggcacct gagctttat

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 15
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from
SEQ ID N0,5

<400> SEQUENCE, 15
gacgagccct tggacatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg

60

gaactgataa tagcgcctcg cctggcacct gagctttat

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 99
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Partial coding sequence selected from
SEQ ID N0,7

<400> SEQUENCE, 16
gatgagccct tggatatgaa agaaggtgca ggcataacta tacgtaaggt aaatcctgtg

60

aaagtgataa ttacgcctcg cttggcacct gagctttat

99

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 17
cgctctagaa ctagtgatc

19
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<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 18
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 18
tttttgggac aatcagtcaa

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 19
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 19
gttagattta tcgtactcga att

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 20
LENGTH, 26
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 20
ttcatttcaa attattttat gcacca

<210>
<211>
<212>
<213>
<220>
<223>

26

SEQ ID NO 21
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 21
atggtttttc ccatagaagc c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 22
LENGTH, 17
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 22
tcgaggtcga cggtatc

<210>
<211>
<212>
<213>

17

SEQ ID NO 23
LENGTH, 1118
TYPE, DNA
ORGANISM, Nicotiana sp.

<400> SEQUENCE, 23
ctgtcattaa agcaacggtg tttgtaagtt catctgtcat ttttcattta ttcactttta

60

ttttgaggag cagacatgtt aataataatt tggagcaact gtaaagttat ctatgtgtac

120

aggttcgagc ctcaggtgca accactaatg cttgtattag attatgttgt ctgcatcata

180

cccctaattg gagtgtggct cttcccgaac cctgcaatgc tggatgctgg atgctttatg

240

tatcagactg acctttttgt taaactatct aaatactaag gatgatttaa taaaaatata

300
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gaatggtaaa cagaaaaaga tgagattatt tttggggcta tatggattcg cccgggcttt

360

gggaggtaaa acggtatcta ccagttgaga ctttactcca gaactttatc tcgagagctc

420

tgaataaaaa tgaaatagta tttaccactc caaaatcttt gatggtaaaa agatgagata

480

taacctctta taattgattg aaccacgttg atagaataaa acttctttac tcccattcag

540

cataagaaaa atgaaaccaa acggaattct tctctttttt agggggaaat tccttaattg

600

cttgttgaat atagattcat gtcgttattc tatttttaat aatgatgaaa atcaatatag

660

tcaaagttaa tacttatgtc atttggtttg cggacaagtt atattggaac tatataatac

720

gtctattata gaatagtgat tatttagagg atatacattt tttttggata aatatttgat

780

ttattggatt aaaaatagaa tatacaggta aggtctaaaa cgtgtgtttg cttttacact

840

aaataaactt gacctcgtac aattctaaga aaatatttga aataaatgaa ttattttatt

900

gttaatcaat taaaaaaatc atagtataga tgagatgtgt gcatacttgg caataactat

960

actaactaaa acaaggtatg tgaataattg atattccttt tttaattatt cttttttcca

1020

gagtttggtc ttggatgcag cagacacagt tgctcttcac ataaattggg gaatggcatt

1080

attgataaac aatcaaaagg ccttgacgaa agcacaag

1118

<210> SEQ ID NO 24
<211> LENGTH, 998
<212> TYPE, DNA
<213> ORGANISM, Nicotiana sp.
<400> SEQUENCE,

24

gtaagttcat ctgtcatttt tcatttattc acttttattt tgaggagcag acatgttaat

60

aataatttgg agcaactgta aagttatcta tgtgtacagg ttcgagcctc aggtgcaacc

120

actaatgctt gtattagatt atgttgtctg catcataccc ctaattggag tgtggctctt

180

cccgaaccct gcaatgctgg atgctggatg ctttatgtat cagactgacc tttttgttaa

240

actatctaaa tactaaggat gatttaataa aaatatagaa tggtaaacag aaaaagatga

300

gattattttt ggggctatat ggattcgccc gggctttggg aggtaaaacg gtatctacca

360

gttgagactt tactccagaa ctttatctcg agagctctga ataaaaatga aatagtattt

420

accactccaa aatctttgat ggtaaaaaga tgagatataa cctcttataa ttgattgaac

480

cacgttgata gaataaaact tctttactcc cattcagcat aagaaaaatg aaaccaaacg

540

gaattcttct cttttttagg gggaaattcc ttaattgctt gttgaatata gattcatgtc

600

gttattctat ttttaataat gatgaaaatc aatatagtca aagttaatac ttatgtcatt

660

tggtttgcgg acaagttata ttggaactat ataatacgtc tattatagaa tagtgattat

720

ttagaggata tacatttttt ttggataaat atttgattta ttggattaaa aatagaatat

780

acaggtaagg tctaaaacgt gtgtttgctt ttacactaaa taaacttgac ctcgtacaat

840

tctaagaaaa tatttgaaat aaatgaatta ttttattgtt aatcaattaa aaaaatcata

900

gtatagatga gatgtgtgca tacttggcaa taactatact aactaaaaca aggtatgtga

960

ataattgata ttcctttttt aattattctt ttttccag

998

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 25
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, PCR Primer

<400> SEQUENCE, 25

US 9,187,759 B2
100

99
-continued
ctgtcattaa agcaacggtg

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 26
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, PCR Primer

<400> SEQUENCE, 26
ggccttgacg aaagcacaag

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 27
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 27
aagctttgac gccatttttt ccaatcg

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 28
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 28
ctcgagtttt ccagcgatca tcttcac

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 29
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 29
acgtgatcct aaactctggt ctg

<210>
<211>
<212>
<213>
<220>
<223>

23

SEQ ID NO 30
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 30
gcctgcacct tccttcatg

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 31
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 31
cggtaatcgg ccatcttttc

<210> SEQ ID NO 32
<211> LENGTH, 21
<212> TYPE, DNA

20
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<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, oligonucleotide primer
<400> SEQUENCE, 32
ccgagttttc gagctaatgg a

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 33
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 33
caatgacgaa cggcgacag

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 34
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 34
atggtttttc ccatagaagc c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 35
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 35
tttttgggac aatcagtcaa t

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 36
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 36
tgaatgaact gcaggacgag

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 37
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, oligonucleotide primer

<400> SEQUENCE, 37
20

aatatcacgg gtagccaacg

What is claimed is:
1. Cured tobacco material or a tobacco product comprising
said cured tobacco material, wherein said cured tobacco
material is made from a tobacco plant comprising a stable
mutation in a wild type allele encoding a nicotine demethylase having an amino acid sequence of SEQ ID N0:4 or a
sequence having 98% identity to SEQ ID N0:4, wherein said
mutation reduces or eliminates the expression or activity of
said nicotine demethylase, wherein the amount of nornicotine

60

65

or N-nitrosonomicotine in said cured tobacco material is
reduced by greater than about 10% compared to cured
tobacco material made from a control tobacco plant comprising said wild type allele; and wherein said tobacco plant is a
Nicotiana tabacum plant.
2. The tobacco product according to claim 1.
3. The tobacco product according to claim 2, wherein said
tobacco plant is homozygous for said mutation.
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4. The tobacco product according to claim 2, wherein said

tobacco material is made by a curing process selected from
the group consisting of flue curing, air curing, and fire curing.
5. The tobacco product according to claim 2, wherein said
tobacco product is selected from the group consisting of a
cigar, a cigarette, pipe tobacco, a cigarillo, a non-ventilated or
vented recess filter cigarette, a dissolving strip, a gum, a
tablet, snuff, and chewing tobacco.
6. The tobacco product according to claim 2, wherein said
tobacco plant has a non-converter phenotype and reduced
nicotine demethylase activity from said nicotine demethylase.
7. The tobacco product according to claim 2, wherein said
tobacco plant has a non-converter phenotype and comprises
less than 5% nicotine demethylation.
8. The tobacco product according to claim 2, wherein said
tobacco plant is a hybrid.
9. The tobacco product according to claim 2, wherein said
tobacco plant is selected from the group consisting of a Burley type, a dark type, a flue-cured type, and an Oriental type.
10. The tobacco product according to claim 2, wherein said
mutation is selected from the group consisting of a point
mutation, a deletion, an insertion, and an inversion.
11. The tobacco product according to claim 2, wherein said
mutation is a nonsense or missense mutation, said missense
mutation resulting in an abolished or reduced nicotine demethylase activity compared to said wild type allele.
12. The tobacco product according to claim 2, wherein said
wild type allele encodes SEQ ID N0:4.
13. The tobacco product according to claim 2, wherein said
stable mutation results in a substitution of the isoleucine at
position 27 4 or the tryptophan at position 329 of said SEQ ID
N0:4.

10

15

20

25

30

14. The cured tobacco material or tobacco product according to claim 1, wherein the amount of nornicotine or N-nitrosonornicotine in said cured tobacco material is reduced by
greater than about 20% compared to cured tobacco material
made from a control tobacco plant comprising said wild type
allele.
15. The cured tobacco material or tobacco product according to claim 1, wherein the amount of nornicotine or N-nitrosonornicotine in said cured tobacco material is reduced by
greater than about 40% compared to cured tobacco material
made from a control tobacco plant comprising said wild type
allele.
16. The cured tobacco material or tobacco product according to claim 1, wherein the amount of nornicotine or N-nitrosonornicotine in said cured tobacco material is reduced by
greater than about 60% compared to cured tobacco material
made from a control tobacco plant comprising said wild type
allele.
17. The cured tobacco material or tobacco product according to claim 1, wherein the amount of nornicotine or N-nitrosonornicotine in said cured tobacco material is reduced by
greater than about 80% compared to cured tobacco material
made from a control tobacco plant comprising said wild type
allele.
18. The cured tobacco material or tobacco product according to claim 1, wherein the amount of nornicotine or N-nitrosonornicotine in said cured tobacco material is reduced by
greater than about 90% compared to cured tobacco material
made from a control tobacco plant comprising said wild type
allele.

* * * * *

